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Main objective of this thesis is to explore factors involved in especially the T-cell 
mediated anti-tumor immune response and to understand and control the force of 
the immune system to effectively search and destroy tumor cells.
ColoreCtAl CAnCer
Colorectal adenocarcinoma is the third most common cancer and accounts for a 
significant number of cancer deaths worldwide 1-3. Colorectal cancer has a lifetime 
risk of about 5-6% with a peak incidence in the 7th decade. Surgery is treatment of 
choice when the disease is only confined to the bowel wall. However, 30–40% of 
patients have loco-regionally advanced or metastatic disease on presentation which 
cannot be cured by surgery alone 4. Adjuvant radiation therapy, chemotherapy, or 
both are beneficial in selected patients 4-6. Despite intended curative therapy still a 
large proportion of the patients eventually die of their disease leaving room for new 
treatment modalities such as T-cell mediated immunotherapy 7.
CAnCer And the iMMune SySteM
Both spontaneous and therapeutic induced tumor specific immune responses require 
induction of cell-mediated immunity, to attack and eliminate tumor cells. This calls for 
close collaboration between cells of the innate immune system, in particular antigen 
presenting Dendritic Cells (DCs), and cells of the adaptive immune system, notably 
B-cells, CD4+ T-helper cells (TH) and CD8
+ cytotoxic T cells (CTL). Despite scientific 
progress, the interaction between the immune system and cancer remains elusive. 
Growth of tumor cells that escaped the immune system may implicate selective pres-
sure of the immune system. These mechanisms include active down-regulation of 
immune responses by the tumor by producing immunosuppressive agents, altered 
expression of major histocompatibility complex (MHC) and/or tumor-associated 
antigens (TAAs) by tumor cells, altered expression of adhesion molecules by tumor 
and/or DCs, and the use of host immune responses to the advantage of the cancer. 
















































tuMor inFiltrAted leukoCyteS rePreSent the PreSenCe oF An 
ongoing Anti-tuMor reSPonSe
Presence of both myeloid and lymphoid cells in different intra- and peri-tumoral 
compartments in colorectal cancer represents one of the most evident witnesses of an 
active involvement of the immune system in cancer growth and progression. Immuno-
histochemical techniques comprise one of the most frequent techniques used to study 
infiltration of leukocytes in colorectal tumors. These studies determined the clinical 
impact of many different leukocyte subpopulations such as dendritic cells, macrophages 
and different (sub-)populations of lymphocytes 8-23. However, there is still a lot unclear 
about the exact type and role of leukocytes that infiltrate into tumors. Only the infil-
tration of intra-tumoral or more precise intra-epithelial located CTLs is without doubt 
associated with good prognosis in colorectal cancer patients 8;10;12;16;18;19;23. In addition, 
several studies showed that intra-epithelial compared to stromal CD8+ T-cells express 
more molecules involved in target cell killing such as higher expression of Granzyme B 
and TIA-1 and showed higher proliferative activity, suggesting that intra-epithelial CD8+ 
T-cells are active effectors 8;12;24. Limitation of most immunohistochemical techniques is 
that in general per staining only one antigen is identified. Unfortunately most leuko-
cytes characterized with one antigen fulfill different and even opposing functions. This 
is one of the explanations why it is difficult to assess the clinical impact of leukocytes 
using immunohistochemical techniques. Studies using different techniques revealed 
that especially tumor-specific CD4+ TH1 cells are associated with a supportive cancer 
microenvironment that is beneficial to the prognosis of colorectal cancer patients 25-27. It 
has been well documented that CD4+ T-cells not only license the priming of CD8+ T-cells 
but are important to sustain their fitness 28, and also enhance CD8+ T-cell proliferation 
and cytolytic function 29. Expression of the IL-17-associated genes in colorectal cancer 
patients correlated with poor prognosis 30. The expression of TH2- and regulatory T cells 
has no or opposing effects on clinical outcome 30-33.
role oF huMAn leukoCyte Antigen ClASS i in ColoreCtAl CAnCer
Expression of MHC class I, for humans also called Human Leukocyte Antigen (HLA) 
class I, presenting TAAs on the tumor cell surface, is considered as a prerequisite for 
effective T-cell mediated immunity 34. As a consequence, tumor cells with down-
regulated HLA class I expression might escape this immune response, resulting in a 
selective outgrowth of these tumor cells. HLA class I molecules comprise the classi-
cal (class Ia) HLA-A, -B, and -C alleles, and the non-classical (class Ib) HLA-E, -F, and 









































They form a trimolecular complex consisting of a highly polymorphic heavy chain, 
a peptide antigen, and the non-polymorphic ß2-microglobulin (ß2m) light chain 35. 
The heavy chain molecules are encoded by genes located within the HLA region on 
chromosome 6, whereas ß2m is encoded by a gene mapped on chromosome 15. 
HLA class I is constitutively expressed by many cells, although the intensity of expres-
sion varies between different tissue types. Peptides presented in the context of HLA 
class I molecules are generated from degraded proteins by the antigen processing 
machinery. After processing, the peptide is associated with the heavy chain and ß2m 
and expressed on the cell surface to present the antigen to CTL.
In addition to T cell-induced tumor cell killing, tumor cell lysis can also be induced by 
activated NK cells. NK cell activation is regulated by a balance between signals mediated 
through activating and inhibitory receptors 36. HLA class I is a ligand for inhibitory recep-
tors on NK cells. Loss or down-regulation of HLA class I is a possible strategy to escape T 
cell control 37, and is frequently found in colorectal cancer 38;39. Loss or down-regulation 
of HLA class I might however activate NK cells and induce tumor cell lysis 40. Defects 
in one of the processes that are involved in antigen presentation, will lead to loss of 
expression of HLA class I molecules on the cell surface. Complete loss of HLA class I is 
usually caused due to loss of ß2m expression or TAP deficiency 41;42. This is mostly found 
in microsatellite unstable (MSI-H) tumors when compared to microsatellite stable (MSS) 
tumors 41;42. Loss of one of the HLA heavy chains (A, B or C alleles) is usually caused by 
chromosomal aberrations of chromosome 6 43. Only limited studies have reported on 
the clinical impact of HLA class I expression in colorectal cancer using mixed cohorts of 
genetic instability and reporting contrasting results 44-47. None of these studies deter-
mined the prognostic inpact of HLA class I expression with regard to genetic instability.
leukoCyte trAFFiCking iS CoordinAted by CheMokineS
Chemokines are a superfamily of small secreted cytokines that were initially charac-
terized through their ability to coordinate trafficking of leukocytes 48. Chemokines 
bind to specific cell surface transmembrane receptors coupled with G proteins, 
whose activation leads to formation of intracellular signaling cascades that prompt 
migration toward the chemokine source. To date, studies have identified in humans, 
more than 50 chemokines and 20 chemokine receptors 48-50. Chemokines coordinate 
migration of all types of cells including tumor cells, influencing tumor development 
and organ selective metastases 51-53. The role of chemokines in gastrointestinal 
disorders and cancer has been extensively reviewed 49;54. As described, high T-cell 
infiltration in colorectal cancer is associated with good prognosis and might protect 















































therefore represent an important factor in coordinating an anti-tumor immune 
response. This concept that (over-)expression of specific chemokines causes tumor 
infiltration by distinct leukocyte subsets, resulting in tumor regression and tumor 
specific immunity has been described in several tumor models 55-61. However, under-
standing this complex network of factors involved in trafficking of leukocytes in the 
cancer microenvironment remains further exploration 62.
t-Cell MediAted iMMunotherAPy
In search for new treatment options to cure patients from colorectal cancer, much 
effort has been put in exploiting the immune system and evoking tumor-specific 
immune responses using T-cell-mediated immunotherapy. The unique advantage of 
this type of treatment is that theoretically the immune system is able to specifically 
target and destroy tumor cells. Despite great progress in the field of tumor immunol-
ogy, clinical application of T-cell-mediated immunotherapy yielded only limited success 
63. So far cellular immunotherapy is not part of the clinical routine to treat colorectal 
cancer patients. However, recent studies have revealed the dawn of a new era in 
which the activation of tumor-specific T-cells starts to make a difference. Sipuleucel-T 
is the first therapeutic cancer vaccine to demonstrate effectiveness in Phase III clini-
cal trials by prolonging the life of advanced or late stage metastatic, asymptomatic 
hormone refractory prostate cancer patients (HRPC) 64;65. The vaccine was approved 
by the U.S. Food and Drug Administration to treat patients with HRPC 66. Treatment 
with Ipilimumab, a monoclonal antibody that targets the immune regulatory mol-
ecule CTLA-4 represents the first modality that had a significant impact on the overall 
survival of patients with metastatic melanoma 67. These results are the first positive 
demonstration that blockade of a T-cell activity inhibitory pathway can be an effective 
cancer treatment. Also adoptive T-cell therapy (ACT) has been found to be effective in 
the treatment for metastatic melanoma patients 68-70. Last but not least, vaccination 
with a synthetic long-peptide (SLP) vaccine against the HPV-16 oncoproteins E6 and 
E7 resulted in the complete regression of human papillomavirus-16-positive, grade 
3 vulvar intraepithelial neoplasias in 47% of the patients 71. Complete responses in 
this study were correlated with the strength of HPV-16-specific immunity 71. These 
encouraging results in patients with different types of carcinomas positively stimulate 









































FrAMeShiFt-MutAted gene ProduCt-derived PePtideS, A ClASS oF 
tuMor-SPeCiFiC AntigenS
Despite many years of work, the number of antigens recognized by tumor infiltrated 
lymphocytes (TILs) of colorectal cancer identified is limited 40;72-74. Consequently, 
vaccines so far have been developed on the basis of proteins that are selectively 
expressed by tumor cells. A possible unique group of TAAs comprises MSI-H tumors 
that, due to numerous of frameshift mutations in microsatellites express neo-anti-
gens (Figure 1). MSI-H is a molecular feature of tumors associated with the familial 
Lynch syndrome also known as hereditary non-polyposis colorectal cancer (HNPCC) 
syndrome, accounting for approximately 5% of all colorectal cancer cases 75-77 and 
for approximately 15% of all sporadic colorectal, gastric and endometrial cancers, as 
well as at lower frequencies for various other sporadic cancers 78-82. MSI-H colorectal 
tumors are predominantly localized in the proximal colon, comprising 50% of all 
proximal colon tumors 83;84. Since frameshift-mutated products (FSPs) are foreign 
to the immune system, they represent a unique group of tumor-specific antigens. 
As no tolerance and consequently strong T-cell responses are expected against the 
non-self-segment encoded by sequences downstream of the mutation, they are 
considered promising candidates for prophylactic vaccination of subjects with Lynch 
syndrome or HNPCC, or as adjuvant therapy in combination with surgery for patients 
…tgc.att.atg.aag.gaa.aaa.aaa.aag.cct.ggt.gag.act.ttc… 
… C   I   M   K   E   K   K   K   P   G   E   T   F … 
…tgc.att.atg.aag.gaa.aaa.aaa.agc.ctg.gtg.aga.ctt.tct… 
… C   I   M   K   E   K   K   S   L   V   R   L   S …(34aa) 
…tgc.att.atg.aag.gaa.aaa.aaa.gcc.tgg.tga.gac.ttt.ctt… 






Normal encoded part New foreign encoded part 
Frameshift encoded protein 
Wild-type protein 
Figure 1. insertion or deletion of mutations in microsatellites result in frameshift mutations 
and if ‘translated’ in proteins with a ‘foreign’ part.
A part of the TGFβR2 gene and corresponding amino-acid translation is depicted of the wild-
type (wt.), and containing a -1 or -2 deletion in the microsatellite (red). As shown a -1 deletion 
in the microsatellite results in a new foreign encoded part after the frameshift mutation and a 
new stop after 34 amino acids (aa), while a -2 deletion results in a frameshift mutation and a 















































with (sporadic) MSI-H tumors. Unfortunately, relatively little is known on the immu-
nogenic behavior of most of the FSPs 40.
vACCineS tArgeting P53-overexPreSSing ColoreCtAl tuMorS
Defined antigens to be used as vaccine candidates should ideally be overexpressed in 
the context of HLA at the cell surface of tumor cells and not (or at very low) levels by 
other cells of the human body. FSPs are a unique example of tumor specific antigens. 
Unfortunately only a minority of the colorectal tumors comprises MSI-H tumors 
that express these FSPs. The majority of the colorectal cancers are chromosomal 
unstable (CIN). CIN tumors lack tumor specific antigens to be used in vaccination 
trials. Antigens used in vaccination studies for colorectal cancer comprise TAA and 
consequently are likely to be expressed by normal cells 85-87. Different TAA such as: 
p53, CEA, MUC1, Sialyl-Tn, 5T4, SART3, MAGE have been applied in clinical trials to 
vaccinate colorectal cancer patients 85-89. The use of antigens potentially expressed 
by normal cells bears the risk of immune tolerance. Indeed, tolerance too many TAA 
such as p53, CEA and MUC1 has been found 90-96. These results indicate that toler-
ance forms a potential hurdle for immunotherapies of cancer when using TAA.
One of the TAA frequently used in cancer vaccination trials and much studied 
in the Leiden University Medical Center comprises p53. Due to a mutation, p53 is 
overexpressed, while wildtype (wt) p53 in normal cells is not or in very low levels 
expressed 97-100. The most common way to disrupt the p53 pathway is through a 
point mutation that inactivates its capacity to bind specifically to its cognate recogni-
tion sequence, and often results in overexpression of p53 101. The aberrant expres-
sion of the p53 protein in tumor cells versus the low expression in non-tumor cells 
provides an immunological window for the use of p53 as a tumor antigen for immu-
notherapeutic intervention against cancer 102. P53 is mutated and overexpressed in 
approximately 34-45% of all colorectal cancers 103.
The presence of humoral and proliferative immunity against p53 in the blood of 
humans has been described for a long time. Both IgM and IgG type antibodies against 
p53 have frequently been detected in the sera of cancer patients, including patients 
with colorectal cancer 104;105. Because p53 is not expressed at the cell surface, only 
p53-specific T-cell mediated immunity is likely to exert therapeutic antitumor effects. 
T-helper responses have been described in humans especially in cancer patients 25;106-
108. However, there are strong indications that the p53-specific CD8+ T-cell repertoire 
is severely restricted by self-tolerance 90;91;109, as high-avidity self-reactive T cells 
are suspected to be deleted in the thymus 110. Most of the described human p53-









































against p53 might mainly induce p53-specific CD4+ T cells, these are important in 
cancer immunotherapy because IFNγ secreting CD4+ TH1-cells play an important role 
in orchestrating and sustaining the local immune attack by CD8+ CTL and innate 
immune effector cells 116-118.
Several different antigen delivery systems have been tested to immunize patients 
against p53. In previous studies adenoviral vector encoding wt.p53 119, recombinant 
canarypox virus encoding wt.p53 108;120, and adenoviral vector encoding wt.p53 
transfected DCs 121 were used. These modalities were safe and capable of stimulating 
p53-specific T-cell responses in some of the vaccinated patients. Unfortunately, pres-
ence and enhancement of anti-vector immunity were found in almost all patients, 
which may have hampered the induction of a truly effective p53-specific T-cell 
response. In addition, DC pulsed with known p53 HLA-A2.1 binding peptides have 
been used and this resulted in safe induction of specific T-cell responses against p53 
peptides in some of the treated patients 122. This concept but has the disadvantage 
that patients with other HLA types cannot be treated 109.
Synthetic long peptides (SLP®) can also be used as vaccines 28;123. When injected, 
these SLP® are predominantly taken up by DC resulting in the presentation of both 
helper T-cell epitopes and CTL epitopes that are present in the SLP® 124;125. A SLP® 
vaccine for the induction of p53-specific T-cell immunity was developed. Injection 
of p53-SLP® resulted in a strong p53-specific CD4+ T-cell response to three different 
epitopes in mice 91. This p53-SLP® vaccine is to be tested for its safety and immuno-
genicity cancer patients.
oPtiMizAtion oF vACCinAtion StudieS reSultS in CliniCAl SuCCeSS
The most recent vaccine developments suggest that some of the current vaccine strate-
gies do harbor the capacity to induce immune responses in cancer patients even to 
self-antigens. However, lack of clinical results in phase I/II trials in colorectal cancer 
patients suggests that the vaccine-induced T-cell responses against these antigens 
are at this point not robust enough or of sufficient quality to confidently progress 
to efficacy trials. A stronger focus should be put on how to induce the strongest and 
best qualified leukocyte population by vaccination. A clear positive relation between 
survival of colorectal cancer patients and high expression of a type 1 response has 
been established 30. The presence of tumor-specific CD4+ T cells in the cancer micro-
environment is a prerequisite for support, proliferation, recruitment and cytolytic 
function of tumor-specific CD8+ T cells 29;126. This unique function of the tumor-specific 
CD4+ T cells is greatly accelerated by production of IFN-γ and IL-2 25;29. For example, 















































against the tumor antigen 5T4 were found to have more clinical benefits when 
5T4-specific IFN-γ ELIspot responses were induced. 127. Altogether, these data suggest 
that clinical responses after vaccination not only depend on the induction of vaccine-
specific responses, but merely require the induction of a strong and broad type 1 T-cell 
response. Therefore, in order to benefit from the local effect of tumor-specific T cells, 
vaccines should be combined with immune modulating adjuvants that specifically 
induce polarization of the induced immune response into a type 1 response.
A possible candidate adjuvant might be Interferon-alpha (IFN-α) as it plays a 
major part in the differentiation of the Th1 subset, as well as in the generation 
of CTL and the promotion of the in vivo proliferation and survival of T cells 128. 
Moreover, several studies have shown that type I IFNs promote the differentiation 
of monocytes into DC in vitro and can markedly enhance DC activities 129-134. Only 
one study in humans has combined IFN-α injections with peptide vaccination 135. This 
study showed that the concomitant combination of a peptide-based vaccine with 
IFN-α was safe, resulted in a consistent enhancement of vaccine-specific CD8+ T cells 
and yielded a general increase of the percentage of blood circulating DC precursors/
CD14+ monocytes 135. It would be interesting to study if addition of IFN-α to the 
p53-SLP® vaccine not only induced a stronger p53-specific but also a better polarized 
Th1 response.
theSiS outline
The studies described in this thesis aim to increase the knowledge on the interac-
tion between the immune system and colorectal tumor cells, with final purpose, the 
design of effective T-cell mediated immunotherapy. As there are strong indications 
that presence of intra-tumoral CD8+ T cells is associated with prognosis of colorectal 
cancer patients and most tumor associated antigens comprise intracellular proteins 
and might therefore not be accessible for antibodies, this thesis primarily focuses on 
T-cell mediated anti-tumor immunity.
Conflicting results have been described for the association between expression 
of HLA class I and prognosis in colorectal cancer patients, possibly due to the use 
of cohorts with mixed types of genetic instability 44-47. Therefore in chapter 2 we 
evaluated the association between HLA class I expression and prognosis in patients 
curatively operated for rectal cancer consisting of mainly MSS cancers. The infiltra-
tion of diverse types of NK and T-cells in the different types of tumor compartments is 










































Interaction of chemokines with their cognate receptors allows attraction of 
immune cells into a tumor, but also influences migration of disseminated tumor cells. 
In chapter 4, a specific chemokine, CXCL5 that in rats was found to be associated 
with aggressive growth, was studied for its association to survival and T-cell infiltra-
tion in rats and humans.
MSI-H tumors are characterized by mutations in microsatellites that result in the 
expression of frameshift-mutated proteins. In chapter 5 the use of an expression 
system to systematically analyze the characteristics and immunogenic properties of 
proteins encoded by frameshift mutated genes that are commonly found in MSI-H 
cancers is described.
In chapter 6 the results of a phase I trial are presented, studying both safety and 
immunogenicity of a vaccine consisting of a pool of synthetic long p53 peptides in 
patients treated for metastasized colorectal cancer. Chapter 7 describes the results 
from a phase I trial that studied if addition of IFN-α to the p53-SLP® vaccine enables 
polarization of the induced p53 CD4+ T-cell response into a strong Th1 response.
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Purpose: To determine the clinical impact of Human Leukocyte Antigen (HLA) class I 
expression in irradiated and non-irradiated rectal carcinomas.
experimental design: Tumor samples in tissue micro array format were collected 
from 1135 patients. HLA class I expression was assessed after immunohistochemical 
staining with two antibodies (HCA2 and HC10).
results: Tumors were split into two groups: 1) tumors with >50% of tumor cells 
expressing HLA class I (high) and 2) tumors with ≤50% of tumor cells expressing HLA 
class I (low). No difference in distribution or prognosis of HLA class I expression was 
found between irradiated and non-irradiated patients. Patients with low expression 
of HLA class I (15% of all patients) showed an independent significantly worse prog-
nosis with regard to overall survival and disease free survival. HLA class I expression 
had no effect on cancer specific survival or recurrence free survival.
Conclusions: Down-regulation of HLA class I in rectal cancer is associated with poor 
prognosis. In contrast to our results, previous reports on HLA class I expression in 
colorectal cancer described a large population of patients with HLA class I negative 
tumors, having a good prognosis. This difference might be explained by the fact that 
a large proportion of HLA negative colon tumors are microsatellite instable (MSI). 
MSI tumors are associated with a better prognosis than microsatellite stable (MSS). 
As rectal tumors are mainly microsatellite stable (MSS), our results suggest that it is 
both, oncogenic pathway and HLA class I expression, that dictates patient’s prognosis 
in colorectal cancer. Therefore, to prevent confounding in future prognostic analysis 
on the impact of HLA expression in colorectal tumors, separate analysis of MSI and 








































HLA class I expression in rectal cancer 29
introduCtion
The immune system is thought to have an important function in controlling tumor 
growth and eliminating metastasizing tumor cells. Expression of Human Leukocyte 
Antigen (HLA) class I, presenting tumor-associated antigens on the tumor cell sur-
face, is considered as a prerequisite for an effective T cell immune response 1. As a 
consequence, tumor cells with down-regulated HLA class I expression might escape 
this immune response, resulting in a selective outgrowth of these tumor cells.
Many studies described HLA class I expression in cancer 2-5. Only limited studies 
have reported on the clinical impact of HLA class I expression in colorectal cancer with 
contrasting results. Some studies found no significant correlation between staining 
intensity and survival 6-8, while others found a prognostic correlation between HLA 
expression and survival 9;10. The latter two studies had in common that total absence 
of HLA class I resulted in a favorable prognosis compared to patients with down-
regulated expression HLA class I of tumor cells. Discrepancy between the two studies 
is, that one described high expression of HLA class I in tumor cells to result in a better 
prognosis compared to partial down-regulation of HLA class I 9, while the other 
found the opposite 10. These studies both analyzed a mixed population of colon and 
rectal cancer patients. For rectal cancer patients, the clinical impact of HLA class I 
expression is still unknown. Since HLA class I expression is often absent in microsatel-
lite instable (MSI) tumors 11;12 and MSI is more frequently observed in right-sided 
colon tumors than in rectal tumors 13, results obtained from a mixed population of 
colon and rectal cancer patients might not hold true for rectal cancer patients.
Purpose of this study was to analyze the clinical relevance of HLA class I expression 
for rectal cancer patients. In addition to determine the impact of MSI on HLA class 
I expression, tumors most at risk for MSI i.e. HLA negative tumors were examined 
for MSI by determining the expression of the mismatch repair proteins, mismatch 
mutL homolog 1 (MLH1) and postmeiotic segregation increased 2 (PMS2), that are 
most absent in sporadic MSI tumors 14;15. Radiotherapy has been described recently 
to increase cell surface expression of Major Histocompatibility Complex (MHC) class 
I molecules in a murine colon adenocarcinoma cell line 16. Therefore, our study 
also evaluated the effect of radiotherapy on HLA class I expression in rectal cancer 
patients. For these purposes, HLA class I expression was evaluated in a set of 1135 
formalin-fixed paraffin-embedded rectal cancer specimens. The tumors studied were 
obtained at time of surgery from patients of a prospective multicenter trial, who 
were randomized between standardized pre-operative radiotherapy treatment fol-

















































Patients were obtained from the Dutch TME trial, a multicenter trial that evaluated 
total mesorectal excision (TME) surgery with or without preoperative radiotherapy 
(5x5 Gray) 17. Radiotherapeutical, surgical and pathological procedures were stan-
dardized and quality-controlled 17;18. Tumor staging was determined using the Tumor 
Node Metastasis (TNM) classification 19. Patients with the hereditary Lynch syndrome 
also known as hereditary non-polyposis colorectal cancer (HNPCC) were excluded 
from the TME trial. Sufficient formalin-fixed paraffin-embedded tumor material 
was available for 1135 Dutch patients. Three 2mm cores of each tumor sample were 
arrayed into tissue microarrays (TMA) as previously described 20.
Immunohistochemistry and microscopic analysis
TMAs 20 were immunohistochemically stained for HLA class I using the mAb antibod-
ies HCA2 and HC10 and the rabbit anti-β2m polyclonal Ab (A 072; DAKO Cytomation, 
Glostrup, Denmark). The HCA2 and HC10 antibodies were applied in immunohisto-
chemistry as hybridoma culture supernatant, kindly provided by Prof. J.J. Neefjes 
from the Netherlands Cancer Institute (Amsterdam, The Netherlands) The reactivity 
spectrum of HCA2 includes HLA-A (except HLA-A24), HLA-B73 and HLA-C molecules 
as well as HLA-E, HLA-F and HLA-G antigens 21-23. HC10 reacts with HLA-B and HLA-C 
molecules and HLA-A10, -A28, -A29, -A30, -A31, -A32 and -A33 heavy chains 23-26. 
The immunohistochemical procedures are described in detail elsewhere 10. All tumor 
specimens were stained simultaneously to avoid intra-assay variation. Microscopic 
analysis was assessed by two independent observers (M.M. v. B. and M. v. V.) in a 
blinded manner. HCA2, HC10 and β2m stainings were scored in 6 categories. Essen-
tially, the scoring was divided into quartiles but for tumors with less than 25% stained 
cells there was a distinction made between those with 6%–25% positively stained 
tumor cells, those with approximately 1%-5% positively stained cells and those with 
absolute no positively stained tumor cells. 27;28. Where discrepancies arose between 
the staining of cores from the same tumor, an average of the scores was taken, with 
confirmation by 2 observers using a double-headed microscope with a consensus 
decision taken in all cases. Tissue stromal cells, normal epithelium or lymph follicles 
served as positive internal controls to ascertain the quality of the staining. Patients 
were excluded if stromal cells of tumor were not stained for HCA2 or HC10. Twenty 
five tumors with negative staining of the stromal cells for HCA2 were excluded. 
HC10 showed in all tumors staining of the stromal cells. Also TNM stage 0 patients, 
tumors lost due to technical failure and ineligible patients were excluded, leaving 
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results for HCA2 and HC10 staining resulted in 1008 eligible stage I-IV rectal cancer 
patients for analyses of clinical impact of HLA class I expression.
Tumors negatively stained for HCA2 and/or HC10 were stained for mismatch repair 
proteins MLH1 and PMS2. MLH1 and PMS2 are deficient in sporadic MSI tumors. 
Therefore, expression of these proteins was used to differentiate between MSI and 
MSS rectal cancers. Tissue stromal cells, normal epithelium or lymph follicles served 
as positive internal controls when analyzing MLH1, PMS2 expression. Expression of 
MLH1 and PMS2 was scored positive if tumor cells showed expression and scored 
negative if tumor cells showed no expression of either MLH1 or PMS2 and tissue 
stromal cells did show expression, indicating respectively Microsatellite Stable (MSS) 
and Microsatellite Instable (MSI) tumors 14.
Statistical analyses
All analyses were performed with SPSS statistical software (version 12.0 for Windows, 
SPSS Inc, Chicago, USA). Mann-Whitney U, T-test and c2-tests were used to compare 
variables. Kaplan-Meier analyses were performed to analyze patient survival. The 
entry date for the survival analyses was the time of surgery of the primary tumor. 
Events for time to local recurrence, distant recurrence, cancer specific survival, dis-
ease free and overall survival were defined as follows; from time of surgery to time 
of local disease relapse (for local recurrence), time of distant disease relapse (for 
distant recurrence), time of disease relapse or death by disease (for cancer specific 
survival), time of disease relapse or death (for disease free survival) and time of 
death, respectively, (for overall survival). Non-irradiated and irradiated patients were 
first separately analyzed in univariate analysis and second, variables with a p-value 
of ≤0.10 in the univariate analyses were subjected to a multivariate analysis. Multi-
variate analysis was performed on the whole group of irradiated and non-irradiated 
patients with the following variables: HLA class I, randomization for radiotherapy, 
TNM and circumferential margin. Cox’ regression analyses were used to calculate 
Hazard Ratios (HR) with 95% confidence intervals (CI).
reSultS
Scoring methods
Several methods are described to analyze HLA class I expression in cancer. The 
standard is defined by the International HLA and Immunogenetics Workshop (IHIW) 
27;28. A recent paper describing HLA class I expression in colorectal cancer used an 
adjusted form of this scoring method 9. Our scoring was primarily adapted from 















































distinction was made between those with 6%–25% positive tumor cells, those with 
approximately 1%-5% positive tumor cells and those with absolute no HLA class I 
positive stained tumor cells. After scoring and analyzing this method we found that 
patients in the groups with absolute no, 1%-5%, 6%-25% and 26%-50% HLA class 
I expression of tumor cells did not differ in prognosis but had a worse prognosis 
compared to patients with HLA class I expression in groups with 50-75% and >75% 
of tumor cells expressing HLA class I. Therefore, we distinguished two categories. 
These two categories were 1) 0%-50%; and 2) >50%-100% of tumor cells expressing 
HLA class I.
HCA-2 and HC10 staining in rectal cancer
Immunohistochemical staining with HCA2 and HC10 antibodies demonstrated strong 
positive membrane staining of stromal cells and tumor-infiltrating inflammatory 
cells, indicating the success of the staining. A total of 1035 and 1092 tumors were 
evaluated with HCA2 and HC10. 324 (65%) irradiated tumors and 312 (58%) non-
irradiated tumors showed at least 50% of all tumor cells positive for HCA2. Staining 
with HC10 resulted in 403 (76%) irradiated tumors and 436 (77%) non-irradiated 
tumors that showed more than 50% positive tumor cells. Complete results are shown 
in Table 1. Representative examples of the immunohistochemical stainings of tumors 
are displayed in Figure 1A-F. These results show that about 35% of irradiated and 
42% of non-irradiated patients showed in less than 50% of the tumor cells expres-
sion of HCA2. HC10 is expressed in less than 50% of the tumor cells in about 25% of 
both irradiated and non-irradiated rectal cancer patients.





hCA2 High 324 (65%) 312 (58%)
Low 142 (28%) 174 (32%)
Absence 31 (6.2%) 52 (9.7%)
hC10 High 403 (76%) 436 (77%)
Low 117 (22%) 116 (21%)
Absence 8 (1.5%) 12 (2.1%)
Numbers (N) of patients are indicated with percentages shown in parentheses, showing: 
expression of HCA2 and HC10 in more than 50% of the tumor cells (High), expression in less 
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Analysis of HLA class I expression in rectal tumors
Together, the results obtained with HCA2 and HC10 are expected to reflect HLA class I 
expression in rectal cancer. In a group of 64 tumors it was studied whether an additional 
staining for β2m would better define HLA class I expression. The results of the addition 
of β2m to HCA2 and HC10 were comparable with those obtained with HCA2 and HC10, 
i.e. only 1 of 64 tumors was differently classified. Therefore, β2m was not scored in the 
whole cohort and HLA class I expression was assessed by combining HCA2 and HC10.
A total of 406 (85%) irradiated and 445 (84%) non-irradiated tumors exhibited 
expression of at least one of the two markers showing >50% positive staining of all 
tumor cells (further referred to as ‘the HLA class I high expression group’). A total of 
70 (15%) irradiated and 87 (16%) non-irradiated tumors showed reduced numbers 








Figure 1. examples of hCA2 and hC10 immunohistochemical staining of rectal tumors; (A-C) 
hCA2, (d-F) hC10 expression.
(A, D) expression of HLA class I in >50% tumor cells; (B, E) expression of HLA class I in <50% 
tumor cells; (C, F) epithelial cells show total absence for HCA2 or HC10 and only stromal and 















































(1.5%) non-irradiated tumors showed total loss of HLA class I (negative for both 
HCA2 and HC10). Survival results of patients with total absence of HLA class I on 
tumor cells did not show significant difference from patients with reduced numbers 
of HLA class I positive tumor cells. Therefore, these groups were combined and will 
be further referred to as ‘the HLA class I low expression group’. Complete results 
are shown in Table 2. The number of patients in the group of the HLA class I high 
expression group and the HLA class I low expression group was equally distributed 
between irradiated and non-irradiated tumors (c2=0.519, p=0.471), indicating that 
irradiation had no effect on HLA class I expression in these patients.
table 2. expression of hlA class i in rectal cancer using hCA2 and hC10 antibodies.
hCA2 hC10 hlA class i
High (N) Low + Absence (N)  N (%)
irradiated High (N) 270 37 406 (85%)
  Low + Absence (N) 99 70 70 (15%)
non-irradiated High (N) 277 32 445 (84%)
  Low + Absence (N) 136 87 87 (16%)
Expression of results of HCA2 and HC10 staining in a cross table for numbers (N) of irradiated 
and non-irradiated patients; expression of HCA2 and HC10 in more than 50% of the tumor cells 
(High) versus expression in less than 50% of the tumor cells (Low) is shown. A significant correlation 
was noted between HCA2 and HC10 staining for both irradiated (c2 = 53.947, p<0.001) and non-
irradiated patients (c2 = 61.257, p<0.001). The right side of the table displays HLA class I expression 
estimated on HCA2 and HC10 expression. A total of 406 (85%) irradiated and 445 (84%) non-
irradiated tumors exhibited expression of at least one of the two markers showing >50% positive 
staining of all tumor cells. A total of 70 (15%) irradiated and 88 (16%) non-irradiated tumors 
showed reduced numbers (≤50%) of HLA class I positive tumor cells. The number of patients in the 
group of the HLA class I high expression group and the HLA class I low expression group was equally 
distributed between irradiated and non-irradiated tumors (c2 = 0.519, p = 0.471).
HLA class I negative cells and microsatellite instability
It has been described that a majority of MSI colorectal tumors do not express HLA class 
I, while only a minority of MSS tumors do not express HLA class I 12;29. Therefore, HLA 
class I negative rectal tumors are most at risk to be MSI tumors. To evaluate the numbers 
of sporadic MSI tumors in our study, HCA2 or HC10 negative tumors were analyzed for 
the expression of PMS2 and MLH1. PMS2 and MLH1 are mismatch repairs proteins 
that are most frequently absent in MSI sporadic tumors 30. Of the HLA class I negative 
tumors only one out of 11 tumors did not express PMS2 and MLH1. In the tumor group 
negative for only one of the two HLA class I markers, 2 of 81 tumors displayed no 
PMS2 and MLH1 staining. These results indicate that HLA class I down-regulation is not 
associated with MSI in rectal cancer and are in accordance with previous findings that 
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HLA class I expression and clinicopathological parameters
The relationship between HLA class I expression and patient/tumor characteristics 
was assessed (Table 3). HLA class I expression levels were distributed equally in 
non-irradiated and irradiated patients with regard to most clinical and pathologi-
cal parameters. Three significant differences were observed. For the non-irradiated 
patients, significantly more men appeared in the HLA class I low expression group 
(p=0.03). The group of irradiated tumors with HLA class I low expression contained 
significantly more stage III and IV tumors (p=0.01) and also more patients with a 
tumor positive circumferential resection margin (p=0.02) when compared with 
tumors with high HLA class I expression.
table 3. Clinicopathological characteristics of irradiated and non-irradiated patients with high 
or low numbers of hlA class i positive tumor cells.










   Male, (%) 63 75 0.03 65 66 0.90 
Age
   median years 65 68 0.32 65 65 0.99 
tnM stage, (%)
   I 31 24 0.52 33 24 0.01 
   II 27 30 30 21 
   III 36 38 32 40 
   IV 5 8 5 14 
Circumferential margin
   Negative, (%) 83 77 0.28 86 74 0.02 
distant from anal verge, (%)
   ≥ 10 cm 28 33 0.17 27 32 0.30 
   5-10 cm 41 31 46 36 
   < 5 cm 31 36 27 32 
operation type, (%)
   Low anterior resection 66 61 0.77 65 66 0.89 
    Abdomino-perineal 
resection 
29 33 29 30 
   Hartmann 5 6 6 4 
Number (N) of patients with expression of total HLA class I expression in more than 50% of the 
tumor cells (High) and expression in less than 50% of the tumor cells (Low).















































Expression of HLA class I and clinical prognosis
Because radiotherapy might influence local tumor recurrences 17, irradiated and non-
irradiated tumors were analyzed separately in order to evaluate the impact of HLA class 
I expression on tumor recurrence and patient survival. HLA class I expression was not 
related with distant or local recurrence rates. Patients with low expression of HLA class 
I had a worse overall survival and disease free survival when compared to patients with 
HLA class I high expression, irrespective of treatment (Fig 2; overall survival: p=0.008 and 
p=0.01; disease free survival: p=0.01, p=0.006 in irradiated and non-irradiated patients 
respectively). Irradiated patients with low HLA class I expression also had a worse cancer 
specific survival (p=0.003). For non-irradiated patients, HLA class I expression had no 
significant effect on cancer specific survival (Fig 2). All results of univariate analysis are 
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Figure 2. examples of kaplan-Meier curves showing overall survival and cancer specific survival 
for irradiated and non-irradiated patients.
Kaplan-Meier curves for overall survival (A, B) and cancer specific survival (C, D); curves show 
prognosis for non-irradiated (A, C) and irradiated patients (B, D) for HLA class I expression in more 
than 50% of the tumor cells (High) versus expression in less than 50% of the tumor cells (Low). 
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shown in table 4. Univariate analysis showed a better outcome for overall survival and 
disease free survival in patients with high HLA class I expression.
table 4. both irradiated and non-irradiated patients with high expression of hlA class i have a 
better overall -, and disease free survival.
non-irradiated patients irradiated patients
High Low p-value High Low p-value
overall survival 65.5% 58.5% 0.012 67.5% 51.3% 0.008
disease free survival 62.2% 53.5% 0.015 62.2% 48.3% 0.006
Cancer specific survival 74.3% 71.4% 0.41 80.1% 61.8% 0.003
local recurrence 8.9% 13.7% 0.22 4.7% 3.2% 0.72
distant recurrence 26.7% 28.7% 0.88 24.7% 29.3% 0.34
Survival and recurrence rates indicated in percentages after 5-years of follow-up for non-
irradiated and irradiated patients for HLA class I expression in more than 50% of the tumor 
cells (High) versus expression in less than 50% of the tumor cells (Low). P-value is based on 
univariate log rank analyses for overall survival, disease free survival, cancer specific survival, 
local recurrence and distant recurrence.
* Statistical significant p-values are in bold
Multivariate analysis
Multivariate analysis was performed to identify factors with independent prognostic 
significance and to calculate hazard ratios (HR). Analyses included TNM, circumferen-
tial margin, randomization for pre-operative radiotherapy and HLA class I expression 
(low versus high HLA class I positive tumor cells) (table 5). Advanced pathological 
(TNM) stage and tumor positive circumferential resection margins retained their 
strength as independent prognostic factors in these survival analyses. HLA class I 
expression showed independent prognostic value for overall survival and disease 
















































table 5. Multivariate analysis confirms independent better overall -, and disease free survival 
for rectal cancer patients with high expression of hlA class i.
overall survival disease free survival Cancer specific survival
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
hlA
   High
   Low
1
1.3 (1.0 – 1.6)
0.042 1
1.4 (1.1 – 1.8)
0.006 1
1.1 (0.8 – 1.5)
0.653
randomization
   TME
   TME + RT
1
1 (0.8 – 1.2)
0.632 1
0.9 (0.7 – 1.1)
0.214 1
1.1 (0.9 – 1.5)
0.282
tnM
   I
   II
   III
   IV
1
2.2 (1.7 – 3.0)
3.1 (2.4 – 4.1)





2.1 (1.6 – 2.8)







9.0 (5.4 – 14.9)





   negative
   positive
1
1.3 (1.1 – 1.5)
<0.001 1
1.8 (1.4 – 2.2)
<0.001 1
1.3 (1.1 – 1.5)
<0.001
Multivariate analysis for cancer specific, overall and disease free survival was performed to 
identify factors with independent prognostic significance and to calculate hazard ratios (HR) 
with 95% confidence intervals (CI) shown in parentheses. HLA class I expression in more than 
50% of the tumor cells (High) versus expression in less than 50% of the tumor cells (Low); Total 
mesorectal excision (TME); Radiotherapy (RT); circumferential margin (CRM); p-value is based 
on Cox’ regression analyses.
* Statistical significant p-values are in bold
diSCuSSion
We showed that rectal cancer patients from the HLA class I low expression group had 
an independent worse overall and disease free survival when compared to patients 
from the HLA class I high expression group. These data imply that expression of HLA 
class I in tumor cells predicts survival for rectal cancer patients. Although, significant 
better cancer specific survival for irradiated patients with high HLA class I was found 
in univariate analysis, the predictive value was lost in multivariate analysis. This 
observation can be explained by the fact that the group with low HLA class I included 
significant more stage III/IV and more patients with a positive circumferential margin 
compared to the group patients with high expression of HLA class I. Also no predic-
tive value of HLA class I expression was found with regard to recurrence free survival 
of these patients. Therefore, we have no indications that support the notion that 
better survival of high HLA class I expression is due to the better antigen presenting 
function of these tumor cells, as has been suggested 9;10.
In our study, no difference was found between irradiated and non-irradiated 
patients for HLA class I expression in tumor cells. It has been described that 
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class I in a colorectal mouse tumor cell line 16. The fact that we could not find more 
HLA class I expression in irradiated tumors than in non-irradiated tumors indicates 
that radiotherapy does not induce HLA class I expression in vivo. Immunohistochem-
istry, however, is less suitable to measure subtle expression changes. Therefore addi-
tional research is required to determine the impact of radiotherapy on expression 
levels of HLA class I in human tumors.
In our study, more tumors showed HLA class I down-regulation after immunohis-
tochemical staining using HCA2 than using HC10. This difference might be due to 
differences in reactivity spectrum of both antibodies (see ‘materials and methods’) or 
to the fact that HLA alleles are differently affected in colorectal cancer. If the latter is 
the case, our results suggest that HLA A alleles preferentially show down-regulation 
in rectal cancer.
Previous reports evaluated HLA class I expression in mixed patient populations 
of colon and rectal cancer patients 9;10. Watson et al also found in a large group of 
colorectal cancer patients that patients with low expression of HLA class I had a poor 
prognosis 9. However, in contrast to our results, both studies described a substantial 
population of patients with tumors showing absence of HLA class I. In addition, they 
described that absence of HLA class I was associated with better prognosis compared 
to tumors expressing reduced numbers of HLA class I positive tumor cells. A relatively 
low number (1.1%) of HLA class I negative tumors was observed in our cohort of 
rectal cancer patients only. These patients showed no survival advantage when 
compared with patients with reduced numbers of HLA class I positive tumor cells. 
There are several explanations for the discrepancy in number of HLA class I negative 
tumors between the study of Watson et al. and ours, like different definition for HLA 
class I expression, differences in staining techniques, different patient cohort and 
number of MSI tumors.
We showed that tumors that do not stain HC10 can stain positive for HCA2 and 
thus are still able to present antigens. Therefore, an explanation for the differences 
with the results of Watson et al. is that we used strict criteria to classify tumors as 
HLA class I absent (defined as both HCA2 and HC10 negative) compared to Watson 
et al. (defined as negative for HC10 or negative for beta2M instead of negative for 
both). Another important explanation is that we examined HLA class I expression in 
a relative more homogeneous population of patients with a rectal tumor, while the 
other cohorts are more heterogeneous, consisting of both colon and rectal cancer. 
Although combining results from colon and rectum is generally accepted when 
predicting prognosis, this might influence results 33.
In colon cancer patients, approximately 50% of all proximal colon tumors show 
MSI, whereas almost all distal colon and rectal cancers are MSS tumors 13;34. Loss 















































colorectal tumors but in only 17% of MSS right-sided colon tumors loss of HLA class I 
is found 12;29. In our cohort, only one out of 11 HLA negative tumors and two out of 
81 tumors negative for HCA2 or HC10 did not express MLH1 and PMS2 and were thus 
likely MSI tumors. This indicates that rectal cancers are mainly MSS tumors, as has 
previously been described 31-33. Of the multiple mechanisms that have been shown 
to underlie defects in HLA class I expression in colorectal cancer (mutations in the 
individual HLA class I genes, mutations in β2- microglobulin (β2m) 12, and defects in 
components of the HLA class I-associated antigen processing machinery (APM) 12;35), 
only the first will result in allele-specific aberrancies while the other affect total HLA 
class I expression and may result in total absence in a tumor cell.
These observations imply that a population of colorectal tumors with total 
absence of HLA class I probably contains a disproportionate large number of MSI 
tumors when compared with colorectal tumors expressing HLA class I. In addition, 
MSI colorectal tumors have a better prognosis when compared with MSS colorectal 
tumors 34;36. Therefore, HLA class I negative tumors are more likely to be MSI tumors 
with a different clinical behavior compared to MSS colorectal tumors. It is likely 
that MSI influences prognostic results when considering HLA class I expression in 
colorectal tumors.
Our results show that HLA class I expression in rectal cancer affects patient’s 
prognosis. We hypothesize that both, oncogenic pathway and HLA class I expression, 
dictates clinical tumor progression. We suggest that in future prognostic studies, 
analyzing expression of HLA class I or other biomarkers in colorectal cancer, impact 
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Purpose: A majority of colorectal adenocarcinomas displays diminished MHC class I 
expression, making them particularly vulnerable for NK cell-mediated killing. Gener-
ally, these tumors also show a substantial inflammatory infiltrate. Most inflammatory 
cells, however, reside in the tumor stroma, where they do not have direct contact 
with tumor cells in the tumor epithelium. In this study we investigated the correla-
tion between colorectal tumor MHC class I aberrations and infiltration of NK cells.
experimental design: We studied 88 tumor specimens obtained from 88 colorectal 
cancer patients for locus specific HLA aberrations and correlated these data to infil-
tration of CD4, CD8 and CD56 positive lymphocytes. The lymphocyte markers were 
individually combined with laminin as a second marker to facilitate quantification in 
the different tumor compartments, i.e. tumor epithelium and tumor stroma.
results: Locus specific partial -or total HLA class I loss was detected in 72% of the 
tumors studied. Twenty-eight percent had no HLA loss at all. Mean overall intra-
epithelial infiltration of CD56 positive lymphocytes was 7 cells per mm2 compared 
to 76 cells per mm2 for CD8 and 19 cells per mm2 for CD4 positive lymphocytes. 
Locus specific partial or total loss of tumor cell MHC class I expression was positively 
correlated with intra-epithelial infiltration of CD8 positive cells (p = 0.01), but not 
with CD4 or CD56 positive lymphocytes. Triple immunofluorescence staining showed 
that these cells were CD8 -and granzyme-B positive T-lymphocytes.
Conclusions: Our data showed that colorectal tumors are sparsely infiltrated by CD56 
positive cells compared to CD8 positive T-cells and that loss of MHC is associated 
with T cell infiltration instead of NK cell infiltration. Considering the fact that MHC 
loss is quite common in colorectal cancer and that, due to local absence of NK cells, 
it is unlikely that there has been selection for NK-escape variants, improvement of 
the intra-epithelial infiltration/migration of NK cells may be an important basis for 
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introduCtion
Colorectal cancer is the most common gastrointestinal cancer in the world and 
potentially curable with surgical resection of the primary tumor. The clinical problem 
of colorectal cancer, however, is the spread and outgrowth of metastases. Once the 
disease has spread to distant organs, treatment options are limited to aggressive 
systemic therapies with high treatment-related morbidity and/or mortality, while a 
cure can rarely be obtained. Development of new adjuvant therapeutic strategies 
focuses on more selective and safer therapeutic options, including immunotherapy. 
The major advantage of using immune-based adjuvant therapeutic strategies is the 
potentially high selective focus of immune effector cells on malignant cells, which 
may limit treatment-related morbidity and/or mortality. However, there are still 
questions unanswered concerning the immunological mechanisms in an anti-tumor 
response. A classisal way to gain insight in the immunological mechanisms in the 
host defense against malignant cells, is to evaluate the histopathology of the host’ 
natural infiltration patterns 1.
The leukocyte infiltrate of primary colorectal tumors is presumed to represent 
the natural defensive activity of the host against the tumor. A majority of infiltrat-
ing leukocytes consists of T-lymphocytes infiltrating the stromal compartment of 
the tumor. These infiltrating immune cells do not seem to interact directly with the 
tumor cells, since they are separated by stromal structures (i.e. basal membrane-like 
structures) that seemingly form a physical barrier preventing interaction 2. Colorectal 
tumors show a varying amount of leukocytes in direct contact with tumor cells, i.e. 
in the tumor-epithelial compartment. This leukocyte fraction consists mainly of CD8 
positive lymphocytes 3. It is generally presumed that these cells are specific anti-
tumor CTL. However, as different types of leukocytes may express CD8, among which 
NK cells, the exact background of these cells still remains unclear.
In vitro, NK cells function well as effector cells against tumor target cells 4-6. In 
vivo however, NK cells migrating from the bloodstream into a solid tumor only form 
a minor fraction of the total tumor-infiltrating leukocyte population 3. Their exact 
loco-regional function in relation to the tumor is still obscure. One major significance 
of NK cells is believed to lay in the clearance of tumor cells lacking classical MHC class 
I surface molecules. Several studies have shown that 70-90% of colorectal tumors 
show aberrant MHC class I expression 7-10.
To investigate the possible relationship between loss of MHC class I expression and 
NK cell infiltration in colorectal cancer, we evaluated a series of 88 colorectal tumors 
obtained from 88 patients for their MHC class I expression and type of leukocyte 

















































A randomly selected group of 88 colorectal cancer patients from a previously 
described database of consecutive colorectal cancer patients was analyzed 11. 
Clinical -and histopathological data are shown in Table 1. Tumors were evaluated 
for differentiation grade and lymphocytic infiltration according to Jass’ criteria 12 on 
hematoxylin-eosin stainings. Patient follow-up was completed until January 2003.
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Patient and tumor characteristics of 88 curatively resected colorectal cancer patients. Parameters 
were assessed according to standard clinical and pathology protocols.
*Right-sided location: caecum – flexura lienalis
Immunohistochemistry
Tissue sections were stained as described by Menon et al 3;11. Either one of the 
following monoclonal antibodies (culture supernatant) for immunohistochemical 
staining was used: mouse anti-human HLA-A (Clone HCA2, isotype IgG1, generously 
provided by dr. J. Neefjes, NKI, Amsterdam), mouse anti-human HLA-B/C (Clone HC10, 








































Natural Killer cells in colorectal cancer 49
anti-human CD4 (Clone 1F6, isotype IgG1, Novocastra Ltd, Newcastle, UK), mouse 
anti-human CD8 (Clone 4B11, isotype IgG2b, Novocastra Ltd, Newcastle, UK) and 
mouse anti-human CD56 (Clone 123C3, isotype IgG1, Zymed Inc, San Francisco, USA). 
Four micrometers thick paraffin sections were mounted on aminopropylethoxysilane 
(APES) coated slides, and dried overnight at 37°C. Tissue sections were de-paraf-
finized and rehydrated. Endogenous peroxidase was blocked for 20 minutes in 0.3% 
hydrogen-peroxide methanol. Antigen retrieval was achieved by boiling in 10mM 
citrate buffer (pH = 6.0) for 10 minutes in a microwave oven. After washing in PBS 
the slides were incubated overnight at room temperature with primary antibodies. 
Sections for HCA2 and HC10 were washed in PBS and incubated with biotinylated 
rabbit-anti-mouse (1:200, DAKO, Glostrup, Denmark) for 30 minutes, washed again 
with PBS, and incubated with Streptavidin-Biotin-Complex (DAKO, Glostrup, Den-
mark) for 30 minutes. Sections for other antibodies were washed and incubated with 
mouse Envision labeled with Horse Radish Peroxidase (m-EnvisionHRP) for 30 minutes, 
washed in PBS and rinsed in 0.05M Tris-HCl buffer (pH 7.6) for 5 minutes. Sections 
were washed and developed in 3,3-di-amino-benzidine (DAB) tetrahydrochloride 
substrate solution containing 0.002% hydrogen-peroxid, for 10 minutes, resulting 
in a brown staining. HCA2 and HC10 stained sections were counterstained with 
hematoxylin and mounted with pertex (Histolab, Götenborg, Sweden). Lymphocyte 
stained sections were subsequently incubated in 0.01% trypsin in 0.1 mM CaCl2 for 
10 minutes. After washing in demineralized water, sections were incubated over-
night with a rabbit polyclonal antibody against laminin (Sigma-Aldrich, Zwijndrecht, 
The Netherlands). After washing, sections were incubated with a swine-anti-rabbit 
conjugate labeled with biotin (DAKO) for 30 minutes. Subsequently, sections were 
incubated for 30 minutes with Streptavidin-Biotin-complex (DAKO) labeled with 
alkaline phosphatase. Sections were developed in a NBT/BCIP solution, resulting in 
a blue signal.
For additional immunofluorescent staining we selected 6 tumors with absent HLA-A 
and B/C expression. Sections were initially treated as described above except that the 
endogenous peroxidase blocking step was replaced for a 20 minute incubation with 
10% human AB serum followed by a 10 minute incubation with 0.1% cationic BSA 
(Aurion, Wageningen, The Netherlands). Antigen retrieval was performed by boiling 
in 1 mM EDTA for 10 minutes. First overnight antibody incubation was done with 
an antibody directed against cytokeratin 8 (DAKO). Next we incubated for 2 hours 
with ultra-small gold (USG) labelled Goat-anti-Mouse (Aurion) diluted in 0.1% w/v 
BSAc in PBS. After washing three times with MQ a 40 minute silver enhancement was 
performed using a silver enhancement kit (Aurion). After washing, sections were 















































mouse anti-human CD56 (Clone 123C3, Zymed Inc, San Francisco, USA), mouse anti-
human Granzyme-B (Clone GRB-7, Monosan, Uden, The Netherlands) and one rabbit 
polyclonal: anti-CD3 (rabbit polyclonal, Abcam). Next slides were incubated with a 
mix of three matching fluorescent conjugates: goat-anti-rabbit-IgG2a-Alexa-546, 
goat-anti-mouse-IgG1-Alexa-488 and goat-anti-mouse-IgG2a-Alexa-647 (Molecular 
Probes Inc, Leiden, The Netherlands), for 1 hour followed by washing in PBS. Slides 
were mounted in Mowiol mounting medium and stored in the dark at 4°C until 
scanning.
Microscopic evaluation of tumor sections
Pictures of the immunofluorescent slides were taken with a confocal Laser Scanning 
Microscope (Zeiss LSM510; Zeiss, Jena, Germany) in a multi-track setting. For the 
detection of the silver stain we used bright field microscopy using the 633nm laser 
in a very low intensity to prevent excitation of the Alexa-647 fluorochrome. Micro-
scopic analysis was performed separately by two observers who had no knowledge 
of the clinical outcome of the patients. The percentage of the tumor cells expressing 
HLA-A and HLA-B/C was estimated in each case. Eventually in all cases a consensus 
was met. Normal HLA expression was defined as a situation in which all tumor cells 
expressed HLA. HLA expression was defined as reduced when tumor cells showed 
partial absence of either HLA-A or B/C. Total loss of HLA expression was noted when 
no tumor cell expressed HLA-A or B/C. The tumor stroma (fibroblasts, lymphocytes, 
endothelial cells) served as an internal positive control.
Statistical analysis
All statistical analyses were done using the SPSS software package (SPSS, Chicago, 
Illinois, USA). Disease-free survival data were analyzed using Kaplan-Meier survival 
estimation and the log-rank test was used for comparison of the survival curves. 
Statistical analyses between groups were performed using the Chi-squared test for 
comparing proportions and Krukas Wallis test for comparing means. P values less 
than 0.05 were considered significant.
reSultS
Patient characteristics
A panel of 88 primary tumors of colorectal origin was investigated. The patients’ 
characteristics and clinicopathological parameters are given in Table 1. The panel 
consisted of about equal numbers of stage II (Dukes B; n=38, 43%) and stage III 
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26.0 – 85.0 years). As expected, tumor stage significantly correlated inversely with the 
time of disease-free survival (p=0.002, data not shown). None of the other patient 
-or tumor characteristics as described in Table 1 correlated with DFS.
HLA-I expression
Locus specific down-regulation was detected in 63 (72 %) of 87 colorectal tumors, 
using antibodies against HLA-A and HLA-B/C (resp. HCA2 and HC10). One case could 
not be evaluated due to the absence of HLA-A signal on repeated evaluations. In 6 (7 
%) tumors HLA expression was absent, i.e. there was no signal detectable for either 
HLA-A or B/C. Twenty-four tumors (28 %) had no HLA loss at all. HLA-A expression 
correlated significantly with a longer disease-free survival (p = 0.02).
Tumor-infiltrating lymphocytes
Mean overall intra-epithelial infiltration of CD56 positive lymphocytes was 7 cells per 
mm2 versus 76 cells per mm2 for CD8 and 10 cells per mm2 for CD4 positive lympho-
cytes. Immuno-histochemical analysis of primary tumor sections revealed that locus 
specific MHC aberrations significantly correlated with the intra-epithelial infiltra-
tion of CD8 positive cells (p = 0.02), but not with CD4 or CD56 positive lymphocytes 
(Table 2).
We performed an additional immunofluorescent triple staining on the total HLA-I 
down-regulated tumors and found that the majority of the intra-epithelial infiltrat-
ing cells consisted of CD3 -and Granzyme-B positive lymphocytes (Figure 1). These 
results show that not NK cells, but T cells preferentially infiltrate colorectal tumor 
specimens that show down-regulated MHC class I expression.
table 2. tumor-infiltrating lymphocytes according to hlA class i aberrations
hlA class i expression
normal reduced absent p-value
[mean cells per 
mm2]
n [mean cells per 
mm2]




CD4 8 21 9 56 27 2 0.13
CD8 18 19 79 56 203 2 0.01
CD56 5 21 8 54 6 2 0.30
The number of intra-epithelial lymphocytes according to the HLA-I status of the tumor cells. 
Nine tumor specimens were not evaluated for infiltration by CD4-positive cells and 11 cases for 
















































Ample studies have shown an accumulation of inflammatory cells in the direct vicin-
ity of solid tumors 3;14-16. In most studies, patients with a relatively dense infiltrate 
performed better in the clinical outcome. Detailed analysis of this infiltrate in various 
adenocarcinomas showed that only cells infiltrating the tumor-epithelium, i.e. cells 
in direct contact with tumor cells, contributed to this survival benefit 3;14;17. NK cell 
infiltration in colorectal cancer has not been studied extensively in the past. Several 
studies found that the infiltration of NK cells in malignant tumors was associated 
with a favorable outcome 18-20. However, they used an antibody against CD57 to 
identify NK cells, which is not an exclusive NK cell marker, since it is also expressed 
on a subset of T-lymphocytes. We recently found that the majority of infiltrating 
CD57 positive cells in colorectal tumors also expressed the T-cell receptor (data not 
shown). We therefore used the marker CD56, which however is not an exclusive NK 
cell marker, since it is also expressed on a subset of T lymphocytes, but in combina-
tion with CD3 we were able to distinguish these subpopulations.
Figure 1. tumor-infiltrating lymphocytes in a hlA-i down-regulated colorectal tumor. 
Combined silver-gold immunofluorescence staining of a HLA-I down-regulated colorectal tumor. 
Picture shows both stromal and intra-epithelial infiltrating CD3 (red) and granzyme B (blue) 
positive lymphocytes. Only few CD56 positive cells (green) are present in the tumor stroma. 








































Natural Killer cells in colorectal cancer 53
Other studies have shown that loss of MHC class I expression is quite common 
in colorectal cancer and that these patients show a survival benefit 3;7-9;11;21;22. We 
asked ourselves whether this survival benefit could be due to specific infiltration in 
tumors showing loss of MHC class I expression. We found that both CTL as well as NK 
cells infiltrate colorectal tumors, but the NK cell fraction is relatively small, especially 
in the tumor-epithelium. Furthermore, our staining demonstrated that tumors show-
ing loss of MHC class I expression were more vigorously infiltrated by CD8 positive 
lymphocytes. At first we hypothesized that these were CD8 positive NK cells, but our 
triple immunofluorescence staining surprisingly revealed that the majority of these 
intra-epithelial infiltrating CD8 cells also carried the T-cell receptor CD3 and did not 
express CD56. It remains unclear why HLA-I aberrant tumors contain significantly 
more intra-epithelial CD8 positive T-lymphocytes than HLA intact tumors. Further 
characterization of these cells, as to their exact T cell receptor (αβ or γd), is necessary 
to illuminate their role and function. It is possible that in these tumors, due to T 
cell-mediated tumor cell killing, there have been a selection for MHC class I negative 
variants and that these tumors have maintained the capacity to attract T cells.
In a previous study we found that patients with primary tumors showing loss of 
MHC class I expression developed fewer distant metastases. Therefore, it is possible 
that the survival benefit is due to the fact that metastasizing tumor cells in these 
patients are efficiently cleared by NK cells in the circulation. This hypothesis is further 
supported by the observation that in a paired series of primary colorectal tumor and 
distant metastases from the same patient, less loss of MHC class I was observed than 
in a random series of primary colorectal cancer 23. These data suggest that NK cells 
play an important role in the prevention of metastatic spread rather than locally in 
the primary tumor.
We hypothesize that if NK cells are capable of infiltrating solid tumors, they may 
kill tumor cells that show loss of MHC class I expression, and thus may contribute to 
treatment of colorectal cancer. The success of such NK based immunotherapy will 
depend on the ability of NK cells to infiltrate the tumor-epithelium. If this can be 
attained, for example through activation of NK cells by specific pro-infiltration che-
















































 1. Dalerba P, Maccalli C, Casati C, Castelli 
C, Parmiani G. Immunology and immu-
notherapy of colorectal cancer. Crit Rev 
Oncol Hematol 2003;46:33-57.
 2. Menon AG, Fleuren GJ, Alphenaar EA et 
al. A basal membrane-like structure sur-
rounding tumour nodules may prevent 
intraepithelial leucocyte infiltration 
in colorectal cancer. Cancer Immunol 
Immunother 2003;52:121-126.
 3. Menon AG, Janssen-van Rhijn CM, 
Morreau H et al. Immune system and 
prognosis in colorectal cancer: a detailed 
immunohistochemical analysis. Lab 
Invest 2004;84:493-501.
 4. Grimm EA, Mazumder A, Zhang HZ, 
Rosenberg SA. Lymphokine-activated 
killer cell phenomenon. Lysis of natural 
killer-resistant fresh solid tumor cells 
by interleukin 2-activated autologous 
human peripheral blood lymphocytes. J 
Exp Med 1982;155:1823-1841.
 5. Lotze MT, Grimm EA, Mazumder A, 
Strausser JL, Rosenberg SA. Lysis of 
fresh and cultured autologous tumor 
by human lymphocytes cultured in T-cell 
growth factor. Cancer Res 1981;41:4420-
4425.
 6. Rosenstein M, Yron I, Kaufmann Y, 
Rosenberg SA. Lymphokine-activated 
killer cells: lysis of fresh syngeneic natu-
ral killer-resistant murine tumor cells by 
lymphocytes cultured in interleukin 2. 
Cancer Res 1984;44:1946-1953.
 7. Lopez-Nevot MA, Esteban F, Ferron A et 
al. HLA class I gene expression on human 
primary tumours and autologous metas-
tases: demonstration of selective losses 
of HLA antigens on colorectal, gastric 
and laryngeal carcinomas. Br J Cancer 
1989;59:221-226.
 8. Cordon-Cardo C, Fuks Z, Drobnjak M, 
Moreno C, Eisenbach L, Feldman M. 
Expression of HLA-A,B,C antigens on 
primary and metastatic tumor cell popu-
lations of human carcinomas. Cancer Res 
1991;51:6372-6380.
 9. Momburg F, Degener T, Bacchus E, 
Moldenhauer G, Hammerling GJ, Moller 
P. Loss of HLA-A,B,C and de novo expres-
sion of HLA-D in colorectal cancer. Int J 
Cancer 1986;37:179-184.
 10. Garrido F, Cabrera T, Concha A, Glew S, 
Ruiz-Cabello F, Stern PL. Natural history 
of HLA expression during tumour devel-
opment. Immunol Today 1993;14:491-
499.
 11. Menon AG, Morreau H, Tollenaar RA et 
al. Down-regulation of HLA-A expres-
sion correlates with a better prognosis 
in colorectal cancer patients. Lab Invest 
2002;82:1725-1733.
 12. Jass JR, Ajioka Y, Allen JP et al. Assess-
ment of invasive growth pattern and 
lymphocytic infiltration in colorectal 
cancer. Histopathology 1996;28:543-548.
 13. Stam NJ, Vroom TM, Peters PJ, Pastoors 
EB, Ploegh HL. HLA-A- and HLA-B-
specific monoclonal antibodies reactive 
with free heavy chains in western blots, 
in formalin-fixed, paraffin-embedded 
tissue sections and in cryo-immuno-
electron microscopy. Int Immunol 
1990;2:113-125.
 14. Naito Y, Saito K, Shiiba K et al. CD8+ T 
cells infiltrated within cancer cell nests as 
a prognostic factor in human colorectal 
cancer. Cancer Res 1998;58:3491-3494.
 15. Dolcetti R, Viel A, Doglioni C et al. High 
prevalence of activated intraepithelial 
cytotoxic T lymphocytes and increased 
neoplastic cell apoptosis in colorectal 
carcinomas with microsatellite instabil-
ity. Am J Pathol 1999;154:1805-1813.
 16. Jackson PA, Green MA, Marks CG, King 
RJ, Hubbard R, Cook MG. Lymphocyte 
subset infiltration patterns and HLA 
antigen status in colorectal carcinomas 
and adenomas. Gut 1996;38:85-89.
 17. Zhang L, Conejo-Garcia JR, Katsaros D et 
al. Intratumoral T cells, recurrence, and 
survival in epithelial ovarian cancer. N 








































Natural Killer cells in colorectal cancer 55
 18. Coca S, Perez-Piqueras J, Martinez D et 
al. The prognostic significance of intra-
tumoral natural killer cells in patients 
with colorectal carcinoma. Cancer 
1997;79:2320-2328.
 19. Ishigami S, Natsugoe S, Tokuda K et al. 
Prognostic value of intratumoral natural 
killer cells in gastric carcinoma. Cancer 
2000;88:577-583.
 20. Villegas FR, Coca S, Villarrubia VG et al. 
Prognostic significance of tumor infil-
trating natural killer cells subset CD57 in 
patients with squamous cell lung cancer. 
Lung Cancer 2002;35:23-28.
 21. Moller P, Momburg F, Koretz K et al. 
Influence of major histocompatibility 
complex class I and II antigens on sur-
vival in colorectal carcinoma. Cancer Res 
1991;51:729-736.
 22. Stein B, Momburg F, Schwarz V, Schlag P, 
Moldenhauer G, Moller P. Reduction or 
loss of HLA-A,B,C antigens in colorectal 
carcinoma appears not to influence 
survival. Br J Cancer 1988;57:364-368.
 23. Menon AG, Tollenaar RA, van de Velde 
CJ et al. p53 and HLA class-I expression 
are not down-regulated in colorectal 




Disrupted expression of CXCL5 in colorectal 
cancer is associated with rapid tumor 
formation in rats and poor prognosis in 
patients
Frank M. Speetjens1, Peter J.K. Kuppen1, Maro H. Sandel1, Anand G. 
Menon1, Danny Burg2, Cornelis J.H. van de Velde1, Rob A.E.M. Tollenaar1, 
Hans J.G.M. de Bont2, J.Fred Nagelkerke2
1Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands
2Division of Toxicology, Leiden/Amsterdam Center for Drug Research, Leiden University, 
Leiden, the Netherlands
















































Purpose: We isolated a sub-line (CC531M) from the CC531S rat colon carcinoma cell 
line, which grows and metastasizes much more rapidly than CC531S. We found, 
using RNA expression profiling that one of the major changes in the CC531M cell 
line was a 5.8-fold reduction of the chemokine CXCL5. The purpose of this study 
was to determine the impact of CXCL5 expression on colorectal tumor growth and 
metastasis.
experimental design: CC531 clones were generated with either knock-down or 
restored expression of CXCL5. These clones were inoculated in the liver of rats. In 
addition, in two independent cohorts of colorectal cancer patients, the level of 
CXCL5 expression was determined and associated to clinical parameters.
results: Knock-down of CXCL5 expression in CC531S resulted in rapid tumor growth 
and increased number of metastasis, while restored expression of CXCL5 in CC531M 
resulted in a return of the ‘mild’ tumor growth pattern of the parental cell line 
CC531S. In vitro no difference was found in proliferation rate between clones with 
either high or low expression of CXCL5, suggesting that environmental interactions 
directed by CXCL5 determine tumor outgrowth. Finally, the importance of our find-
ings was established for patients with colorectal cancer. We found that low expres-
sion of CXCL5 was significantly associated with poor prognosis for colorectal cancer 
patients. CXCL5 showed a trend (p=0.05) for a positive correlation with intra-tumoral 
CD8+ T-cell infiltration, suggesting a possible explanation for the observed poorer 
prognosis.
Conclusions: Our results show that CXCL5 is important in growth and development 
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introduCtion
Colorectal cancer is one of the three leading causes of cancer-related death among 
men and women in the western world 1;2. Despite curative surgical resection of 
the primary tumor, 40 to 50 percent of the patients ultimately die of metastases 3. 
Tumor growth and metastasis result from a complex cascade of biological processes. 
Therefore, knowing key factors in these processes is crucial to design new treatment 
modalities.
In a previous paper we reported the in vivo selection of an aggressive rat colorectal 
cell line (CC531M) from the well described CC531S cell line 4;5. The present study was 
initiated to identify factors that contribute to rapid growth and metastatic capacity 
of CC531M. In this study we focus on the chemokine CXCL5.
CXCL5 is a member of the subfamily of lipopolysacharide (LPS)-inducible ELR+ CXC 
chemokines 6. It functions, mainly through interaction with the CXCR2 receptor, both 
as a chemoattractant and as an angiogenic factor 7-10. CXCL5 is expressed in the 
epithelial cells of the colon and over-expressed in colorectal cancer 11;12. It has been 
reported that CXCL5 plays a role in development and metastasis of several cancer 
types 13-15. CXCL5 contributes to the in vivo growth and angiogenic potential of 
non-small cell lung cancer (NSCLC). Homogenates of human NSCLC specimens were 
angiogenic in the rat corneal micropocket assay, and the development of vasculature 
can be blocked by antibodies that neutralize CXCL5 14. The role of CXCL5, produced 
by colorectal tumors, in relation to cancer progression and prognosis is poorly under-
stood.
In this study, we investigated expression of CXCL5 on tumor growth and metas-
tasis in a colorectal tumor rat model. CC531 cells, expressing different levels of 
CXCL5, were inoculated in the livers of syngenic rats and both tumor formation and 
metastasis were determined. CXCL5 expression was determined in two different 
independent large panels of human colorectal tumors and correlated with clinical 
follow-up and T-cell infiltration data.
exPeriMentAl deSign
CC531S and CC531M cell lines and culture conditions
The rat colon carcinoma cell line CC531S was originally developed using dimethyl-
hydrazin in Wag/Rij rats 5. The aggressive CC531M was isolated from CC531S using 
an in vivo selection protocol 4;16. Cells were cultured at 37°C and 5% CO2, in cell 















































(Gibco, Paisley, Scotland), supplemented with 10% heat-inactivated FCS, 100 μg/ml 
streptomycin, 100 IU/ml penicillin and 2 mM L-glutamine (all Gibco, Paisley, Scotland).
Development of CXCL5 knock-down and CXCL5 expressing CC531 clones
RNAi techniques were used to generate CC531S CXCL5 knock-down clones. A 
19-nucleotide sequence (AACGGAGCTACGCTGTGTT), separated by a 9-nucleotide 
non-complementary spacer (TTCAAGAGA) from the reverse complement of the 
19-nucleotide sequence, was cloned and sequenced after digestion with BglII and 
HindIII and inserted into the pSUPER backbone (OligoEngine, Seattle, USA), using 
standard procedures. To obtain stably transfected CC531S CXCL5-knock-down and 
control clones, the pSUPER-CXCL5 siRNA or empty vectors were co-transfected with 
the pcDNA3 vector, using Lipofectamine2000 (Invitrogen, California, USA). Three 
CXCL5-knock-down CC531S clones (S1CXCL5-, S2CXCL5- and S3CXCL5-) and three control 
clones (S4Control, S5Control and S6Control) were selected.
To restore CXCL5 expression in CC531M clones, CXCL5 was amplified by routine 
PCR using cDNA derived from CC531S. Forward and reversed primers were designed, 
using the first or last complementary 20 base pairs in addition of a HindIII or EcoRI 
sequence respectively. In front of the initial ATG code a KOZAK sequence was placed. 
PCR products were directly cloned with the pGEM-T-Easy cloning kit (Promega, Wis-
consin, USA) and sequenced. Expression plasmids for CXCL5 were obtained, through 
unidirectional cloning of the sequence into the mammalian expression vector 
pcDNA3 (Invitrogen, California, USA). To obtain stably transfected CC531M CXCL5-
expressing and control clones, CC531M cells were transfected with pcDNA3-CXCL5 or 
control empty vector. Two CC531M clones expressing CXCL5 (M1CXCL5+ and M2CXCL5+) 
and two control clones (M3Control and M4Control) were selected. Selection was based 
upon expression of CXCL5 as indicated by immunostaining. Stably transfected clones 
were grown under selective pressure, in culture medium supplemented with 200μg/
ml G418 (Sigma, St. Louis, MO, USA).
Immunocytochemistry
Cells were cultured on 12-mm glass coverslips and stained as previously described 17, 
using the primary antibody rabbit anti-murine LIX 18 (Peprotech EC Ltd, London, UK) 
and Cy3-conjugated goat anti rabbit secondary antibody (Jackson, Suffolk, UK) in 
TBP (1h RT). Finally, cells were stained with 2 μg/ml Hoechst 33258 (Invitrogen, Cali-
fornia, USA). Cells were analyzed using a Nikon Eclipse E600 fluorescence microscope 
with a 40x plan fluor Nikon objective (Nikon, Tokyo, Japan). The percentage CXCL5 
positive tumor cells and the CXCL5 pixel intensity per cell were determined. For every 
clone or cell line at least 5 randomly chosen fields were analysed to determine the 
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Cell proliferation
DNA content was used to determine the proliferation rate of CC531 cells and clones 
by a method previously described 19. In short: 25000 cells were seeded into a 24 
well plate. Medium was replaced daily. From 24h up to 144h after the start of seed-
ing cells, each day plates were removed, rinsed with PBS, and stored at -80°C until 
assayed. On the day of assay, cells were thawed, 200 μl of distilled water was added 
(1h at 37°C). The plates were frozen at -80°C and thawed. From each well 50μl was 
taken and placed into a 96 well plate. DNA content was determined after addition of 
50μl of 20μg/ml Hoechst 33258 fluorochrome (Invitrogen, California, USA) and mea-
sured on a fluostar optima platereader (BMG Labtech GmbH, Offenburg, Germany).
Rat experiments
All animal experiments were approved by the animal experiment committee of 
Leiden University. Animals were kept in our own animal facilities. Male Wag/Rij rats 
(Charles River, Zeist, The Netherlands) were anesthetized with halothane, underwent 
laparotomy, and were double blind randomized for induction of a liver tumor. A 
suspension of 5*104 viable CC531 tumor cells in 50μl was injected sub-capsulary at 
four sites into the liver. Per clone, four rats were inoculated. Rats were sacrificed by 
abdominal bleeding under halothane anesthesia, liver and tumor were removed and 
weight was determined. To determine the number of lung metastasis, lungs were 
removed and filled with an ink solution, as previously described 20;21.
RT-PCR of CXCL5 in a patient cohort
Tumours from a cohort of 70 patients that were curatively treated by surgery for 
colorectal cancer, between 1990 and 2001, were used to associate level of CXCL5 
RNA expression with prognosis. Fifty percent of the patients were female. The mean 
age at the time of surgery was 67.2 years. Tumors were staged according to the 
American Joint Committee on Cancer (AJCC) criteria 22: 47 (67%) stage I/II; 23 (33%) 
stage III. At the time of censoring 41 (59%) had died of whom 22 (54%) died from 
their disease, and 29 patients were still alive; four of them were alive with recur-
rence of the tumor. Mean follow up was 99 months (range 50-172 months). Patient 
material was obtained with approval of local medical ethics committee. RNA from 
snap-frozen tumors, containing at least 60% tumor cells as determined by a patholo-
gist, was isolated using RNeasy columns (Qiagen Sciences, Germantown, MD, USA). 
Quantative reverse transcriptase PCR (RT-PCR) primers for the detection of house-
keeping genes (Cleavage and polyadenylation specificity factor subunit 6 (CPSF6), 
Heterogeneous nuclear ribonucleoprotein M (HNRPM) and TATA-binding protein 
(TBP) and CXCL5 were designed in PRIMER Express (Applied Biosystems, Foster 















































CPSF6, 5’-AAGATTGCCTTCATGGAATTGAG-3’, 5’-TCGTGATCTACTATGGTCCCTCTCT-3’; 
HNRPM, 5’-GAGGCCATGCTCCTGGG-3’, 5’-TTTAGCATCTTCCATGTGAAATCG-3’, TBP, 
5’-CACGAACCACGGCACTGAT-3’, 5’-TTTTCTTGCTGCCAGTCTGGAC-3’ CXCL5, 5’- ctgt-
gttgagagagctgcgt-3’, 5’-gttttccttgtttccaccgtc-3’. RT-PCR reactions were performed 
on an ABI Prism 7900ht (Applied Biosystems) using the SybrGreen RT-PCR core-kit 
(Eurogentec, Seraing, Belgium). Cycle conditions were 10 minutes at 94°C followed 
by 40 cycles of 10 s at 94°C and 1 minute at 60°C. Cycle threshold extraction was 
performed using the SDS software (version 2.2.2, Applied Biosystems). For all PCRs, 
a standard curve was generated using a five-step, five-fold dilution of pooled cDNA 
from the HCT81 colorectal cancer cell line. Relative concentrations of mRNA for each 
gene were calculated from the standard curve. After RT-PCR, dissociation curves 
were made to check the quality of the reaction. Reactions with more than one peak 
in the dissociation curve were discarded. For normalization, the expression values for 
each gene were divided by the normalization factor of the gene (the average of the 
three house keeping genes).
Immunohistochemistry of CXCL5 in a patient cohort
In a second independent cohort of 58 patients, curatively operated for colorectal can-
cer was used to associate protein level of CXCL5 to prognosis. The cohort comprised 
43% females; mean age at the time of surgery was 66.2 years; 29 stage I/II (50%) and 
29 (50%) stage III colorectal tumors. At the time of censoring 46 (79%) had died, 
mean follow up was 49 months (range 1.2-162 months). Standard two-step, indirect 
immunohistochemistry was performed on 4-μm paraffin tissue sections, including 
blockage of endogenous peroxidise, EDTA antigen retrieval (not for CXCL5 detec-
tion) and di-aminobenzidine development. To be able to distinguish intra-epithelial 
from stromal infiltration, an additional staining for laminin was performed on CD4 
and CD8 stained sections, including trypsin antigen retrieval and development using 
NBT/BCIP solution, as previously described 23. The following primary antibodies were 
used: the mAb anti- CXCL5 (clone MAB254, R&Dsystems, Minneapolis, USA), the mAb 
anti-CD4 (clone 1F6, Novocastra, UK), the mAb anti-CD8 (clone 4B11, Novocastra, 
UK) and rabbit anti-human laminin polyclonal Ab (Sigma-Aldrich, USA). Secondary 
reagents used were anti Mouse HRP EnVision+ (K400111, Dako, USA), biotinylated 
swine anti-rabbit IgG antibodies (DAKO Cytomation, Denmark), and biotinylated-
peroxidase streptavidin complex (SABC; DAKO Cytomation, Denmark). CXCL5 expres-
sion was scored by microscopically assessing the percentage CXCL5 positive tumor of 
the whole section. Infiltration in the tumor tissue was scored in three compartments 
of the tumor tissue, i.e. intra-epithelially, intra-stromally and in the advancing tumor 
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Statistical analysis
All analyses were performed with SPSS statistical software (version 12.0 for Windows, 
SPSS Inc, Chicago, IL). Mann-Whitney U test was used to compare variables. Kaplan-
Meier analyses were performed to analyze patient survival. The entry date for the 
survival analyses was the time of surgery of the primary tumor. Events for time to 
disease free survival were defined as follows: from time of surgery to time of disease 
relapse or death. Events for time to cancer specific survival were defined as follows: 
from time of surgery to time of disease relapse or death by disease. Cox’ regression 
analyses were used to calculate Hazard Ratios (HR) with 95% confidence intervals 
(CI). Variables with a p-value of ≤0.10 in the univariate analyses were subjected to 
a multivariate analysis. Pearson’s product-moment correlation was used to analyze 
correlations between level of CXCL5 expression and T-cell infiltration.
reSultS
Expression of CXCL5 is lost in CC531M compared to CC531S cells
We showed previously that subcapsular inoculation of the colorectal cell line, CC531M 
in the liver of rats resulted in rapid tumor growth and induction of larger number 
of metastases as compared to inoculation of the parental CC531S 4. Affymetrix micro 
array analysis was performed in triplicate to determine differences in gene expres-
sion between the parental cell line CC531S and CC531M. The major change was a 
5.8-fold (SD=0.7) reduction of CXCL5 RNA content in CC531M cells as compared to 
expression in CC531S. To confirm RNA expression data, cells were stained for the 
presence of CXCL5 protein using immuno-fluorescence techniques. In CC531S cells a 
strong cytoplasmic staining was found, while CC531M cells hardly showed any stain-
ing (figure 1A). The percentage of CXCL5 positive cells was significantly (p<0.0001) 
higher in CC531S cells compared to CC531M cells (figure 1B). In vitro, CC531S and 
CC531M showed the same proliferation rate (figure 1C).
Knock-down of CXCL5 expression results in aggressive tumor growth in vivo
To study the contribution of CXCL5 to tumor outgrowth and metastatic potency of 
CC531S cells, RNAi technology was used to knock-down CXCL5 in this cell line. Three 
CXCL5 siRNA transfected CC531S clones (S1CXCL5-, S2CXCL5- and S3CXCL5-) and three con-
trol clones (S4Control, S5Control and S6Control) transfected with the empty vector, were 
selected. Immuno-fluorescence staining for CXCL5 expression showed a significant 
(p<0.0001) CXCL5 down-regulation in S1CXCL5-, S2CXCL5- and S3CXCL5- compared to 
S4Control, S5Control and S6Control (figure 2A). In vitro, no significant difference in mean 















































clones (figure 2B). To study the effect of loss of CXCL5 in CC531S on tumor formation, 
each individual clone was subcapsularly injected in the liver of four rats. At sacrifice, 
rats injected with clones S1CXCL5- or S2CXCL5- showed large tumors over-growing the 
whole liver and, in addition, also large tumor masses in the peritoneal cavity and lungs 
were found. Due to the massive tumor outgrowth it was impossible to determine 
weight and surface of the individual tumors of rats inoculated with clones S1CXCL5- or 
S2CXCL5-. Therefore, the weight of both tumor and liver of all rats was determined. 
The third clone, CC531S clone S3CXCL5-, showed somewhat less aggressive outgrowth: 
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Figure 1. CxCl5 expression is reduced in CC531M cells.
(A) Immuno-fluorescent staining of CXCL5 expression of CC531S and CC531M (CXCL5 – red; 
nuclei – green). (B) Displays the percentage CXCL5 positive CC531S and CC531M cells; columns 
- mean; error bars - standard error mean (SEM). (C) Represents in vitro proliferation rate of 
CC531S and CC531M cells on different time points; error bars - SEM. Statistically significant 
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the 3 control clones, S5Control, showed 4 small tumors at the place of inoculation, the 
others (S4Control, S6Control) did not show any tumor formation in the liver. The average 
weight of tumor and liver of the three CXCL5 knock-down clones was significant 
(p=0.001) higher than the control clones (figure 2C). Furthermore, injection of CXCL5 
knock-down clones resulted in significant more lung metastases compared to the 
control CC531S clones (p=0.007) (figure 2D). Images of in vivo tumor growth are 
displayed in figure 3. Together, these results show that while knock-down of CXCL5 
in vitro did not result in difference in proliferation rate; in vivo CXCL5 knock-down in 
CC531S resulted in aggressive tumor growth accompanied with increased formation 
of metastases.
Restoration of CXCL5 expression results in less aggressive tumor growth in vivo
Stable transfection of CXCL5 into CC531M cells was used to study whether restored 
expression of CXCL5 would inhibit tumor growth and metastasizing capacity of 
CC531M in vivo. Two CXCL5 transfected clones (M1CXCL5+ and M2CXCL5+) and two 
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Figure 2. knock-down of CxCl5 expression results in massive tumor outgrowth and formation 
of metastasis in vivo.
(A) The percentage CXCL5 positive cells of all knock-down and control clones was determined. 
Top bars represent the average (Av.) number of CXCL5 positive cells, error bars - SEM. (B) In vitro 
growth rate of all knock-down and control CC531S clones on several time points connected 
by a line. (C) Represents the average liver and tumor weight of both control clones versus the 
knock down clones after inoculation in the liver of rats at sacrifice. Top bars show the average 
(Av.) of the knock-down versus the control clones. (D) The number of lung metastases found 
after inoculation of the knock-down and control clones in the liver. Statistically significant 















































control clones (M3Control and M4Control) transfected with the empty vector were used. 
Analysis showed significant (p<0.0001) up-regulation of CXCL5, in CXCL5-transfected 
clones (figure 4A). Restoration of CXCL5 expression had no significant impact on in 
vitro proliferation rate (figure 4B). To determine the in vivo growth capacity of the 
different clones, each individual clone was inoculated in the liver of four rats. All 
clones showed solitary tumors at the site of inoculation, as determined at sacrifice. 
Tumors were enucleated from the liver and tumor weight was determined. The 
mean tumor weight of the CXCL5-transfected clones was significantly less compared 
to the tumor weight of the control clones (p=0.005) (figure 4C). Only very few lung 
metastases were found, not differing among clones. These results demonstrated that 
CXCL5 reconstitution in CC531M resulted in inhibition of tumor growth in vivo.
Figure 3 
S1cxcl5- 
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Figure 3. examples of tumor outgrowth in the rat of a CxCl5 knock-down and a control CC531S 
clone.
Top panels (A-C) display tumor outgrowth of CXCL5 knock-down clone S1cxcl5- after inoculation 
of the clone in the liver of a rat at sacrifice. (A) Displays the peritoneal cavity with tumor 
throughout the liver and peritoneal metastasis. (B) Shows the same liver after resection, 
overgrown with tumor mass, individual sites of inoculation cannot be distinguished. (C) Displays 
the lungs of this rat after ink injection, with 4 metastases (one is indicated by an arrow). Bottom 
panels (D-F) display tumor growth after inoculation with CXCL5 positive CC531S control clone 
S5control. (D) Tumor is only found in the liver at the four sites of inoculation and not in other 
places in the peritoneal cavity. (E) Shows the liver in detail, with 4 individual tumors (numbered 































































































































































































Figure 4. restoration of CxCl5 expression inhibits tumor growth, in vivo.
(A) CXCL5 expression of the CXCL5 and control CC531M clones; columns - mean; bars - SEM. 
(B) In vitro growth rate of all CXCL5 transfected versus control clones at several time points. 
(C) The mean weight of the total tumor mass per clone in four rats at sacrifice is shown. The 
two columns on top represent the average weight of the CXCL5 transfected versus the control 















































Low expression of CXCL5 in human colorectal cancer is associated with decreased 
survival
The relation between expression of CXCL5 in human colorectal tumors and prognosis 
was studied in two cohorts of colorectal cancer patients, using different techniques 
to determine the level of CXCL5 expression. The RNA level of expression of CXCL5 
in the first cohort was determined using quantitative RT-PCR and linked to clinical 
follow-up data. The impact of high versus low expression of CXCL5 was assessed using 
the 25th percentile as cut off point, leaving 53 patients with high expression of CXCL5 
(11.2±2.1; mean±sd) and 17 patients with low expression (7.1±1.3) of CXCL5. CXCL5 
expression levels were distributed equally with regard to clinical and pathological 
parameters (table 1). Univariate cox regression analyses were performed to identify 
prognostic factors for disease free survival. Advanced patient age, advanced patho-
logical stage, and low CXCL5 expression proved to be significant predictors of poor 
prognosis in the univariate analyses (table 1). The Kaplan Meyer curve for disease 
free survival is shown for low versus high CXCL5 expression (figure 5) and revealed 
that low expression was associated with a significantly worse prognosis (p=0.016). 
Parameters, significant in univariate analysis, were subjected to Cox multivariate 
analysis. Patient age above the median (HR: 2.3, C.I.: 1.2-4.2, p=0.01), advanced 
pathological stage (HR: 3.1, C.I.: 1.6-5.7, p<0.001), and low CXCL5 expression (HR: 2.3, 
C.I.: 1.2-4.4, p=0.016) all retained their strength as independent prognostic factors 
for disease free survival (table 1). 
Figure 5 
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Figure 5. Correlation between disease free survival and expression of CxCl5 assessed by rt-
PCr in a cohort of colorectal cancer patients.
Kaplan Meier survival curve is displayed, patients with low expression of CXCL5 have a significant 
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table 1. rnA level of CxCl5 in relation to clinicopathological and prognostic parameters




High N (%) Low N (%) p-value p-value HR (95% CI) p-value
gender
 Male (%) 27 (51%) 8 (47%) 0.78 0.78 --- --- 
location tumor
 Proximal (%) 29 (55%) 7 (41%) 0.34 0.51 --- --- 
Median age at diagnosis (years)
 <68.5 27 8 0.78 0.006 1 0.010 
 >68.5 26 9 2.3 (1.2 – 4.2) 
Stage
 I and II 36 (68%) 11 (65%) 0.81 0.0001 1 <0.001 
 III 17 (32%) 6 (35%) 3.1 (1.6 – 5.7) 
Pathway
 MSI 1 (6%) 11 (21%) 0.16 0.60 --- --- 
 MSS 16 (94%) 42 (79%) 
CxCl5
 High 53 (76%) --- --- 0.016 1 0.016 
 Low --- 17 (24%) 2.3 (1.2 – 4.4) 
NOTE: Table 1 displays level of CXCL5 in a panel of colorectal cancer patients determined by 
quantitative RT-PCR. The 25th percentile was used to define high versus low expression of CXCL5. 
On the left side of both tables, the distribution of high versus low expression of CXCL5 with 
respect to clinical and pathologic characteristics and the relation of CXCL5 to clinicopathologic 
factors are displayed. On the right side of the table, prognostic factors are displayed. Univariate 
Cox regression analyses were done to identify prognostic factors for survival. All factors with a 
P-value of ≤0.10 were subjected to Multivariate Cox regression analysis. Statistically significant 
P-values are in bold.















































In a second independent cohort of colorectal cancer patients, the protein level of 
CXCL5 expression was determined using immunohistochemical staining of tissue 
sections. After staining, the percentage positive tumor cells was scored. Staining 
confirmed previous data showing that tumor cells displayed increased expression 
of CXCL5 compared to normal colon epithelium (figure 6) 11;12. Fifty tumors showed 
CXCL5 expression in more than 50% of the tumor cells, while 8 tumors showed 
expression of CXCL5 in less than 50% of the tumor cells. CXCL5 levels were distrib-
uted equally to clinicopathological parameters (table 2). Univariate analysis showed 
that CXCL5 (p=0.009) and stage (p=0.03) both predicted prognosis. Cox multivariate 
analysis confirmed the value of low level of CXCL5 (HR: 3.6, C.I.: 1.3-9.9, p=0.01) as 
independent predictor of poor prognosis in addition to advanced pathological stage 
(HR: 2.6, C.I.: 1.1-6.3, p=0.04) (table 2). Of the latter cohort also the CD4 and CD8 
infiltration was scored in three compartments of the tumor (intra-epithelial, stromal 
and advancing margin). Using Pearson’s product-moment correlation a trend was 
found for significant positive correlation between level of CXCL5 and intra-epithelial 
and stromal infiltration of CD8+ T-cells (r=0.21, p=0.12; r=0.26, p=0.05 respectively), 
(table 3). Neither CD4+ T cell infiltration, nor CD8+ T-cell Infiltration, scored at the 
border of the tumor (advancing margin) was correlated with expression of CXCL5. 
Low CXCL5 expression was an independent predictor of decreased disease free sur-
vival in colorectal cancer patients, showing a trend for a positive correlation for level 
of CXCL5 and intra-tumoral cytotoxic T-cell infiltration.
Figure 6 
C B A 
Figure 6. examples of CxCl5 immunohistochemical staining of human colorectal tumors.
(A) displays CXCL5 expression in almost colon cancer cells; (B) shows heterogeneous expression 
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table 2. Protein level of CxCl5 in relation to clinicopathological and prognostic parameters




High N (%) Low N (%) p-value p-value HR (95% CI) p-value
gender
 Male (%) 27 (54%) 6 (75%) 0.27 0.15 --- --- 
Median age at diagnosis (years)
 <68.5 25 4 1.0 0.83 --- --- 
 >68.5 25 4 
Stage
 I and II 24 (48%) 5 (62%) 0.45 0.03 1 0.04 
 III 26 (52%) 3 (38%) 2.6 (1.1 – 6.3) 
CxCl5
 High 50 (86%) --- --- 0.009 1 0.01 
 Low --- 8 (14%) 3.6 (1.3 – 9.9) 
NOTE: Table 2 displays the results after immunohistochemical staining and scoring the 
percentage of CXCL5-positive tumor cells. For immunohistochemical staining, high was defined 
as <50% of tumor cells showing CXCL5 expression and low was defined as <50% of tumor cells 
showing CXCL5 expression. On the left side of both tables, the distribution of high versus low 
expression of CXCL5 with respect to clinical and pathologic characteristic and the relation of 
CXCL5 to clinicopathologic factors are displayed. On the right side of the table, prognostic 
factors are displayed. Univariate Cox regression analyses were done to identify prognostic 
factors for survival. All factors with a P-value of ≤0.10 were subjected to Multivariate Cox 
regression analysis. Statistically significant P values are in bold.
table 3. Correlation between expression of CxCl5 and infiltrative t-cell markers
location infiltrate Cd8+ Cd4+
Pearson correlation (r) p-value Pearson correlation (r) p-value
intra-epitelial 0.21 0.12 0.12 0.38
Stromal 0.26 0.05 0.15 0.27
Advancing margin -0.02 0.87 -0.93 0.50
NOTE: a trend for positive correlation between expression of CXCL5 and intratumoral T-cell 
infiltration was found. T-cell infiltration was scored in different compartments of the tumor: 
intraepithelial, stromal, and at the advancing margin. Infiltration in each of these different 

















































Many chemokines play a pivotal role in colorectal cancer 24. We decided to study 
CXCL5 because our initial rat experiments indicated that the absence of this che-
mokine was associated with an aggressive tumor phenotype. CXCL5, an important 
homeostatic factor in the colon, is mainly produced in epithelial cells and is in general 
more highly expressed in cancer tissue compared to normal tissue 11;12. This pattern, 
higher expression in tumor tissue than in normal tissue was also found in our experi-
ments. However, absence of CXCL5 expression in tumor tissue was correlated with 
poor prognosis. To our knowledge, the only report describing mechanisms by which 
CXCL5 expression is abrogated is provided by Dimberg et al. showing that CXCL5 gene 
variants are related to expression of CXCL5 protein in colorectal cancer 12. Besides 
(epi-)genetic explanations, other mechanisms influencing CXCL5 expression might 
be involved in the nuclear factor-kappaB (NF-κB) that controls expression of CXCL5 
25. Functions of CXCL5 include chemo-attraction and promotion of angiogenesis, 
mainly by interaction with the CXCR2 receptor 7;8. Our data indicate that CXCL5 is 
involved in growth and development of colorectal cancers. The importance of CXCL5 
for tumor formation in vivo was confirmed by comparing the growth of transfected 
CC531 clones that expressed either high or low levels of CXCL5. Importantly, our 
findings in the rat proved to be relevant for colorectal cancer patients as in two 
different tumor tissue cohorts of these cancer patients, low expression of CXCL5 was 
associated with shorter survival.
Well established is the chemo-attraction of neutrophils into inflamed regions 
after CXCL5-CXCR2 interaction 9;26. Antagonists to the CXCR2 receptor prevent neu-
trophil attraction and reduce the inflammatory response 27;28. CXCR2 is also involved 
in chemokine-induced migration of NK and T-cells 28;29. CXCL5 produced by tumor 
cells may attract CXCR2 expressing leukocytes as T-cells, NK cells and neutrophils, 
triggering an anti-tumor immune response. A trend for positive correlation between 
level of CXCL5 and intratumoral cytotoxic T-cell infiltration was found. This trend 
was not found for infiltration in the advancing border of the tumor, suggesting that 
CXCL5 indeed especially contributes to intratumoral infiltration of cytotoxic T-cells. 
High tumor infiltration of these inflammatory immune cells is positively associated 
with good prognosis in colorectal cancer 30-32. This concept that over-expression of 
specific chemokines causes tumor infiltration by distinct leukocyte subsets, resulting 
in tumor regression and tumor specific immunity, has also been described for other 
chemokines 33-41. Thus, CXCL5 may contribute to an anti-tumor response.
Another mechanism by which CXCL5 may be involved in colorectal tumor growth 
is based on the fact that the CXCR2 receptor has been found on colorectal tumor 
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This may indicate that CXCL5 functions as an autocrine growth inhibitory factor. This 
is in contrast with other reports that described a positive effect of CXCR2 ligands on 
tumor growth 43;44. In our results the presence or absence of CXCL5 expression had no 
influence in vitro on proliferation rate of any of our cell lines. Moreover, we found in 
vivo that low expression of CXCL5 promotes tumor growth. These data indicate that 
the effect of CXCL5 is not very likely to depend on an autocrine signaling pathway.
CXCL5 may play opposing roles in tumor formation in general. On the one 
hand CXCL5 may induce an anti-tumor response by chemo-attraction of immune 
cells; on the other hand it may promote angiogenesis that supports tumor growth. 
Our results indicate that in colorectal cancer formation, the anti-tumor response 
is dominant. In support of our results for head and neck squamous cell carcinoma 
HNSCC higher expression of CXCL5 was also found in mortal tumors associated with 
a better prognosis compared to immortal tumors having a poorer prognosis 45. In 
other cancers a tumor promoting role for CXCL5 has been reported 13-15;46. Arenberg 
et al. found a strong correlation between levels of CXCL5 and the level of vascular-
itzation in human NSCLC. In addition they showed, using a SCID mouse model that 
expression of CXCL5 in developing human NSCLC correlated with tumor growth 14. 
The data presented by Arenberg and others may seem in contrast with our findings. 
However, in addition to the different tumor type studied, our findings were derived 
from a syngeneic rat model for colorectal cancer, with a competent immune system, 
while their results were obtained in immune deficient mouse models. Therefore, 
in the study by Arenberg et al. the potential effect of a CXCL5-dependent immune 
response on tumor development would not have been manifested.
In conclusion, our results show that CXCL5 is an important factor in growth and 
development of colorectal cancer. Our data suggest that expression of CXCL5 by 
tumor cells enhances the recruitment of tumor infiltrating lymphocytes thereby 
bringing about better prognosis in colorectal cancer patients. Therefore CXCL5 
should be further studied for its potential role as a therapeutic target and prognostic 
biomarker in colorectal cancer.
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Purpose: Microsatellite instable (MSI) cancers express frameshift-mutated antigens, 
the C-terminal polypeptides of which are foreign to the immune system. Conse-
quently, these antigens constitute a unique pool of tumor-specific antigens that 
can be exploited for patient diagnosis and selective, immune-mediated targeting of 
cancers. However, other than their sequence, very little is known about the charac-
teristics of the majority of these proteins.
experimental design: We therefore developed a methodology for predicting their 
immunogenic behavior that is based on a gene expression system in which each of 
the proteins was fused to a short C-terminal polypeptide comprising two epitopes 
that can be readily detected by T-cells and antibodies respectively. In this manner, 
accumulation of the antigens, and processing of peptides derived thereof into MHC, 
can be monitored systematically. The antigens that accumulate in the cells in which 
they are synthesized are of primary interest for cancer immunotherapy, because 
peptide epitopes derived thereof can be presented by dendritic cells in addition to 
the tumor cells themselves. As a result, these antigens constitute the best targets for 
a coordinated immune response by both CD8+ and CD4+ T-cells, which increases the 
likelihood that tumor-induced immunity would be detectable against these antigens 
in cancer patients, as well as the potential value of these antigens as components of 
anti-cancer vaccines.
results and conclusions: Our data indicate that, of fifteen frameshift-mutated 
antigens examined in our present study, four (TGFβR2-1; MARCKS-1; -MARCKS-2; 
CDX2-2) are of primary interest and four additional antigens (TAF1B-1; PCNXL2-2; 
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introduCtion
A high frequency of microsatellite instability (MSI-H) is a molecular feature of tumors 
associated with the Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome 
1;2. Furthermore approximately 15% of sporadic colorectal, gastric and endometrial 
cancers, as well as lower frequencies of various other sporadic cancers, are character-
ized by widespread MSI 3-7. Microsatellites are repetitive nucleotide sequences of 
different length, distributed throughout the human genome that are prone to small 
insertion/deletion mutations, caused by DNA polymerase slippage during DNA rep-
lication 8. Usually, these errors are corrected by the inherent proofreading capacity 
of a group of proteins involved in mismatch repair 9;10. Defects in mismatch repair, 
like in MSI-H tumors, allow the accumulation of errors in microsatellites. Deletion or 
insertion of one or two base pairs in a coding gene results in a shift of the reading 
frame downstream of the mutation and thereby translation of an abnormal protein 
product.
These frameshift-encoded products constitute “foreign” antigens for the immune 
system and therefore represent an unique pool of tumor specific antigens 11. Specific 
T-cell and antibodies responses have indeed been found against a limited number 
of frameshift products 12-14. Furthermore, MSI-H tumors are associated with several 
treats that point at immune surveillance, such as increased lymphocyte infiltrate, 
increased incidence of MHC class I loss, and better patient survival prognosis as 
compared to microsatellite stable tumors. 15-17. Therefore, these frameshift-mutated 
proteins, in particular the non-self segment encoded by sequences downstream of 
the mutation, are considered promising candidates for preventive vaccination of 
subjects with HNPCC, or as adjuvant therapy in combination of surgery for patients 
with sporadic MSI-H tumors. The potential of these antigens for development of 
anti-cancer vaccines is further supported by the notion that mutations in several 
genes are found at high (>50%) frequencies in MSI-H cancers 18-22.
Unfortunately, little is known about the immunogenic properties of most proteins 
encoded by these commonly mutated genes. In order to predict their potential for 
inclusion in vaccines, it is of particularly interest to know whether they accumulate 
in tumor cells or are rapidly degraded. Accumulation of stable frameshift mutated 
antigens in tumor cells can result in cross-presentation of antigen-derived peptides 
by “professional” antigen presenting cells (APCs), in particular dendiritic cells (DCs), 
in the tumor-draining lymphoid tissues and, thereby, in pre-existing antigen-specific 
T-cell responses in cancer patients. Furthermore, vaccination-induced CD4+ T-cells are 
in this case expected to provide ‘help’ to the anti-tumor response, because they will 
encounter their cognate antigen on DCs in the peritumoral area. In contrast, instable 















































cross-presented 23-25. Consequently, neither ‘spontaneous’ priming of anti-tumor 
T-cell immunity, nor efficacy of vaccine-induced CD4+ T-helper cells against such 
antigens are to be expected. Nevertheless, break down of these instable antigens 
through the ubiquitin-proteasome pathway can result in peptides that may be pre-
sented in the context of MHC class I at the tumor cell surface. In that case, vaccine-
induced CD8+ T-cells recognizing these peptides could be used to target the tumor.
In the present study, we made use of an expression system to systematically analyze 
the characteristics and immunogenic properties of proteins encoded by a selection 
of frameshift mutated genes that are commonly found in MSI-H cancers. This inven-
tory provided important information on the manner in which these antigens should 
be used for further studies concerning patient diagnosis and cancer immunotherapy.
MAteriAl And MethodS
Tumor cell lines
The cell lines B3Z, HeLa and HeLa-Kb were used in experiments. HeLa-Kb is a stable 
transfectant of the human HeLa cell line, expressing the mouse H-2Kb MHC class I 
molecule 26. All cells were cultured at 37°C and 5% CO2, in cell culture flasks (Corn-
ing, NY, USA) containing culture medium, composed of IMDM (BioWhitaker), supple-
mented with 10% heat-inactivated FCS, 100μg/ml streptomycin, 100IU/ml penicillin 
and 4mM L-glutamine (all from Gibco).
Selection of frameshift products
Twelve genes, containing a microsatellite, were selected. Selection was based on 
known high mutation frequency in MSI-H colon cancer 18;19;22, previously described 
immunogenicity 12-14 or combinations of these factors. Insertion of 1 base pair or a 
deletion of two base pairs (-2/+1) result in the same reading frame but differ one 
amino difference in length. The same is valid for an insertions of 2 base pairs or a 
deletion of one base pair (-1/+2). Therefore only one type of a -2 or +1 and -1 or +2 
mutation was used and only if the mutation resulted in a stretch of more than 4 new 
amino acids behind the microsatellite. Table 1 summarizes selected genes, mutation 
frequency in different types of cancer, whether -2/+1, -1/+2 or both sequences were 
constructed (15 in total), function and other characteristics.
Construction of frameshift products and transfection
Sequences of selected frameshift products were amplified by routine PCR using 
cDNA derived from several human colorectal MSI-H cell lines or were synthetically 
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of the sequence. A KOZAK sequence was added before the initial ATG code of 
each fragment. PCR products were directly cloned with the pGEM-T-Easy cloning 
kit (Promega) and sequenced, using standard procedures. Expression plasmids for 
each of the selected frameshift were obtained, through unidirectional cloning of 
the sequences concerned into the mammalian expression vector, pcDNA3-OVA/
Flag containing an in-frame OVA/Flag tag. The tag was located downstream of the 
sequence direct behind the restriction site containing the H-2Kb restricted CD8+ T-cell 
epitope of chicken ovalbumine (OVA: SIINFEKL) and the Flag epitope (DYKDDDDK), 
table 1. Characteristics of frameshift-mutated antigens included in study.










Fto U79260 82 6.7 42 14T Unknown -1 (51)
tgFßrii M85079 75 63 12 10A Signal transducer -1 (34)
tAF1b L39061 75 87 58 11A Transcription factor -1 (25)





-1 (11) & -2 (27)
PCnxl2 / 
FlJ11383
AK021445 66.0 --- --- 10A Unknown -2 (18)





AK002048 49 --- --- 11A Unknown -1 (23) & -2 (7)
Caspase 5 U28015 46 47 14 10A Apoptosis -1 (25)
tCF7l2 / 
tCF-4
Y11306 45 12 3.8 9A Transcription factor -1 (22) & -2 (7)
baxα L22473 43 36 24 8G Apoptosis -1 (18) & +1 (31)
Cdx2 Y13709 1.8 --- --- 7G Proliferation & 
differentiation
-2 (29)
The majority of frameshift-mutated antigens included in this study were selected on basis of 
high incidence (>40%) in at least one type of cancer and a minimal length of the non-self 
amino acid stretch, C-terminal of the mutation, of more than 4 residues. Antigen CDX2 was 
included despite its low mutation incidence, because antibody responses were found against 
this antigen in a cancer patient 14, indicating that it could be employed as a positive control for 
a stable, accumulating antigen in our assays.
Names of genes and loci are based on GenBank nomenclature. Incidence of frameshift mutations, 
and (putative) functions are based on previously published data 18;19;22. The mutations studied 
are indicated with the length of the foreign amino acid sequences between parentheses. The 
















































which were spaced by a triple alanine sequence to allow efficient processing of the 
OVA T-cell epitope. These plasmids were transiently transfected into cells using Lipo-
fectamine 2000 (Invitrogen) in 6 wells plate. Per well 2μg DNA was added. In some 
experiments 0.5μg eGFP-pcDNA3 vector was added to the transfection medium to 
determine transfection efficiency. Cells were harvested 48 h after transfection and 
used in experiments.
Detection of localization of frameshift products
Immunofluorescence was used to detect the localization of the different frameshift 
products. Cells were grown on Laboratory-Tech 8 well culture slides (Nalge-Nunc) 
precoated with poly-L-lysine (Sigma-Aldrich). Two days after transfection, cells were 
fixed with 1% paraformaldehyde for 5 minutes, permeabilized with methanol at 
–20°C for 10 min and incubated with a mouse monoclonal anti Flag antibody M2 
(F3165, Sigma-Aldrich) for 1h at room temperature followed by incubation for 1h 
with Alexa-546-conjugated goat anti mouse secondary antibodies (Invitrogen). 
Stained cells were examined using a laser scanning confocal microscope (LSM510, 
Zeiss).
Expression of frameshift products
The expression of frameshift products was determined by flow cytometry with the 
PE labeled α-Flag antibody M2 (F3165, Sigma-Aldrich). Briefly, cells were harvested 
48 h after transfection with one of the sequences and in addition of some eGFP 
to detect transfection efficiency. Cells were fixed in 1% paraformaldehyde for 5 
minutes on ice, permeabilized by incubation in methanol for 10 minutes at -20oC 
and stained with monoclonal anti-Flag antibody M2 (Sigma-Aldrich) followed by 
PE-conjugated Goat anti mouse IgG1 polyclonal antibody (PickCell Laboratories BV). 
Expression was measured on a flowcytometer LSRII (BD Biosciences) equipped with 
the FACSDIVA software (BD Biosciences). Approximately 10,000 single cell events (as 
predicted by size) were analyzed per sample. The green (eGFP) and the red (PE) 
fluorescence were measured using a 530/30 nm and a 575/26 nm band pass filter 
respectively. Compensation was set using single positive stained controls. Analysis 
was performed using Winlist 5.2 software (Verity Software House). Expression was 
found positive when fluorescent signal was shifted to the right side. Experiments 
were performed in duplicate.
Direct class I MHC presentation
Hela-Kb cells were plated in a 96-well flat-bottom plate and after overnight incuba-
tion transfected. Two days after transfection, B3Z hybridomas were added to the 
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B3Z is a T-cell hybridoma that recognizes the SIINFEKL peptide in the context of 
H-2Kb and expresses ß-galactosidase (ß-Gal) upon activation 27. After 24h at 37°C, 
the medium was replaced with 100 μl lysis buffer (PBS, 100 mM 2-mercaptoethanol, 
9 mM MgCl2, 0.125% NP-40, and 0.15 mM chlorophenol red-ß-D-galactopyranoside 
(Calbiochem) per well. Following color change, the absorbance at 590 nm was read 
using a 96 well plate reader. Per frameshift product 4 wells were transfected and 
analyzed. Experiments were done in duplo.
Mice
C57BL/6 mice and OT-1 TCR-transgenic mice (specific for OVA257-264/H2-Kb on Rag 
-/-CD45.1+ background) were bred in our own animal facilities (Leiden, The Neth-
erlands) but were originally obtained from the Jackson Laboratory (Maine, USA). 
The experiments were approved by the animal experimental committee (UDEC) of 
Leiden University.
Cross presentation of frameshift products studied in a mouse model
Transfected HeLa cells were harvested, lethally irradiated (4000 rad) and washed 
twice in PBS. C57BL/6 mice (n=3-4) received an intra peritoneal injection of 2*106 
irradiated cells suspension or 50μg OVA peptide. After three days T cells freshly iso-
lated from spleen and lymph nodes of OT-1 TCR-transgenic mice were labelled with 
5μM CFSE (InVitrogen, California, USA) and injected intravenous via the tail vein 
at a final concentration of 2*106 cells in PBS. After three days mice were sacrificed 
and mesenteric lymph nodes were isolated. Single cells suspensions of lymph nodes 
were prepared by mechanical disruption and prepared for flow cytometric detection 
CFSE intensity of OT-1 cells using PerCP conjugated α-CD8α (53-6.7), APC conjugated 
α-CD45.1 (A20) antibodies. FACS data were analyzed using CellQuest software. All 
antibodies and analysis software were purchased from BD Pharmingen (New Jersey, 
USA). Calculations of average fluorescent intensity of groups of mice (n=3-4) and 
Student’s T test statistical analyses were performed by comparing all groups to the 
‘mock transfected’ group using GraphPad software (GraphPad software Inc.).
reSultS
Validation of a fusion gene expression system for assessment of immunogenic 
properties of potential tumor antigens
For many of the genes that are frequently mutated in MSI-H cancers no information 
is available with respect to the immunogenic properties of these proteins. Because 















































at hand to enable analysis of the expression and immunogenicity of the individual 
antigens, we designed a gene expression system in which each of these proteins can 
be fused to a short C-terminal polypeptide comprising sequences that can readily be 
detected by T-cells and antibodies respectively: the H-2Kb-restricted CD8+ T-cell epit-
ope of chicken ovalbumin (OVA; SIINFEKL) 28 and the Flag tag epitope (DYKDDDDK) 
29 (Fig. 1A). To validate this screening methodology, we chose to insert the coding 
sequences of wild-type (wt) and mutated (V143A) p53 into the expression vector, as 
these constitute prime examples of proteins (in fact, versions of the same protein) 
with very different expression characteristics 30. Whereas wt.p53 has a very short 
half life, resulting in very low nuclear expression levels, mutations in p53 result in 
accumulation of this protein in both nucleus and cytoplasm of the cell. Furthermore, 
the degradation of p53 through the ubiquitin/proteasome pathway can result in 
efficient presentation of peptides derived thereof into MHC class I, even at the 
surface of cells that do not exhibit detectable intracellular levels of this protein 31.In 
accordance with the above, cells transiently transfected with the mutated p53 gene 
construct displayed high levels of p53 that are detected in nucleus and cytoplasm, 
while wt.p53-transfected cells displayed exclusive nuclear localization of this antigen 
(Fig 1B). Flow cytometry, used to further quantify the level of expression, confirmed 
that mutated p53 accumulated in a major fraction of the transfected cells. Trans-
fection of wt.p53 resulted in positive staining in a considerably smaller fraction of 
cells, even though transfection efficiencies as determined by co-transfection of an 
eGFP-encoding gene construct were comparable (Fig. 1C). The high levels of antigen 
detected in a minor fraction of the wt.p53 transfected cells (Fig 1B, C) is probably 
due to the uptake of massive amounts of DNA by the cells concerned and the very 
high synthesis of the protein resulting from this. As shown in Figure 1D, optimal 
distinction between accumulation of wt and mutated p53 is obtained when cells are 
transfected with 1-2 μg of p53-encoding DNA.
To evaluate processing and presentation of p53 degradation products into MHC 
class I, the recognition of the transfected cells by OVA-specific T-cell hybridoma 
cells (B3Z) was evaluated. Because the octamer peptide recognized by this T-cell 
constitutes only a very small part of the fusion proteins tested, we deem it highly 
conceivable that the behavior of the OVA T-cell epitope in the context of the fusion 
protein reflects that of putative T-cell epitopes within the sequences of the wt and 
mutated p53 sequences. In concordance with its accumulation in a large fraction of 
transfected cells, expression of the fusion protein comprising mutated p53 resulted 
in efficient presentation of the OVA T-cell epitope in MHC class I (Fig. 1E). However, 
also transfection of the fusion gene comprising wt.p53 resulted in clearly detectable 
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Figure 1. design of screening methodology and validation of assays on basis of characteristics 
wild type and mutant p53.
(A) Full length coding sequences of frameshift mutated genes that lack stop codons were fused 
in frame to a sequence encoding the H-2Kb-restricted CD8+ T-cell epitope of chicken ovalbumin 
(OVA; SIINFEKL, 28) and the FLAG tag epitope (DYKDDDDK, 29), which were spaced by a triple 
alanine sequence to allow efficient processing of the OVA T-cell epitope 40. (B) Detection of 
tagged fusion gene products comprising wild-type (wt) and mutant (V143A) human p53 by means 
of immunofluorescence in paraformaldehyde-fixed HeLa cells that were transfected with the 
indicated constructs 48 hrs. prior to analysis. (C) Detection of p53 antigen by flow cytometry in 
wt.p53, V143A p53 and mock transfected HeLa cells. Percentage of cells with FLAG-tag-specific 















































of p53 is not required for direct MHC-restricted presentation of CTL epitopes derived 
from this antigen 31.
Cross-presentation of cell-derived antigens by professional APC does depend on 
the availability of these antigens in sufficient amounts 23-25. To test whether our 
fusion gene expression system can also be used to address the behavior of antigens 
in cross-presentation, we transfected human cells with genes comprising wt or 
mutated p53 and injected these xenogeneic cells into mice that were infused with 
naïve, CSFE-labeled T-cells (OT-1) that recognize the OVA CTL epitope. The use of this 
xenogeneic system is justified by the notion that the antigen processing machinery is 
highly conserved between mouse and human 32. Fig. 1F shows that in vivo challenge 
of OT-1 through injection of cells transfected with a fusion gene comprising mutated 
p53 elicited strong proliferation of OT-1, while injection of cells transfected with the 
wt.p53 gene construct induced only modest OT-1 proliferation.
In conclusion, the wt.p53 OVA/FLAG fusion construct encoded a protein with 
short half life that failed to accumulate in the majority of transfected cells and was 
therefore not available for efficient uptake and cross-processing by professional 
APC, while the turn over of this protein nevertheless resulted in direct MHC class 
I-restricted presentation by the antigen-expressing cell. In contrast, the OVA/FLAG 
fusion gene comprising mutated p53 encoded a stable protein that accumulated in 
transfected cells, and that could serve as a basis for both direct and cross-presentation. 
Taken together these results demonstrate that the behavior of these fusion proteins 
properly reflects that of the antigens under examination, and that our expression 
system is a suitable tool for evaluating the characteristics of additional antigens, 
such as those encoded by the frameshift mutated genes commonly found in MSI-H 
cancers.
Steady state expression levels of frameshift-mutated antigens
After validation of our expression system, we cloned multiple frameshift mutated 
genes into the OVA/FLAG gene cassette. All but one of genes to be examined in 
(D) Percentage of positive cells of positive fraction in relation to amount of DNA transfected is 
plotted. Comparable transfection efficiency between samples was ensured by co-transfection of 
DNA encoding eGFP. (E) Direct MHC class I-restricted presentation of the OVA (SIINFEKL) epitope 
in fusion-gene transfected HeLa-Kb cells, as measured by reactivity of B3Z T-cell hybridoma cells. 
Magnitude of response is measured on base of β-galactisodase activity in stimulated B3Z cells and 
expressed as absorbance (OD 590nm) of converted substrate in quadruplicate samples. (F) In vivo 
cross-presentation of the OVA epitope derived from fusion-gene transfected HeLa cells (lacking 
H-2Kb expression) cells, as determined by proliferation of SIINFEKL-specific OT-1 TCR-transgenic 
CD8+ T-cells. Hela cells transfected with wt.p53, V143A p53 or control DNA were injected in mice 
that received naïve, CFSE-labeled OT-1 cells. Proliferation of OT-1 on basis of dilution of CSFE was 
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our proof of concept study were selected on basis of two criteria. First the high 
prevalence of a given frameshift mutation in MSI-H cancers as reported in previous 
studies, in particular a reported frequency of at least 40% in at least one type of 
MSI-H cancer. Second, we focused on frameshift mutations that gave rise to for-
eign sequences, downstream of the frameshift mutation, of at least 5 amino acids 
in length, because shorter sequences are unlikely to render immunogenic T-cell 
epitopes. An overview of the selected frameshift-mutated genes is shown in Table 
1. The mutated CDX2 gene was included in our studies despite its low incidence, 
because antibody responses were found against its gene product in a cancer patient 
14, arguing that this antigen could be used in our screening as a positive control for 
a stable, accumulating antigen.
Steady state expression levels and intracellular localization of the selected frame-
shift product were initially determined by performing immunocytochemistry on 
transiently transfected cells, using the FLAG tag-specific antibody. The resulting data 
showed that only four of the gene constructs (TGFβR2-1, MARCKS-1, MARCKS-2, 
CDX2-2) gave rise to high protein levels in a large fraction of the cells (Figure 2). 
Expression of the different frameshift proteins was further quantified by means of 
flow cytometry. These experiments confirmed that only 4 of the gene constructs 
tested (TGFβR2-1, MARCKS-1, MARCKS-2, CDX2-2) encoded antigens that accumu-
lated in a large fraction of the transfected cells (Figure 3A, B). Five additional gene 
products (TAF1B-1; PCNXL2-2; TCF7L2-1; -2; Baxα+1) were found expressed in a mod-
est fraction of transfected cells, while expression of the remaining genes did not 
surpass that of background levels. Transfection efficiencies were comparable for all 
assays, as determined by co-transfection of an eGFP-encoding gene construct.
Direct antigen processing and presentation into MHC class I
As shown for wt.p53, failure of antigens to accumulate does not necessarily pre-
clude processing of peptides derived thereof into MHC class I (Fig 1E). Accordingly, 
recognition of the OVA CTL epitope by the B3Z hybridoma on transfected cells was 
not limited to the 4 gene constructs that encode stable antigens (figure 3B). In addi-
tion, efficient CTL epitope recognition was observed for cells transfected with gene 
constructs encoding PCNXL2-2, Caspase5-1, Baxα-1 and Baxα+1, while transfection 
of four other constructs (FTO-1, C14orfl06-2, TCF7L2-1 and TCF7L2-2) resulted in 
moderate T-cell recognition (Figure 3C). These results confirm that accumulation of 
















































In vivo cross-presentation of antigen-derived epitopes
Whereas T-cell action at the effector level requires direct presentation of epitopes 
by the target cell, the prevailing view on priming of T-cell responses is that successful 
activation of T-cell immunity requires uptake, processing and presentation of antigen 
by dendritic cells. We therefore analyzed the capacity of the frameshift-mutated 
antigens to give rise to cross-presented T-cell epitopes by immunizing mice with tran-
siently transfected xenogeneic (human) cells. Presentation of the OVA CTL epitope 
was monitored by analyzing the antigen-specific proliferation of CSFE-loaded OT-1 
cells that were infused into the mice. The capacity of gene constructs to give rise to in 
vivo cross-presentation of the OVA epitope correlated with the accumulation of the 
corresponding antigen in transfected cells (figure 4A and 4B). Most efficient cross-
presentation was restricted to the four gene constructs that gave rise to accumulating 
antigen in a large fraction of transfected cells (TGFβR2-1, MARCKS-1, MARCKS-2, 
CDX2-2). Four of the five gene constructs that gave rise to protein accumulation in a 
modest fraction of transfected cells (Figure 3B), resulted in low but detectable levels 
of cross-presentation, (BAXα+1, PCNXL2-2, TCF7L2-2 and TAF1B-1). No in vivo cross-
presentation above background was found for the fifth of this set of genes (TCF7L2-1). 
This can most likely be explained by our finding that protein accumulation in trans-
fected cells for this gene was lower than for the other four genes (Fig. 3B).
derived thereof into MHC class I, even at the surface of cells that
do not exhibit detectable intracellular levels of this protein.31
In accordance with the above, cells transiently transfected with
the mutated p53 gene construct displayed high levels of p53 that
are detected in nucleus and cytoplasm, whereas wt.p53-transfected
cells displayed exclusive nucle r localization of this antigen (Fig.
1b). Flow cytometry, used to further quantify the level of expres-
sion, confirmed that mutated p53 accumulated in a major fraction
of the transfected cells. Transfection of wt.p53 resulted in positive
staining in a considerably smaller fraction of cells, even though
transfection efficiencies as determined by cotransfection of an
eGFP-encoding gene construct were comparable (Fig. 1c). The
high levels of antigen detected in a minor fraction of the wt.p53
transfected cells (Figs. 1b and 1c) is probably due to the uptake of
massive amounts of DNA by the cells concerned and the very
high synthesis of the protein resulting from this. As shown in Fig-
ure 1d, optimal distinction between accumulation of wt and
mutated p53 is obtained when cells are transfected with 1–2 lg of
p53-encoding DNA.
To evaluate processing and presentati n of p53 degradation
products into MHC class I, the recognition of the transfected cells
by OVA-specific T-cell hybridoma cells (B3Z) was evaluated.
Because the octamer peptide recognized by this T-cell constitutes
only a very small part of the fusion proteins tested, we deem it
highly conceivable that the behavior of the OVA T-cell epitope in
the context of the fusion protein reflects that of putative T-cell epi-
topes within the sequences of the wt and mutated p53 sequences.
In concordance with its accumulation in a large fraction of trans-
fected cells, expression of the fusion protein omprising mutated
p53 resulted in efficient presentation of the OVA T-cell epitope in
MHC class I (Fig. 1e). However, also transfection of the fusion
gene comprising wt.p53 resulted in clearly detectable epitope pre-
sentation. This is in line with our previous observation that accu-
mulation of p53 is not required for direct MHC-restricted presen-
tation of CTL epitopes derived from this antigen.31
Cross-presentation of cell-derived antigens by professional
APC does depend on the availability of these antigens in suffi-
cient amounts.23–25 To test whether our fusion gene-expression
system can also be used to address the behavior of antigens in
cross-presentation, we transfected human cells with genes com-
prising wt or mutated p53 and injected these xenogeneic cells
into mice that were infused with na€ıve, CSFE-labeled T-cells
(OT-1) that recognize the OVA CTL epitope. The use of this xen-
ogeneic system is justified by the notion that the antigen-process-
ing machinery is highly conserved between mouse and human.32
Figure 1f shows that in vivo challenge of OT-1 through injection
of cells transfected with a fusion ge e comprising mutated p53
elicited strong proliferation of OT-1, while injection of cells
transfected with the wt.p53 g ne construct induced only modest
OT-1 proliferation.
In conclusion, the wt.p53 OVA/FLAG fusion construct encoded
a protein with short half-life that failed to accumulate in the ma-
jority of transfected cells and was therefore not available for effi-
ci nt uptak and cross-process g by professional APC, while the
turn over of this protein nevertheless resulted in direct MHC class
I-restricted presentation by the antigen-expressing cell. In contrast,
the OVA/FLAG fusion gene comprising mutated p53 encoded a
stable protein that accumulated in transfected cells and that could
serve as a basis for both direct and cross-presentation. Taken to-
gether, these results demonstrate that the behavior of these fusion
proteins properly reflects that of the antigens under examination,
and that our expression system is a suitable tool for evaluating the
characteristics of additional antigens, such as those encoded by
the frameshift-mutated genes commonly found in MSI-H cancers.
Steady-state expression levels of frameshift-mutated antigens
After validation of our expression system, we cloned multiple
frameshift mutated genes into the OVA/FLAG gene c ssette. All
but one of genes to be examined in our proof of concept study was
selected on the basis of 2 criteria. First, the high prevalence of a
given frameshift mutation in MSI-H cancers as reported in previ-
ous studies, in particular, a reported frequency of at least 40% in
at least one type of MSI-H cancer. Second, we focused on frame-
shift mutations that gave rise to foreign sequences, downstream of
the frameshift mutation, of at least 5 am o acids in length,
because shorter sequences are unlikely to render immunogenic T-
cell epitopes. An overview of the selected frameshift mutated
genes is shown in Table I. The mutated CDX2 gene was included
in our studies despite its low incidence, because antibody
responses were found against its gene product in a cancer
patient,14 arguing that this antigen could be used in our screening
as a positive control for a stable, accumulating antigen.
FIGURE 2 – Steady-state expression of frameshift antigens. Detection of tagged fusion gene products by means of immunocytochemistry in
fixed HeLa cells, transfected with the indicated constructs 48 hr before analysis. Cells shown in pictures are representative for positive cells
obtained after transfection with indicated gene construct. Frequency of positively staining cells depends on gene construct used (see Fig. 3c).
Images were made under standardized conditions, using 403 magnification and the same exposure. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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Figure 2. Steady state expression of frameshift antigens.
Detection of tagged fusio  gene products by means of mmunocytochemistry in fixed HeLa 
cells, transfected with the indicated constructs 48 hrs. prior to analysis. Cells shown in pictures 
are representative for positive cells obtained after transfection with indicated gene construct. 
Frequency of positively staining cells depends on gene construct used (see Fig. 3C). Images were 








































Immunogenicity of frameshift-mutated antigens 89
Steady-state expression levels and intracellular localization of
the selected frameshift product were initially determined by per-
forming immunocytochemistry on transiently transfected cells,
using the FLAG tag-specific antibody. The resulting data showed
that only 4 of the gene constructs (TGFbR2-1, MARCKS-1,
MARCKS-2 and CDX2-2) gave rise to high protein levels in a
large fraction of the cells (Fig. 2). Expression of the different fra-
meshift proteins was further quantified by means of flow cytome-
try. These experiments confirmed that only 4 of the gene con-
structs tested (TGFbR2-1, MARCKS-1, MARCKS-2 and CDX2-
2) encoded antigens that accumulated in a large fraction of the
transfected cells (Figs. 3a and 3b). Five additional gene products
(TAF1B-1, PCNXL2-2, TCF7L2-1, TCF7L2-2 and Baxa11)
were found expressed in a modest fraction of transfected cells,
whereas expression of the remaining genes did not surpass that of
background levels. Transfection efficiencies were comparable for
all assays, as determined by cotransfection of an eGFP-encoding
gene construct.
Direct antigen processing and presentation into MHC class I
As shown for wt.p53, failure of antigens to accumulate does not
necessarily preclude processing of peptides derived thereof into
MHC class I (Fig. 1e). Accordingly, recognition of the OVA CTL
epitope by the B3Z hybridoma on transfected cells was not limited
to the 4 gene constructs that encode stable antigens (Fig. 3b). In
addition, efficient CTL epitope recognition was observed for cells
transfected with gene constructs encoding PCNXL2-2, Caspase5-
1, Baxa-1 and Baxa11, whereas transfection of 4 other constructs
(FTO-1, C14orfl06-2, TCF7L2-1 and TCF7L2-2) resulted in mod-
erate T-cell recognition (Fig. 3c). These results confirm that accu-
mulation of protein is not a prerequisite for direct processing and
presentation of epitopes into MHC class I.
In vivo cross-presentation of antigen-derived epitopes
Whereas T-cell action at the effector level requires direct pre-
sentation of epitopes by the target cell, the prevailing view on pri-
ming of T-cell responses is that successful activation of T-cell im-
munity requires uptake, processing and presentation of antigen by
dendritic cells. We therefore analyzed the capacity of the frame-
shift-mutated antigens to give rise to cross-presented T-cell epi-
topes by immunizing mice with transiently transfected xenogeneic
(human) cells. Presentation of the OVA CTL epitope was moni-
tored by analyzing the antigen-specific proliferation of CSFE-
loaded OT-1 cells that were infused into the mice. The capacity of
gene constructs to give rise to in vivo cross-presentation of the
OVA epitope correlated with the accumulation of the correspond-
ing antigen in transfected cells (Figs. 4a and 4b). Most efficient
cross-presentation was restricted to the 4 gene constructs that gave
rise to accumulating antigen in a large fraction of transfected cells
(TGFbR2-1, MARCKS-1, MARCKS-2 and CDX2-2). Four of the
5 gene constructs that gave rise to protein accumulation in a mod-
est fraction of transfected cells (Fig. 3b) resulted in low but detect-
able levels of cross-presentation, (BAXa11, PCNXL2-2,
TCF7L2-2 and TAF1B-1). No in vivo cross-presentation above
background was found for the fifth of this set of genes (TCF7L2-
1). This can most likely be explained by our finding that protein
accumulation in transfected cells for this gene was lower than that
for the other 4 genes (Fig. 3b).
Discussion
We performed a series of experiments aimed at predicting the
immunogenic behavior of proteins encoded by a selection of fra-
meshift-mutated genes that are frequently found in MSI-H can-
cers. Our data demonstrate that fusion proteins comprising 8 of
the antigens examined (TGFbR2-1, MARCKS-1, -MARCKS-2,
CDX2-2, BAXa11, PCNXL2-2, TCF7L2-2 and TAF1B-1) gave
rise to direct epitope presentation by the cell expressing the anti-
gen as well as to cross-presentation by DCs (Table II). Our proof
of concept study provides important guidelines for further research
FIGURE 3 – Quantitative evaluation of steady-state expression and
direct processing into MHC class I. (a) Flow cytometric analyses of
HeLa cells transfected with 2-lg gene constructs encoding the indi-
cated frameshift proteins. Results for several of the proteins tested are
shown. Percentages of cells with FLAG-tag-specific staining and MFI
of positive fraction are indicated. (b) Summary of the flow cytometric
analyses for all antigens tested. The bars represent percentages of Flag
positive cells. Number behind each bar indicates the MFI of the Flag-
positive cells. These analyses were performed twice with very similar
outcome; data from one experiment are shown. Expression of frame-
shift products is categorized as strong (111, > mutant p53), moder-
ate (11, >wt.p53 2 <mutant p53), low (1, >Mock 2 <wt.p53) and
negative (2,2 <Mock). Comparable transfection efficiency between
samples was ensured by cotransfection of DNA encoding eGFP (not
shown). (c) Overview of direct MHC class I-restricted presentation of
the OVA SIINFEKL epitope in fusion-gene transfected HeLa-Kb
cells, as measured by reactivity of B3Z T-cell hybridoma cells. B3Z
responses against transfected antigens are categorized as strong
(111, >1.0), moderate (11, 0.5–1.0) and low (1, <0.5). Error bars
indicate SD.
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Figure 3. Quantit tive evaluation f steady sta e expres ion and direct processing into MhC 
class i.
(A) Flow cytometric analyses of HeLa cells transfected with 2μg gene constructs encoding the 















































of cells with FLAG-tag-specific staining and MFI of positive fraction are indicated. (B) Summary 
of the flow cytometric analyses for all antigens tested. The bars represent percentages of 
Flag positive cells. Number behind each bar indicates the MFI of the Flag-positive cells. 
These analyses were performed twice with very similar outcome; data from one experiment 
are shown. Expression of frameshift products is categorized as strong (+++, > mutant p53), 
moderate (++, > wt.p53 - < mutant p53), low (+, > Mock - < wt.p53) and negative (-, - < Mock). 
Comparable transfection efficiency between samples was ensured by co-transfection of DNA 
encoding eGFP (not shown). (C) Overview of direct MHC class I-restricted presentation of the 
OVA SIINFEKL epitope in fusion-gene transfected HeLa-Kb cells, as measured by reactivity of 
B3Z T-cell hybridoma cells. B3Z responses against transfected antigens are categorized as strong 
(+++, >1.0), moderate (++, 0.5-1.0) and low (+, <0.5). Error bars indicate SD.
concerning this antigen family in the context of cancer immuno-
therapy. The antigens that, in view of their capacity to accumulate
in tumor cells, are cross-presented by DCs can become visible to
na€ıve T-cells in the tumor-draining lymphoid tissues. Conse-
quently, one can expect cancer patients to display ‘‘tumor-
induced’’ T-cell or IgG-type immunity against these antigens.
Indeed, such responses have been found against the frameshift-
mutated TGFbR2-1 and CDX2-2 proteins.13,14,33 Our results
argue that further evaluation of spontaneous immunity against fra-
meshift-mutated antigens should be focused on the 8 antigens
mentioned earlier and on defining additional antigens with similar
characteristics. Moreover, our data indicate that antigens belong-
ing to this subclass are most valuable as components of vaccines
that are intended to raise antitumor immunity by both CD41 and
CD81 T-cell subsets. Vaccination-induced CD41 T-cells can
only provide efficient ‘‘help’’ to the immune response if they en-
counter their cognate antigen on cross-presenting DCs in the tu-
mor microenvironment and/or draining lymphoid tissue. In addi-
FIGURE 4 – In vivo processing of frameshift-mutated antigens. (a) Hela cells transfected with indicated frameshift gene constructs were
injected in mice that received na€ıve, CFSE-labeled OT-1 cells. Proliferation of OT-1 on the basis of dilution of CSFE was assessed 3 days later.
Percentage of divided CFSE cells is indicated in each graph (examples shown). (b) Summary of the outcome of in vivo cross-presentation experi-
ments for all gene constructs studied. Dashed line indicates mean % of CFSE-low OT-1 cells in mice injected with mock-transfected HeLa cells
plus the SEM of these values. t test was used to calculate significant difference from mock-transfected cells. Samples are categorized as strong
(***, p < 0.001), moderate (**, p < 0.01–p > 0.001), low (*, p < 0.05–p > 0.01) and not significant different from mock (NS, p > 0.05).
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Figure 4. In vivo processing of frameshift mutated antigens.
(A) Hela cells transfected with indicated frameshift gene constructs were injected in mice that 
receive  naïve, CFSE-labeled OT-1 cells. Proliferation of OT-1 on basis of dilution of CSFE was 
assessed three days later. Percentage of divided CFSE cells is indicated in each graph (examples 
show ). (B) Summary f the o tco  of in vivo cross-presentation exp riments for all gene 
construct  studied. D shed l ne indic t  mean % of CFSE-low OT-1 cells in mice injected 
with mock-transfected HeLa cells plus the SEM of these values. T-test was used to calculate 
ignificant differe ce from mock transfect d cells. Samples are categorized as strong (***, 
p<0.001), m der t  (**, p<0.01-p>0.001), low (*, p<0.05-p>0.01) and ot significant different 
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diSCuSSion
We performed a series of experiments aimed at predicting the immunogenic behavior 
of proteins encoded by a selection of frameshift-mutated genes that are frequently 
found in MSI-H cancers. Our data demonstrate that fusion proteins comprising eight of 
the antigens examined (TGFβR2-1; MARCKS-1; -MARCKS-2; CDX2-2; BAXα+1, PCNXL2-
2, TCF7L2-2 and TAF1B-1) gave rise to direct epitope presentation by the cell expressing 
the antigen, as well as to cross-presentation by DCs. (Table 2). Our proof of concept 
study provides important guidelines for further research concerning this antigen fam-
ily in the context of cancer immunotherapy. The antigens that, in view of their capacity 
to accumulate in tumor cells, are cross-presented by DCs, can become visible to naïve 
T-cells in the tumor-draining lymphoid tissues. Consequently, one can expect cancer 
patients to display ‘tumor-induced’ T-cell or IgG-type immunity against these antigens. 
Indeed, such responses have been found against the frameshift-mutated TGFβR2-1 
and CDX2-2 proteins 13;14;33. Our results argue that further evaluation of spontane-
ous immunity against frameshift mutated antigens should be focused on the eight 
antigens mentioned above and on defining additional antigens with similar charac-
teristics. Moreover, our data indicate that antigens belonging to this subclass are most 
valuable as components of vaccines that are intended to raise anti-tumor immunity by 
both CD4+ and CD8+ T-cell subsets. Vaccination-induced CD4+ T-cells can only provide 
efficient ‘help’ to the immune response if they encounter their cognate antigen on 
cross-presenting DCs in the tumor microenvironment and/or draining lymphoid tissue. 
In addition, they may contribute to the effector response by recognizing their antigen 
on MHC class II-expressing colorectal tumors 34-36. On basis of our experiments with 
fusion gene constructs, such class II MHC-restricted presentation by professional APCs 
or by tumor cells, the latter of which lack efficient MHC class II processing, is less likely 
to occur for the seven remaining, non-accumulating antigens (Table 2). Therefore, the 
impact of CD4+ T-cells raised by vaccination against these latter antigens will be limited 
to the vaccination phase. Due to the lack of their cognate antigen in the peritumoral 
area, these CD4+ T-cells will fail to contribute to the effector phase. For the latter 
antigens (FTO-1; ACVR2-2; C14orf106-1; -2; Caspase5-1; TCF7L2-1; Baxα-1), breakdown 
did result in class I MHC-restricted epitope presentation by the antigen-expressing 
cells, indicating that the CD8+ T-cell arm of a vaccine-induced response against these 
antigens could be used to target tumors (Table 2). Whether MHC class I-restricted epi-
tope presentation by the tumor truly occurs in a given human subject will, of course, 
depend on the compatibility between the proteolytic fragments generated and the 
repertoire of class I molecules comprised within the subject’s HLA-type. The available 
HLA-specific peptide-binding motifs can be used for further prediction of such epit-















































The degree at which the fusion proteins comprising frameshift mutated antigens accu-
mulate in transfected cells correlates well with the efficiency by which these antigens 
give rise to in vivo cross-presentation after injection of transfected cells (compare 
Figures 3B and 4B). Protein accumulation and cross-presentation are high for fusion 
proteins containing TGFβR2-1, MARCKS-1, -MARCKS-2 or CDX2-2, while being mod-
est for fusion proteins comprising BAXα+1, PCNXL2-2, TCF7L2-2 or TAF1B-1. Notably, 
the fusion protein comprising wt.p53, although accumulating at considerably higher 
efficiency than the latter four fusion constructs, did not give rise to detectable cross-
presentation (Figure 4B). This suggests that factors other than steady state levels, such 
as efficiency of antigen uptake or intracellular routing after uptake, may impact on 
the handling of antigens by cross-presenting DCs. We would like to emphasize that the 
methodology described in our present paper should be regarded as part of a multifac-
eted selection procedure that also involves evaluation of the immunogenicity of these 
antigens by means of in vitro human T-cell cultures using lymphocytes from MSI-H 
cancer patients and healthy subjects. Furthermore, the potential impact of frameshift 
mutations on mRNA stability through nonsense-mediated RNA decay (NMD) should 
be taken into account, as this might preclude efficient synthesis of gene products 37. 
NMD was reported not to impact on 7 of the 8 frameshift mutations that we found 
to encode accumulating gene products 38;39. Whether NMD affects expression of the 
remaining gene product (PCNXL2-2) still needs to be determined.
In conclusion, the frameshift-mutated antigens expressed by MSI-H cancers are 
promising antigens for selective, immune-mediated targeting of cancers, because 
they comprise sequences foreign to the immune system. However, other than their 
sequence, very little is known about the immunogenic characteristics of the major-
ity of these proteins. By providing a methodology for predicting the immunogenic 
behavior of frameshift-mutated proteins, our study constitutes a valuable step 
towards the systematic selection of target antigens for immune intervention against 
MSI-H cancers.
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table 2. Summary of expression characteristics of frameshift-mutated antigens and their 
expected relevance for evaluation of spontaneous t-cell immunity and vaccine design.
Coding sequence and 
type of mutation












1 TGFßR2-1 +++ +++ +++
2 MARCKS-1 +++ +++ +++ CD4 & CD8 CD4 & CD8
3 MARCKS-2 +++ ++ +++
4 CDX2-2 +++ +++ +++
5 Baxα+1 + +++ +++
6 TCF7L2-2 + ++ +++ Possibly
7 PCNXL2-2 + +++ ++ CD4 & CD8 (CD4 &) CD8
8 TAF1B-1 + + +
9 Caspase5-1 - +++ -
10 Baxα-1 - +++ -
11 FTO-1 - ++ -
12 C14orf106-2 - ++ - - CD8
13 TCF7L2-1 + ++ -
14 ACVR2-2 - + -
15 C14orf106-1 - + -
The results of the experiments concerning steady state protein expression (Fig 3B), direct 
presentation in MHC class I (Fig. 3C) and in vivo cross-presentation (fig 4B) have been 
quantitated as described in the figures. On basis of these data, the top 8 antigens, in particular 
(TGFβR2-1, MARCKS-1, MARCKS-2, CDX2-2), are of interest with respect to evaluation of anti-
tumor immunity in non-vaccinated patients, as well as for inclusion into vaccines that elicit 
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Purpose: The tumor-associated self-antigen p53 is commonly over-expressed in can-
cer, including colorectal cancer, and can serve as a target for immunotherapy. The 
safety and immunogenicity of a p53 synthetic long peptides (p53-SLP®) vaccine was 
investigated in patients treated for metastatic colorectal cancer.
experimental design: Ten patients were vaccinated twice with a set of ten overlap-
ping p53-SLP® in a phase I/II trial. Both safety as well as the breadth, magnitude and 
polarization of vaccine-induced p53-specific T cells was evaluated in blood samples 
drawn before and after vaccination by IFN-γ ELISPOT, proliferation, cytokine secre-
tion and multi-parameter flow cytometry. The migratory capacity of p53-specific T 
cells was evaluated by assessing their presence in a biopsy of the second vaccination 
site.
results: Toxicity was limited to grade I/II, mostly at the vaccination site. P53-specific 
T-cell responses were induced in 9 out of 10 colorectal cancer patients as measured 
by IFN-γ ELISPOT, proliferation and cytokine bead array. In 6 out of 9 tested patients, 
p53-specific T-cell reactivity persisted at least six months. Furthermore, p53-specific T 
cells isolated from the vaccination site were characterized as CD4+ T cells producing 
both T-helper (Th) type 1 and Th2 cytokines upon stimulation with p53 peptide and 
p53 protein. Multi-parameter flow-cytometry revealed that only a minor population 
of the p53-specific CD4+ T cells was optimally polarized.
Conclusions: The p53-SLP® vaccine is safe and capable to induce p53-specific T-cell 
responses in patients treated for colorectal cancer. New trials should focus on improv-
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introduCtion
Colorectal adenocarcinoma is the third most common cancer and the second most 
frequent cause of death due to cancer 1. Despite treatment approximately 45% of all 
colorectal cancer patients die within 5 years. Efforts to improve survival in patients 
with advanced colorectal cancer have had limited success indicating a high need for 
new treatment modalities, which may include immunotherapy. .
Mutations in either the p53 tumor suppressor gene itself or in genes regulating p53 
activity are found in a wide variety of tumors, including colorectal cancers 2;3, leading 
to aberrant expression of p53. Because p53 is not expressed at the cell surface, only 
p53-specific T-cell immunity is likely to exert therapeutic antitumor effects. Wild-
type p53 (wt.p53)-specific cytotoxic T lymphocytes (CTL) and T-helper (Th)-cells have 
been detected in PBMC cultures in vitro 4-8. In addition, wt.p53-specific proliferative 
responses were demonstrated in patients with breast cancer 9, ovarian cancer 10 and 
colorectal cancer 11;12. There are strong indications that the p53-specific CD8+ T-cell 
repertoire is severely restricted by self tolerance 13-16, as high-avidity self-reactive T 
cells are deleted in the thymus 17 leaving available only CD8+ T cells with a low avid-
ity T-cell receptor. In contrast, the CD4+ T-cell repertoire is not affected 13, presum-
ably because the low expression levels and rapid breakdown of p53 in the thymus 
disfavor presentation by MHC class II 18. Even in the case of MHC class II–negative 
cancers, the availability of p53-specific CD4+ T cells is important in cancer immuno-
therapy because IFNγ secreting CD4+ Th1-cells play an important role in orchestrating 
and sustaining the local immune attack by CD8+ CTL and innate immune effector 
cells 19-21. Indeed, adoptively transferred p53-specific CD4+ Th-cells supported the 
anti-tumor response against p53 over-expressing tumors 13;22. Moreover, Th1-cells 
can activate peritumoral DC, which generally display an immature phenotype 23;24, 
a requirement for DC to be able to launch an effective CTL response against one 
or more unique tumor antigens that are present in tumor cells 25;26. Analyses of 
the p53-specific CD4+ Th-cell repertoire in patients undergoing colorectal carcinoma 
resection revealed that these responses were weak and required at least one round 
of in vitro stimulation 11. Examination of the cytokines produced by these Th-cells 
revealed that the majority of the proliferative p53-specific T-cell cultures failed to 
produce any of the key cytokines (IFNγ, TNFα, IL-4, IL-5 and/or IL-10), indicating that 
tumor-induced p53-specific Th-responses are not properly polarized 11. Interestingly, 
the presence of circulating IFNγ-producing p53-specific CD4+ T cells was associated 
with a stronger CD8+ T-cell infiltration of the tumor 12, suggesting that the induction 
















































Several different antigen delivery systems have been tested to immunize patients 
against p53. In previous studies an adenoviral vector encoding wt.p53 27, recombi-
nant canarypox virus encoding wt.p53 28;29, or adenoviral vector encoding wt.p53 
transfected DCs 30 were used. These modalities were safe and capable of stimulating 
p53-specific T-cell responses in some of the vaccinated patients. Unfortunately, pres-
ence and enhancement of anti-vector immunity were found in almost all patients, 
which may have hampered the induction of a truly effective p53-specific T-cell 
response. In addition, DC pulsed with known p53 HLA-A2.1 binding peptides have 
been used and this resulted in safe induction of specific T-cell responses against p53 
peptides in some of the treated patients 31, but has the disadvantage that patients 
with other HLA types can not be treated 14.
Recently, we have developed the concept of using synthetic long peptides (SLP) as 
vaccines 32;33. When injected, these SLP are predominantly taken up by DC resulting 
in the presentation of both helper T-cell epitopes and CTL epitopes that are present 
in the SLP 34;35. The efficacy of SLP vaccines to induce truly strong tumor-specific CD4+ 
and CD8+ T-cell responses was demonstrated in rodents therapeutically treated for 
human papillomavirus induced tumors 36;37 as well as in patients with cervical cancer 
38;39. In parallel, we have developed a SLP vaccine for the induction of p53-specific 
T-cell immunity. Injection of p53-SLP® resulted in a strong p53-specific CD4+ T-cell 
response to three different epitopes in mice 13. Here, we have performed a phase I/
II trial with as primary endpoint the study of the safety and immunogenicity of the 
p53-SLP® vaccine in patients treated for metastatic colorectal cancer
PAtientS, MAteriAlS And MethodS
Patients and vaccination scheme
Patients treated for colorectal cancer metastasis were accrued into this phase I trial 
between January 2007 and March 2008 after oral and written informed consent. 
Primary endpoint of this study was safety and immunogenicity, secondary endpoint 
was tumor reactivity. Based on our previous clinical study, in which 2 out of 5 patients 
injected with canarypoxvirus with human wt.p53 mounted a T-cell response 28;29 
and based on our animal studies, in which the p53-SLP® vaccine was able to induce 
immunity in all mice 13, as well as on the high number of cancer patients responding 
in our HPV16-SLP studies 38;39 it was expected that sufficient subjects in a group 
of 10 patients will show a p53 specific immune response to report on safety and 
immunogenicity. Eligibility required the following criteria: (a) performance status 
of WHO 0 to 1; (b) pretreatment laboratory findings of leukocytes >3 x 109/L, lym-
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mmol/L; (c) no radiotherapy, chemotherapy, or other potentially immunosuppressive 
therapy administered within four weeks before the vaccination; (d) no history of 
autoimmune disease or systemic disease which might affect immunocompetence; 
(e) no other malignancies (previous or current), except adequately treated basal or 
squamous cell carcinoma of the skin; (f) HIV and hepatitis B seronegative and (g) a 
life expectancy of more than 6 months. The patient characteristics are summarized 
in Table 1. The study design was approved by the medical ethical committee of the 
Leiden University Medical Center and registered to the ISRCTN (ISRCTN43704292). 
After written informed consent, a screening visit was performed and after enroll-
ment the patients were subcutaneously vaccinated two times with a 3-week interval. 
At baseline and 3 weeks after the last vaccination, 200 mL blood was drawn for 
both immunomonitoring and assessment of hematologic values and organ func-
tion markers. In addition, 3 weeks after vaccination a biopsy (4 mm) of the second 
vaccination site was taken. Furthermore, during the trial smaller blood samples (60 
mL) were drawn for assessment of hematologic values and organ function markers. 
Approximately 6-9 months after vaccination a third blood sample was drawn for 
immunomonitoring. For clinical monitoring a CT-scan was made before and after 
vaccination and the serum tumor-marker carcinoembryonic antigen (CEA) was 
determined at several different time points during the whole trial. The vaccination 










































Speetjens et al.  Figure 1
Figure 1. A schematic overview of the vaccination scheme.















































table 1. Patient characteristics and adverse events observed
















P01 M 71 4 PR+RLi 1 Lu RLu Alive, Rec 
(17)
 4 flu-like 
symptoms (2X), 
atrial fibrillation
P02 M 54 3 PR+Ro 1 Li RLi Alive, NED1 
(13)
2 Pain vaccination 
sites (2X)
P03 M 62 4 PR+RLi - - Alive, NED2 
(15)
4 -
P04 F 57 3 PR+A 1 Lu RFLu Alive, NED 
(12)
0 Pain vaccination 
site (1X)













P08 F 58 3 PR+Ro 1 Li C+RFLi Alive, Rec 
(3)












P10 M 69 3 PR+A 2 Li RLi; RFLi Alive, Rec 
(3)
4 Pain + swelling 
vaccination site 
(1X)
P11 M 50 4 C+RLi - - Alive, NED 
(1)
0 swelling + 
erythema 
injection site + 
itching (2X)
All adverse events of the vaccine were temporarily. The swelling at the injection site was 
only painful direct after injection, lasted approximately 15 minutes and probably due to the 
adjuvant Montanide ISA-51 in the vaccine (not in Table). 1 Seven months after 1st follow up lung 
metastases were found that were resected and treated by isolated lung perfusion; 2 Direct after 
vaccination two metastases in liver that were resected; 3P53 expression 0=absent; 1 >0-25%; 2= 
25-50%; 3= 50-75%; 4= >75. The current clinical status is given, and the time period (in months) 
after enrollment between brackets. Abbreviations: Female (F), Male (M); Primary resection (PR), 
Adjuvant chemotherapy (A), pre-operative radiotherapy (Ro), Resection tumor lungs (RLu), 
Resection tumor liver (RLi), RFA lung lesion(s) (RFLu), RFA liver lesion(s) (RFLi), Chemotherapy 
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Vaccine
The vaccine consisted of 10 overlapping peptides, together representing the p53 
protein from amino acid 70 to 248. This region is recognized by T cells of all colorec-
tal patients displaying p53-immunity 11;12, and it harbors most of the published MHC 
class I and class II epitopes (reviewed in 40). The clinical-grade peptides (10 peptides 
of 20-30 amino acids long with an overlap of 5-14 amino acids) were synthesized 
at the Department of Clinical Pharmacy and Toxicology, Leiden University Medical 
Center as previously described 39. At the day of vaccination, the 10 peptides (0.3 
mg/peptide) were dissolved in Dimethylssulfoxide (DMSO), admixed with Phosphate 
Bufferd Saline (PBS) and emulsified in Montanide ISA-51 adjuvant in a total volume 
of 2.7 ml (DMSO:PBS:Montanide 20:30:50, v/v/v). The dose of the peptides used and 
the number and schedule of vaccinations were based on our previous observations 
in mice 13;36 and patients vaccinated with an HPV16-SLP vaccine 38;39 The results in the 
latter two studies indicated that two vaccinations were sufficient to induce a strong 
T-helper type 1 response in patients with cancer 38;39
Safety and tolerability monitoring
At the day of vaccination, the patients were under observation in the hospital until 
3 hours after vaccination. After the second vaccination, patients were seen at least 
once approximately every 4 months as part of their regular follow up visits to the 
hospital. Prompted and spontaneous adverse events, injection site reactions, clinical 
assessments, and clinical laboratory variables were monitored. Injection site reactions 
were defined as induration, erythema, and tenderness. In addition to their medical 
history, the patients were examined hematologically and physically before and after 
each vaccination. An electrocardiogram was made before and 3 hours after vaccina-
tion. Further vital sign examination included temperature, pulse, blood pressure, 
oxygen saturation, and respiratory frequency before and at 1, 2 and 3 hours after 
vaccine administration.
Immunohistochemistry and evaluation
The expression of p53, HLA class I and HLA class II was determined in the available 
primary and metastatic paraffin-embedded tissue of the vaccinated patients by stan-
dard two-step indirect immunohistochemistry , as described previously 41;42. The fol-
lowing primary antibodies were used: anti-p53 (clone DO-7, 1:500, DAKO), anti-HLA 
class I (EMR 8-5, 1:250, MBL) and anti-HLA-DP/DQ/DR (clone CR3/43, 1:100, DAKO). 
Secondary anti-Mouse HRP EnVision+ (K400111, DAKO) was used. The percentages 
of the tumor cells expressing p53 (nuclear expression), HLA class I and HLA-DP/DQ/
DR (both membranous expression) were estimated in each case. Tissue stroma, lym-















































Analysis of p53-specific T cells by IFNγ-ELISPOT, lymphocyte proliferation assay and 
cytokine polarization analysis
T cells from peripheral blood mononuclear cells (PBMC) or skin biopsies were isolated 
and cultured as previously described 39;43 and either directly used or cryopreserved. 
A set of six pools of long overlapping peptides, indicated by the first and last amino 
acid in the p53 protein were used for the screening of T-cell responses: p53.1: 1-78, 
p53.2: 70-115; p53.3:102-155, p53.4:142-203; p53.5:190-248, p53.6:241-393. Peptide 
pools p53.2-p53.5 represented the area included in the vaccine, while the other 
two peptide pools p53.1 and p53.6 represented the remaining part of p53. As a 
positive control, PBMC were cultured in the presence of a recall antigen mixture, 
the memory response mix (MRM) 44. Analysis of p53-specific T-cell responses from 
PBMC were done using IFNγ enzyme-linked immunospot (ELISPOT), proliferation 
assay (6 days for PBMC and 3 days for the T-cells cultured out of the skin biopsy) and 
supernatants isolated on the last day of the proliferation assay were subjected to a 
Th1/Th2 inflammation cytokine bead array (CBA) kit (BD Biosciences), as previously 
described 29;39. Specific spots in the ELISPOT were calculated by subtracting the mean 
number of spots + 2 x SD of the medium control from the mean number of spots in 
experimental wells. Antigen-specific T-cell frequencies were considered to be posi-
tive when specific T-cell frequencies were ≥1 of 10,000 PBMC 29;39. The average pro-
liferation and SD of the eight medium only wells (negative control) were calculated, 
the cut-off of the proliferation assay was defined as this average plus 3xSD. The 
stimulation index was calculated as the average of eight tested wells divided by the 
average of the medium control wells. A positive proliferative response was defined 
as a stimulation index of at least 3, and the counts of at least six of the eight wells 
must be above the cut-off value 39. Positive antigen-specific cytokine production as 
determined by CBA was defined as a cytokine concentration above the cut-off value 
and >2x the concentration of the medium control 39. According to the manufacturer, 
the proposed detection limit for the CBA was 20 pg/mL for tumor necrosis factor-α 
(TNFα), interleukin (IL-)10, IL-5, IL-4, and IL-2. We deviated with respect to the cut-off 
value of IFNγ (set to 50 pg/mL) because the standard curve showed linearity starting 
at a concentration of 50 pg/mL. A vaccine-induced response was defined as at least a 
3-fold increase in response after vaccination compared to the baseline sample.
Detection of IFNγ, IL-2 and IL-5 production by p53-specific T cells using flow 
cytometry
PBMC were either directly ex vivo used for intracellular cell staining or 10 days pre-
sensitized using the peptides in pools p53.2-p53.5 (2.5 μg/peptide/mL) as previously 
described 43. T cells from the biopsy were directly tested ex vivo. Then the cells were 
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of cytokines was inhibited by the addition of Brefeldin A (Sigma). After fixation cells 
were permeabilized and prepared for multicolor flow analysis 43 using the following 
primary antibodies: anti-CD3 Pacific Blue (clone UCHT1, BD PharMingen), anti-CD8 
PerCP (clone SK1, BD PharMingen), anti–CD4 PEcy7 (clone SK3, BD PharMingen), 
anti-CD154 PEcy5 (clone TRAP1, BD PharMingen), anti-CD137 APC (clone 4B4-1, BD 
PharMingen), anti-IFNγ FITC (clone 45.B3, BD PharMingen), anti–IL-5 PE (clone JES1-
39D10, BD PharMingen) and anti–IL-2 PE (clone MQ1-17H12, BD PharMingen). The 
presence of p53-specific T cells was considered to be positive when the percentage 
of p53-peptide stimulated CD4+CD154+ (activated) T cells or CD8+CD137+ (activated) 
T cells was at least twice the percentage detected in the medium only control, and 
the responding cells should be visible as a clearly distinguishable population in the 
plot of the flow cytometer. The percentage of IFNγ and/or IL-2 producing p53-specific 
T cells was determined by gating on the activated cell population.
Detection of p53-specific CD4+CD25+Foxp3+ T cells
The detection of p53-specific CD4+CD25+Foxp3+ T cells was performed as reported 
previously 39. Briefly, PBMC (1-2 x 106) were cultured for 10 days in medium only or 
in the presence of pooled p53-peptides (5 μg/peptide/mL). Then, the cells were har-
vested and 2 x 105 cells were stained for the surface markers CD25 (anti-CD25 FITC; 
clone M-A251, BD Pharmingen), CD4 (anti-CD4-APC; clone RPA-T4, BD Pharmingen) 
and CD8 (anti-CD8 PerCP; clone SK1, BD Pharmingen) before these cells were fixed, 
permeabilized, blocked with 2% normal rat serum and then stained with anti-human 
Foxp3 (PCH101) antibody or rat isotype IgG2a control. As a positive control a previ-
ously isolated HPV16-specific CD4+CD25+Foxp3+ regulatory T-cell clone (C148.31) and 
as negative control a HPV16-specific CD4+CD25+Foxp3- T-cell clone (C271.9) 45 were 
used. The fluorescence intensity of these two control clones was used to set the 
gates for the other samples in which the Foxp3 positivity of the stimulated poly-
clonal T-cell populations was analyzed. An antigen-induced up regulation of Foxp3 
or CD25 was defined as at least twice the percentages of Foxp3 or CD25 positive cells 
in the medium only control, and a vaccine-induced increase in Foxp3 positive cells 
was defined as at least a 3-fold increase compared to the percentages of the baseline 
















































Safety of the vaccine
A total of ten patients were vaccinated at least one month after their last treatment 
for metastatic colorectal cancer. The patients showed no macroscopic tumor lesions 
in abdomen or thorax at enrollment. The average age of the patients was 61 years 
(Table 1). Analyses of HLA and p53-expression in both primary tumor and metastases 
revealed the expression of HLA class I in at least 50% of all tumor cells and the 
complete absence of HLA class II on tumor cells. Over-expression of p53 was <25% of 
all tumor cells in patients p04, p05, p07, and p11 (Table 1). All patients completed the 
vaccination regimen of two injections. One patient (p06) did not meet the inclusion 
criteria and was therefore not enrolled in the study. The adverse events did not 
exceed grade II toxicity and were transient. All patients experienced the vaccination 
as mildly painful. The pain vanished within 10 to 15 minutes after injection. Flu-like 
symptoms, lasting <1 day (2 of 10 vaccinated patients), swelling and/or redness of 
the injection site (5 of 10 patients), pain and/or itching of the injection site (four 
of ten patients), were observed but did not exceed grade II toxicity of the common 
terminology criteria (Table 1). Interestingly, (re)activation of loco-regional inflam-
matory events at the prior injection site was frequently observed after the second 
vaccination. Two patients experienced grade II systemic adverse events (prostatitis 
and atrial fibrillation) during the trial but these were unlikely to be caused by the 
vaccination. The first event resolved after treatment with antibiotics and the second 
conversed spontaneously within a half an hour into a sinus rhythm (this patient was 
familiar with paroxysmal atrial fibrillation). The time of follow-up and the clinical 
status are given in Table 1. Cancer recurrences were detected in patient seven out of 
ten patients during follow up as shown in Table 1.
Induction of p53-specific IFNγ-producing circulating p53-specific T cells
To determine the effect of the vaccine on the immune system, PBMC isolated before 
and after vaccination were analyzed for the presence of p53 specific T cells by IFNγ 
ELISPOT. No IFNγ-producing T cells were detected in the baseline samples against 
either one of the six different tested long peptide pools. After vaccination, up to 
220 specific spots per 105 PBMC against at least one of the vaccine-representing p53 
peptide pools were observed in six out of the nine tested patients (Table 2). Patient 
p07 only showed a positive response against peptide pool p53.6, which represents 
the C-terminal part of the p53 protein and is not included in the vaccine and, there-
fore, this response was not regarded as a direct vaccine-induced response. Due to 
a low number of isolated PBMC we were not able to perform an ELISPOT assay for 
















































































































































































Figure 2. vaccination with the p53 synthetic long peptides vaccine elicits strong t-cell responses 
in patients.
(A) Two typical examples of the IFNγ-ELISPOT results are shown: p01 (left) and p08 (right).
Columns indicate the number of T cells per 105 PBMC specifically producing a spot of the 
cytokine IFNγ after stimulation with the indicated six peptide pools covering the p53 protein; 
responses before vaccination (white columns), after two vaccinations (black columns). (B) Two 
typical examples of the proliferation assay of p01 and p08, before (white columns), 3 weeks 
after vaccination (black columns) and at least 6 months after last vaccination (grey columns); 
columns indicate proliferation mean (cpm), error bars – SD. (C) Proliferative responses upon 
stimulation with the indicated peptide pools of p53 are depicted as a stimulation index for 
each individual patient before, 3 weeks after vaccination (n=10) and at least 6 months after last 
vaccination (n=9). From patient p11 no late follow-up blood sample was obtained. Each patient 
















































somewhat stronger responses were observed against p53 peptide pools p53.4 and 
p53.5 (Table 2). T-cell frequencies were increased up to 1 per 454 PBMC (p53.4) and 
up to 1 per 694 (p53.5). Only five patients (p02; p03; p07; p08;p09) displayed an IFNγ-
associated T-cell response to the positive control antigen mixture (MRM; data not 
shown). In conclusion, the synthetic long p53 peptide vaccine induced a p53-specific 
immune response in six out of nine vaccinated patients as detected by IFNγ ELISPOT.
table 2. iFnγ elispot analysis before and after two p53-SlP vaccinations
Patient Pre vaccination Post vaccination





















P01 2 2 <1 <1 1 2 <1 <1 3 51 72 3
P02 <1 <1 <1 <1 <1 <1 <1 3 9 111 137 <1
P03 <1 <1 <1 <1 <1 <1 4 20 <1 <1 8 <1
P04 7 4 4 2 4 2 12 31 26 63 14 35
P05 <1 <1 <1 <1 10 <1 <1 <1 <1 <1 <1 <1
P07 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 22
P08 7 1 2 4 4 4 3 7 42 220 144 8
P09 <1 <1 <1 <1 4 <1 4 16 56 126 110 7
P10 <1 <1 <1 <1 <1 <1 4 <1 3 2 2 1
total number of positive reactions
0 0 0 0 0 0 0 3 3 5 5 2
PBMC were tested against six different peptide pools. The numbers indicate the number of T 
cells per 105 PBMC specifically producing a spot of the cytokine IFNγ after stimulation with the 
indicated pool of peptides; in bold the positive responses (definition is described in material 
and methods); V followed by number indicates the amino acid stretch in the peptide pools as 
represented in the p53-SLP vaccine.
Vaccine induced p53-specific T cells proliferate but produce low amounts of 
cytokines
To analyze the proliferative capacity of p53-specific T cells before and after vacci-
nation as well as during follow-up, PBMC were tested in a lymphocyte stimulation 
test. Based on our cut-off criteria, the PBMC of patient p03 displayed a prolifera-
tive response against p53 peptide pools 1 and 5, p04 against pool 6, p05 against 
pool 5 and p11 against pool 4 at baseline. All other patients did not show a p53-
specific proliferative response before vaccination. None of the pre-existing prolif-
erative responses was boosted (>3-fold increase) after vaccination. The p53-specific 
responses detected in patients p05 and p11 were approximately at the same level 
after vaccination and those of patients p03 and p04 had disappeared. After vaccina-
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least one of the four pools of p53 peptides present in the vaccine (Figure 2B, C). Two 
patients showed positive responses against one peptide pool (p04 and p09), while 
five patients showed positive responses for ≥2 different peptide pools (p01, p02, p07, 
p10 and p11; Figure 2B, C). Notably, due to a higher background response (medium 
control) the calculated response of patients p08 and p09 was low. When compared 
to peptide pool p53.1, which is not present in the vaccine, p08 displays positive 
responses against peptide pools p53.3, p53.4 and p53.5 (figure 2B), while p09 not 
only would show a positive response against p53.5 but also against p53.4. In nine 
patients (p01-p10), we were able to obtain a follow-up blood sample approximately 
six months after the last vaccination. Even then, strong proliferative p53-specific 
T-cell responses were observed in six patients (Figure 2C). Except for patient p04 and 
p09, a proliferative response against the antigens in the MRM could be detected 
both at baseline and post vaccination (data not shown). Supernatants isolated from 
the cultures of all PBMC samples tested in the lymphocyte stimulation test were used 
for the analysis of antigen-specific production of cytokines (IFNγ; IL-2; TNFα; IL-10; 
IL-5; IL-4) by cytometric bead array 46. In a minority of the patients (p01, p04, p08, 
p10 and p11), vaccine-induced p53 specific proliferation coincided with the detect-
able production of IFNγ (mean 228; range 35 - 1521 pg/mL). TNFα was produced in 
PBMC of patients p04, p07 and p08 (mean 137; range 20 - 254 pg/mL). IL-5 was found 
in patients p01, p02, p04, p10 and p11 (mean 90; range 24 - 204 pg/mL) and IL-10 
was only induced in patient p02 (28 pg/mL). Production of IL-2 or IL-4 could not be 
detected. These data indicate that the p53-SLP® vaccine can induce a strong and 
sustained p53-specific T-cell reactivity in the majority of cases but also that these 
responses are not associated with the production of high amounts of cytokines.
Only CD4+ p53- specific T cells are detected after vaccination
In order to gain more insight in the p53-SLP®-induced T-cell response, patient-derived 
PBMC were stimulated, directly ex vivo as well as after a 10-day pre-sensitization 
period, with p53 peptides and recombinant p53 protein and analyzed simultane-
ously for the following T cell markers (CD3, CD4 and CD8), activation markers (CD137 
and CD154) and cytokines (IFNγ, IL-2 and IL-5) by multi-parameter flow cytometry. 
The antigen-induced upregulation of the activation markers allowed us to assess 
the percentage, phenotype and cytokine-polarization of p53-specific T cells (e.g. 
CD3+CD4+CD154+ and CD3+CD8+CD137+ for p53-specific CD4+ and CD8+ T cells, 
respectively). In two cases (p01 and p08) we were able to detect p53-specific CD4+ 
T-cell responses directly ex vivo (Figure 3A). Analysis of the pre-sensitized PBMC 
samples revealed the presence of circulating p53 specific CD4+ T cells against at least 
one of the peptide pools in five patients (p01, p02, p08-p10) (Figure 3B, C). Most of 
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Figure 3. only p53-specific Cd4+ t cells are induced.
Measurement of the percentage of p53-specific activated T cells, which produce IFNγ and IL-2, as 
determined by flow cytometry either directly ex vivo as well as after a 10-day pre-sensitization 
period. (A) Left two panels show directly ex vivo stained PBMC isolated after vaccination and 
overnight stimulation with medium or peptide pool p53.2 – p53.5. CD4+ T cells were plotted 
against the activation marker CD154. Numbers indicate percentage CD3+CD4+CD154+ T cells 
of patient p01 (left panels) and of patient p08 (right panels). No p53-specific T cells could be 
detected in the other patients. (B) CD4 and CD154 expression after 10 days pre-sensitization 
in post vaccination PBMC of p01 stimulated with the indicated antigens; numbers indicate 
percentage CD3+CD4+CD154+ T cells. (C) Pie-plots indicating the percentage of CD3+CD4+CD154+ 
T cells in pre-sensitized post-vaccination PBMC of p01, p02, p08, p09 and p10 after stimulation 
with the indicated peptide pool as determined by multi-parameter flow cytometry. Pies indicate 
the fraction of IFNγ (white), IL-2 (shaded), both IFNγ and IL-2 (grey) and neither IFNγ nor IL-2 
(black) producing CD3+CD4+CD154+ T cells. IL-5 was not detected in these cultures. (D) Shows 
directly ex vivo stained T cells isolated from the biopsy and overnight stimulation with medium 
or peptide pool p53.2 – p53.5. In the upper panels are CD3+CD4+ T cells plotted against the 
activation marker CD154, numbers indicate percentage CD3+CD4+CD154+ T cells; IFNγ and IL-2 
expression in CD3+CD4+CD154+ T cells is shown in the lower two panels, numbers indicate the 
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of IFNγ and IL-2 producing p53-specific T cells. Notably, in most cases a high per-
centage of p53-specific T cells was observed which neither produced IFNγ nor IL-2. 
The p53-specific production of IL-5 was never observed. Importantly, no CD8+ T-cells 
reactive to p53 could be detected in any of these samples.
Vaccination does not result in the induction of p53-specific CD4+CD25+Foxp3+ T cells
Recently, we observed that vaccination of cancer patients may result in the induction 
of circulating CD4+CD25+Foxp3+ T cells, which presumably may have regulatory activity 
39. In six cases (p01-p04, p08, p09) we were able to isolate sufficient numbers of PBMC to 
analyze the presence of vaccine-induced p53-specific CD4+CD25+Foxp3+ T cells before 
the first and after the last vaccination. PBMC were stimulated with p53 peptides and 
rested for 10 days, as this allows the measurement of stably Foxp3 expressing T cells 
47 which are specific for p53. As a control, PBMC were cultured without antigen. The 
induction of cell surface expression of CD25 on vaccine-induced p53-specific CD4 T 
cells varied between the subjects, with a high percentage of CD4+ T cells being CD25-
positive in p01 (28.7%) and p02 (8.8%), intermediate percentage in p04 (3.6%) and 
lower percentage in patients p08 (1.1%) and p09 (1.5%) after vaccination, reflecting 
the magnitude of the response observed in the proliferation assays. No overt induc-
tion of p53-specific CD4+CD25+Foxp3+ T cells was found (mean 0.3%, range 0-0.9%).
T cells cultured from skin biopsies display p53 specificity
From four (p01, p07, p08, p09) of the ten vaccinated patients we obtained enough T 
cells from the skin biopsy of the second vaccine site to allow further examination. In 
two cases (p07 and p08) the biopsies contained p53-specific T cells able to proliferate 
when stimulated with p53 peptide or protein pulsed APC (Figure 4A). Analysis of the 
supernatants with proliferation-associated production of cytokines revealed the pres-
ence of large quantities of all cytokines (Figure 4B). Noteworthy, the vaccination sites 
of these patients showed the clearest signs of inflammation, which made it easier 
to take a biopsy from inflamed tissue. In order to characterize the p53-specific T-cell 
population, the vaccine-site infiltrating T cells were stimulated with peptide pools and 
analyzed by multi-parameter flow cytometry. Of the vaccine-site infiltrating T cells of 
p07, 10% responded to p53 peptide and 5% to p53 protein. Analysis of the cytokine 
profile confirmed our data obtained from the PBMC cultures of p07 in that the vaccine-
infiltrating cells did produce IL-2 but no IFNγ (data not shown). Of p08, 35% of the 
infiltrating cells responded to peptide and 10% also to protein pulsed APC. Similarly, 
the majority of the p53-specific cell population produced IL-2 after stimulation but 
only 2.6% of these cells were able to produce IFNγ (Figure 3D). IL-5 production was not 
















































In this phase I/II study, immunotherapy with synthetic long peptides representing 
the sequence of the most immunogenic part of the p53 protein in patients with 
colorectal cancer 11;12 in formulation with Montanide ISA-51 adjuvant has proven to 
be safe and highly immunogenic. The maximum toxicity seen was grade II accord-
ing to the common terminology criteria and mainly consisted of discomfort and 
swelling at the vaccination sites. The application of several complementary assays 
revealed that the p53-SLP® vaccine had induced p53-specific immunity in nine of ten 
vaccinated patients, which was sustained for up to at least 6 months after vaccina-
tion. In contrast to patients vaccinated with a Human Papillomavirus Type 16-SLP 39, 
the p53-SLP® induced only p53-specific CD4+ T cells. This was to be expected as the 
p53-specific CD8+ T cell but not the CD4+ T cell repertoire is severely restricted by 
self tolerance and might only consist of lower affinity p53-specific CD8+ T cells 13;14. 
Notably, the detection of p53-specific Th1/Th2 cytokine producing CD4+ T cells, able 
to recognize both p53 peptide and p53 protein pulsed APC in the site of vaccination, 
suggests that the p53-SLP® vaccine is capable of inducing functionally active p53-
specific T cells which can migrate to areas where antigen is present. Most p53-specific 
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Figure 4. vaccine-site infiltrating t cells are p53-specific.
(A) T cells from the skin biopsy of patients p07 (left) and p08 (right) were tested for their capacity to 
proliferate upon stimulation with peptides or protein pulsed monocytes. Phytohemagglutinine 
(PHA) served as a positive control, while stimulation with HPV16 protein or medium served as 
negative control. The columns indicate the mean and SD of the proliferation. (B) Concentration 
of the concomitantly produced cytokines (pg/mL) as measured in the supernatants isolated 
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responses were found against peptide pools p53.4 and p53.5 indicating that the 
C-terminal part of the vaccine is most immunogenic. These responses appeared to be 
restricted by multiple HLA class II molecules since no particular HLA type was found 
to be present in these responding patients (data not shown).
Previous studies, in which subjects were vaccinated by different antigen delivery 
systems including canarypoxvirus 29, adenovirus 30 or peptide loaded autologous 
dendritic 31 cells, described varying results with regard to induction of p53-specific 
immunity. Two studies induced a p53-specific response in only a very low percentage 
of patients 27;29 while in another study 57% of vaccinated patients mounted a p53-
specific immune response 30, with – based on IFNγ ELISPOT - a comparable magnitude 
as in our trial. Therefore, the p53-SLP® vaccine induces the highest response rate, at 
least in colorectal cancer patients. This is probably attributable to the fact that the 
T-cell epitopes in SLP are efficiently processed and presented by DC, do not have 
to compete with dominant epitopes present in viral vectors and that the response 
induced by this vaccine is not restricted to one HLA type 32;33.
In at least five out of the seven patients p53-specific proliferation was associated 
with the production of detectable amounts of IFNγ. However, the levels of IFNγ (mean 
242 pg/mL) were rather low when compared to what we observed in a trial in which 
cervical cancer patients were treated with a HPV16-SLP vaccine and in which the levels 
ranged from 250 pg/mL to more than 5000 pg/mL 39. In fact, the overall production 
of pro-inflammatory cytokines by the p53-SLP® vaccine-induced T-cell population was 
low and this seems to be reflected by the vaccine-sites, most of which showed no clear 
signs of inflammation (Table 1), while this was the case in the majority of vaccinated 
cervical cancer patients 38. Assessment of all p53-activated CD4+ T cells, by gating on 
the CD4+CD154+ T-cell population by multi parameter flow cytometry, revealed that 
only in some cases the IFNγ producing population of T cells was the major subset 
among the vaccine-induced p53-specific T-cell response. As such, the polarization of 
the p53-specific immune response induced by p53-SLP® vaccine strongly resembles the 
spontaneous p53-specific immune response in colorectal cancer patients 11;12.
The vaccine dose and injection scheme used in the current study was based on 
the results obtained with an HPV16-SLP vaccine in patients with cervical cancer, of 
which our studies indicated that the CD4+ T-cell response was not different between 
two and four vaccinations 38;39 as well as on our studies in mice which showed that 
the same peptide dose used to stimulate HPV16-specific immunity 36 was also able to 
stimulate p53-specific immune responses 13. In patients with metastasized colorectal 
cancer, however, two injections with p53-SLP® only seems insufficient to activate a 
strong Th1-response. Recently, it was described that prolonged antigen presentation 
could elicit full expansion, effector cytokine production and memory cell differen-















































HPV16-SLP vaccinated end-stage cervical cancer patients also four injections were 
required to obtain a strong IFNγ-associated E7-specific T-cell response 38.As such, a 
prolonged vaccination scheme (i.e. multiple instead of two injections) may result in 
a stronger polarized Th1 response and possibly in the expansion of p53-specific CD8+ 
CTL previously observed in patients with cancer 49 but which display a low affinity for 
p53 14. In addition, one could make use of immunomodulatory adjuvants, of which 
chemotherapeutics form an interesting group. A recent study showed that patients 
with advanced colorectal cancer, who developed late signs of autoimmunity after 
treatment with the Golfig chemoimmunotherapy regimen (chemotherapy, GM-CSF 
and IL-2), showed a prolonged time to progression and survival 50. In the PBMC of 
these patients a progressive increase in lymphocyte and eosinophil counts, amplifica-
tion in central memory, a marked depletion of immunosuppressive regulatory T cells 
and activation of colon cancer - specific cytotoxic T cells was found 50. Another study 
combined a cancer vaccine with chemotherapy in patients with extensive stage small 
cell lung cancer showing a trend with induction of immunologic response to vac-
cination and clinical response to subsequent chemotherapy 30. These studies provide 
evidence that combining chemotherapeutics with cancer vaccines might lead to 
better treatment results in colorectal cancer patients.
Finally, our results fit with the safety and immunogenicity experience gathered 
thus far with vaccines consisting of long peptides dissolved in Montanide adjuvant, 
showing only low-grade toxicity and strong immunogenicity 38;51. The p53-SLP® vac-
cine is able to enhance the number of p53-specific CD4+ T cells to a broad array 
of epitopes in approximately 90% of all vaccinated patients, while no p53-specific 
CTLs are induced. Despite the induction of p53-specific T-cell immunity in vaccinated 
patients, the p53-specific Th1 responses are probably too weak to become truly 
effective. Most likely this is due to the fact that the p53-SLP® vaccine did not contain 
a compound able to activate a Th1-promoting DC population. Consequently, the 
addition of a strong Th1-inducing adjuvant to the p53-SLP® vaccine is required to 
obtain strong p53-specific Th1 immunity which, even in the absence of HLA class 
II positive tumor cells, is vital to coordinate a local anti tumor immune attack of 
innate effector cells and CTL directed against unique tumor-specific antigens that 
are cross-presented by dendritic cells 19-21. A new trial with p53-SLP® in combination 
with a Th1 enhancing compound has been initiated.
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Purpose: We previously established safety and immunogenicity of a p53 synthetic 
long peptides (p53-SLP®) vaccine. In the current trial we investigated whether com-
bination of Interferon-alpha (IFN-α) with p53-SLP® is both safe and able to improve 
the induced p53-specific IFN-γ response.
experimental design: Eleven colorectal cancer patients successfully treated for 
metastatic disease were enrolled in this study. Of these, nine patients completed 
follow up after two injections with p53-SLP® together with IFN-α. Safety and p53-
specific immune responses were determined before and after vaccination. Further-
more, cryopreserved PBMCs were compared head-to-head to cryopreserved PBMCs 
obtained in our previous trial with p53-SLP® only.
results: Toxicity of p53-SLP® vaccination in combination with IFN-α was limited to 
grade 1 or 2, with predominantly small ongoing swellings at the vaccination site. All 
patients harbored p53-specific T cells after vaccination and most patients showed 
p53-specific antibodies. Compared to the previous trial, addition of IFN-α signifi-
cantly improved the frequency of p53-specific T cells in IFN-γ ELISPOT. Moreover, in 
this trial, p53-specific T cells were detectable in blood samples of all patients in a 
direct ex vivo multiparameter flowcytometric assay, opposed to only 2 out of 10 
patients vaccinated with p53-SLP® only. Finally, patients in this trial displayed a 
broader p53-specific immunoglobulin-G response, indicating an overall better p53-
specific T-helper response.
Conclusions: Our study shows that p53-SLP® vaccination combined with IFN-α injec-
tion is safe and capable of inducing p53-specific immunity. When compared to a 
similar trial with p53-SLP® vaccination alone the combination was found to induce 








































121Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
introduCtion
The modest to poor prognosis of colorectal cancer patients treated with curative 
intent, calls for additional treatment modalities such as immunotherapy 1. 
p53 is one of the most frequently used tumor-associated antigens in tumor directed 
vaccination studies 2. Due to a mutation, p53 is inactivated and over-expressed in 
34-45% of colorectal tumors, while wild-type p53 is expressed at extremely low lev-
els 3. This provides an appropriate immunological window for T cells, being targeted 
to p53, to discriminate between tumor cells and normal cells 4. 
A clinical-grade p53 synthetic long peptides (p53-SLP®) vaccine was developed 
that was tested in two parallel phase I/II studies in colorectal and ovarian cancer 
patients 5-7. Results from these first trials revealed that in the vast majority of vac-
cinated cancer patients mainly p53-specific CD4+ T cells were induced 6;7.
The presence of tumor-specific CD4+ T cells in the cancer microenvironment is a 
prerequisite for support, proliferation, recruitment and cytolytic function of tumor-
specific CD8+ T cells, greatly accelerated by the production of IFN-γ and IL-2 8-10. 
Patients with metastatic colorectal cancer vaccinated against the tumor antigen 5T4 
were found to have more clinical benefits when 5T4-specific IFN-γ ELISPOT responses 
were induced 11. Also, in women with human papillomavirus (HPV) positive vulvar 
intraepithelial neoplasia, complete responses after vaccination against HPV were 
positively associated with the induction of IFN-γ-producing and proliferative T-cell 
responses 12. Together, these data suggest that clinical responses after vaccination 
depend on the induction of strong and broad vaccine-specific type 1 T-cell responses. 
Results from the first two trials with p53-SLP® showed that vaccine-induced type 1 
T-helper (Th1) cells produced only low amounts of the key cytokines (i.e. IFN-γ and 
IL-2), indicating that tumor-induced p53-specific Th-responses are present but not 
properly polarized 6;7. Therefore, in order to benefit from the tumor-specific Th cells 
at the tumor site, the p53-SLP® should be combined with immune modulating adju-
vants that specifically induce Th1-cell polarization. A possible candidate adjuvant to 
achieve this is Interferon-alpha (IFN-α).
IFN-α is used to treat patients suffering from chronic viral hepatitis infection and 
different malignancies 13. IFN-α plays a major role in the differentiation of the Th1 
subset, the generation of CTL and the promotion of proliferation and survival of T 
cells 14;15. Moreover, several studies have shown that type I IFNs promote the dif-
ferentiation of monocytes into dendritic cells (DC) and enhance DC activity 16-21. In a 
murine melanoma model, it was shown that addition of IFN-α to a gp100 peptide, 
suppressed melanoma growth and increased the accumulation and proliferation of 
gp100-specific, IFN-γ-secreting CD8+ T cells 22. Moreover, adoptive transfer of tumor-















































to successful treatment of metastatic melanoma 23. In humans, peptide vaccination 
has been combined with IFN-α injections showing that the combination was safe, 
resulted in a consistent enhancement of vaccine-specific CD8+ T cells and increased 
the percentage of blood circulating DC precursors 24. We now report the results of 
a phase I/II trial addressing safety and immunogenicity in which successfully treated 
metastatic colorectal patients were subcutaneously vaccinated with p53-SLP® in 
combination with subcutaneous administration of IFN-α. In addition, we analyzed 
whether addition of IFN-α close to the vaccine site not only induced a stronger 
p53-specific but also a better polarized Th1 response by testing and comparing 
cryopreserved peripheral blood mononuclear cells (PBMCs) and serum samples of 
the current trial head-to-head to samples obtained in our previous clinical trial, in 
which a similar group of colorectal cancer patients were vaccinated with the p53-
SLP® vaccine only 6.
PAtientS, MAteriAlS And MethodS
Patients, vaccination scheme and safety and tolerability monitoring
Colorectal cancer patients who were successfully treated with metastasectomy, 
chemotherapy and/or Radiofrequency Ablation (RFA) for disease metastasis to the 
liver and/or the lung were accrued during their follow up visits at the surgical oncol-
ogy out-patient clinic into this phase I/II trial. Primary endpoint of this study was 
safety and immunogenicity of the p53-SLP® in combination with administration of 
IFN-α. The secondary endpoint was to assess whether this combination is able to 
induce an overall significantly stronger p53-specific Th1 response than observed in 
the group of patients vaccinated in our previous trial 6. Patient eligibility criteria for 
in- and exclusion and the study design, including the vaccination schedule (twice 
vaccinated with a three week interval), were identical to those used in the previously 
performed clinical trial with p53-SLP® 6, with the exception that in the current study 
one hour after each vaccination pegylated interferon-alpha-2b (Pegintron, 1 μg/kg 
body weight, Schering-Plough, the Netherlands) was injected within 10 centimeters 
proximity to the vaccination site. Furthermore, patients were discharged within one 
hour after they received their Pegintron injection. The study design was approved 
by the Central Committee on Research Involving Human Subjects in The Hague, the 
Netherlands (NL24089.000.08) and by the medical ethical committee of the Leiden 
University Medical Center. All patients gave their written informed consent before 
they were enrolled in the study.
Patients were asked to monitor and report any adverse event (AE) including fever 








































123Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
spontaneous AEs, injection site reactions, clinical assessments, and clinical laboratory 
variables were monitored during all visits as reported previously 25. Injection site 
reactions were defined as pain, redness, itch and calor on a scale of 0-3 (0 being 
no reaction, 1 as mild, 2 as moderate and 3 as a severe reaction). Local swelling 
was measured bi-directionally in cm. Before each vaccination the medical history 
was taken and blood was drawn (both for safety and immunological assessment). In 
addition, the patients were physically examined before and after each vaccination.
Vaccine
The clinical-grade peptides (9 peptides of 20-30 amino acids long with an overlap 
of 5-14 amino acids) were synthesized at the Department of Clinical Pharmacy and 
Toxicology, Leiden University Medical Center (LUMC), the Netherlands, together 
representing the part of the p53 protein from amino acid positions 70 to 235. In 
comparison to our previous trial one long peptide (i.e. the peptide with amino acid 
sequence 224-248) was not included in the current vaccine mixture, because yields of 
the synthesis and purification of this peptide were very low. At the day of vaccina-
tion, the vaccine was prepared as previously described 6.
Immunohistochemistry and evaluation
The expression of p53 by colorectal tumor cells was determined in the available 
paraffin-embedded metastatic tissue of the vaccinated patients by standard two-step 
indirect immunohistochemical staining as described previously 6. The percentage of 
tumor cells expressing p53 (nuclear expression), together with internal control, was 
estimated and categorized into three groups: (1) expression of p53 in <25% of the 
tumor cells; (2) expression of p53 in ≥25% but <75% of the tumor cells; (3) expression 
of p53 in ≥75% of the tumor cells.
P53-peptide ELISA for IgG antibodies
Serum samples (pre-vaccination and 3 weeks after the second vaccination) of the 
colorectal cancer patients from both trials were subjected to a p53-peptide ELISA for 
detection of p53 peptide-specific immunoglobulin G (IgG). A 96-wells plate (Costar 
3590) was coated overnight at 4oC with the individual p53 peptides (30-mers, 14 
amino acids overlap; 50μl of 1μg/ml diluted in 0.1M carbonate/bicarbonate coating 
buffer; Merck, Darmstadt, Germany). Then, the plate was washed 6 times with phos-
phate buffered saline (PBS; Fresenius Kabi Bad Homburg, Germany) +0.05% Tween 
(Merck) and blocked for 1 hour at room temperature (RT) in 100μl/well PBS+0.05% 
Tween+0.1% bovine serum albumin (BSA; Sigma Aldrich, St Louis, MO, USA), which 
is assigned as blocking buffer. After 6 washings with PBS+0.05% Tween, the serum 















































and incubated at RT for 2 hours. The plate was washed again and 50 μl/well of goat 
anti-human IgG-Horseradish peroxidase (HRP; Southern Biotechnology, Birmingham, 
AL, USA) (diluted 1:3000 in blocking buffer) was added and incubated for 1 hour at 
RT. Finally, after the 6 washings tetramethyl-benzidine liquid substrate (50 μl/well 
TMB, Sigma Aldrich) was added for the colorimetric enzymatic reaction. This reaction 
was stopped by adding 50 μl/well of 2M H2SO4 (Merck) and the plate was read in an 
ELISA reader at 450 nm. A cut-off value was calculated to define a positive response. 
For this the average OD-value plus 2xSD of the triplicate wells for all 12 peptides per 
plate in a pre- or post-vaccination serum sample was calculated. All OD-values above 
this cut-off value were discarded and again the average+2xSD was calculated with 
the remaining OD-values. This process was repeated until all OD-values were below 
the last calculated cut-off value. At least 2 of the 3 OD-values per triplicate peptide 
test needs to be above this cut-off value, then a peptide was considered to yield a 
positive response, i.e. is recognized by specific IgG in the serum. A 2-fold increase of 
the post-vaccination serum sample over that of the pre-vaccination serum sample 
was considered a vaccine-induced positive response and calculated as fold induction. 
The average number of vaccine-induced positive responses for the individual pep-
tides was determined in the group of patients from both clinical trials. Subsequently, 
the number of positive peptide reactions per patient and an overall response rate 
(the number of positive peptides divided by the total number of tested peptides) 
was calculated for both groups. 
We acknowledge the concept of the Minimal Information About T-cell Assays 
(MIATA) reporting framework for human T-cell assays 26;27. 
Cell samples
Hundred mL of heparine blood was drawn prior to vaccination and 3 weeks after the 
second vaccination. PBMCs were isolated using Ficoll density gradient centrifugation 
within 2 hours, washed with PBS, resuspended in cold Fetal Calf Serum (FCS; PAA 
Laboratories, Pasching, Austria) and cooled on ice for 15 minutes. After drop-wise 
addition in a 1:1 ratio of freezing medium (80% FCS and 20% DMSO (Sigma Aldrich)), 
the PBMCs were cryopreserved at 10 million per ml per vial using an automated con-
trolled rate freezer (Cryosolutions, ’s Hertogenbosch, The Netherlands), and stored 
in equal aliquots in a vapor phase liquid nitrogen vessel until use. The handling and 
storage of the PBMCs were done according to the standard operation procedures 
(SOPs) of the department of Oncology at the LUMC by trained personnel.
Antigens
Overlapping peptides (30-mers with 14 amino acids overlap) covering the entire p53 








































125Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
LUMC, with >95% purity 28, dissolved in DMSO at 50 mg/mL and further diluted 
in PBS to obtain a concentration 0.5 mg/mL (in PBS/1% DSMO). The clinical-grade 
peptides of the vaccine were used in the immune monitoring assays. PHA (HA16; 
Murex BioTech,Kent, UK) and memory response mix 25;29 was taken along as a posi-
tive control. 
T-cell assays and data acquisition
The PBMCs were tested for p53-specificity by a set of complementary T-cell immune 
monitoring assays including: IFN-γ ELISPOT, lymphocyte stimulation test (LST) and 
cytometric bead array (CBA), all as previously described 6. Fresh PBMCs and T cells 
cultured out of the vaccination site biopsy were also subjected to the directly ex 
vivo intracellular cytokine staining (ICS) and analyzed as previously described 6. In 
this study the cells were stained for the following markers: CD3, CD4, CD8, CD154, 
CD137, IL-2 and IFN-γ 6;30. For a fair comparison with the results of our previous trial 
with metastasized colorectal patients vaccinated with p53-SLP® only, cryopreserved 
PBMCs from both trials were thawed and subjected to our novel ICS assay 25 under 
the same conditions. As higher concentrations of the peptides (i.e. 50 μg/mL) were 
required in this new ICS assay the non-clinical grade peptides covering the complete 
p53 protein were used.
Data analysis and interpretation
A positive response is predefined per assay and described previously 6. For all T-cell 
assays, a vaccine-induced response was defined as at least a 3-fold increase in the 
response after vaccination when compared to the results before vaccination. Sta-
tistical analyses were conducted in SPSS (version 17.0 for Windows; SPSS, Inc). The 
Fisher’s exact test or the Mann-Whitney test were used to evaluate differences in 
patient characteristics between patients included in the current and the previous 
trial with the p53-SLP® vaccine. The Mann-Whitney test was also used to evaluate 
the difference in number of IFN-γ-producing T cells, the level of IFN-γ production and 
to compare the difference in antibody responses between the two study cohorts.
Laboratory environment
The immunomonitoring assays were performed in the laboratory of the department 
of Clinical Oncology (LUMC) that operates under research conditions, following SOPs 
and using trained staff. This laboratory has participated in all proficiency panels of 
the CIMT Immunoguiding Program (CIP) (http://www.cimt.eu/workgroups/cip/), as 


















































Eleven colorectal cancer patients were enrolled in this study, 9 of whom completed 
all follow-up visits. The clinicopathological characteristics are displayed in Table 1. 
None of these patients showed evidence of any macroscopic disease at enrollment. 
Six out of 9 patients were male. The average age of the 9 patients vaccinated twice, 
was 58 years. Over-expression of p53 in the tumor (i.e. ≥25% of the tumor cells 
table 1. Patient characteristics of patients enrolled
Patient
Number














p21 M 44 1 Rectum Liver,LR PR/RTx/CTx/Rlu/
CTxLu
Alive (14) 2
p22* F 57 4 Sigmoid 
colon
Liver PR/CTx/Rli Withdrew 
consent
X
p23 M 60 4 Rectum Lung PR/RTx/CTx/Rlu/
CTxlu/RFA
Alive (2) 3
p24 F 61 3 Rectum Liver PR/RTx/Rli/CTx/
RFA
Alive (12) 2
p25 F 50 4 Sigmoid 
colon
Liver PR/Rli/CTx/RFA Alive (12) X
p26 M 52 4 Rectum Liver PR/Rli/CTx Alive (2) 3
p27 M 60 4 Cecum Liver PR/Rli/CTx/
CTxli/RFA
Death (5) 1
p28* M 64 4 Rectum Liver PR/RTx/CTx Withdrew 
consent
X
p29 M 65 4 Rectum Liver PR/RTx/CTxli/
RFA/Rli
Alive (7) 1
p30 F 64 3 Ascending 
Colon
Liver PR/CTx/Rli Alive (4) 2
Abbrevations: TNM: Tumor Node Metastasis Stage at time of diagnosis primary tumor. F; female. 
M; male. Lr: local recurrence. RTx; neo-adjuvant radiotherapy, Pr; primary resection. CTx; 
(neo) adjuvant chemotherapy. CTxlu; isolated lung perfusion, CTxLi: isolated liver perfusion, 
Rlu; resection lung lesion. Rli; resection liver lesion. RFA: radiofrequency ablation. NED; no 
evidence of disease (months between second vaccination and disease recurrence or last follow 
up date). P53 status immunohistochemistry (IHC). 1: expression of p53 in <25% of the tumor 
cells; 2: expression of p53 in ≥25% but <75% of the tumor cells; 3: expression of p53 in ≥75% 
of the tumor cells; X: no material was available for IHC. *Patient number 22 withdrew consent 
after the first vaccination due to adverse event (Table 2). Patient number 28 withdrew consent 








































127Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
express p53) was found in 6 patients, while normal p53 expression (i.e. in <25% of 
the tumor cells) was observed in 2 patients (p27, p29). Of 3 patients, the p53 status 
was not determined because no tumor material was available (p25) or because they 
prematurely withdrew consent (p22, p28). 
Safety of the vaccine
The AEs of all vaccinated patients are summarized in Table 2. All patients reported 
swelling confined to the vaccination site. In the majority of the cases the indura-
tion occurred after both vaccinations and was still present at the final check-up visit 
around 28 weeks after the first vaccination. The average size of these swellings at 
the first vaccination site was 3.3 cm and at the second site 3.5 cm. Four patients 
reported fever post vaccination, but it never lasted longer than 1 day. One patient 
also suffered from flu-like symptoms after both vaccinations for one day. Only two 
patients reported pain at the vaccination sites. None of the patients reported any 
pain, swelling or other changes of the skin at the IFN-α injection site. Only patient 
p22 experienced an AE exceeding grade I toxicity based on the Common Terminol-
ogy Criteria (CTC) for AE version 4.0. This patient already experienced pain before 
vaccination in her left arm. After first vaccination, she experienced local swelling 
classified as an AE grade 1 and pain throughout her entire left arm, classified as an 
AE grade 2 and she chose to withdraw consent.
We have previously vaccinated 10 patients with the p53-SLP® vaccine but without 
the administration of IFN-α 6. Clinicopathological parameters of both trial cohorts 
were similar (Table 3). In the current trial all patients developed ongoing swelling 
at either one or both peptide vaccination sites visible at the final check-up visit (28 
weeks after first vaccination), which contrasts with the previous trial in which only 
one patient showed inflammation at the p53-SLP® injection site. In conclusion, addi-
tion of IFN-α to the p53-SLP® resulted in prolonged and increased inflammation at 
the vaccination site, suggesting that addition of IFN-α promotes inflammation at 
p53-expressing sites after injection of p53-SLP®.
p53-SLP® and IFN-α injection elicit both proliferative and IFN-γ producing p53-
specific T cells
Using PBMCs isolated from blood samples taken before and after the second vaccina-
tion, three complementary T-cell assays (LST, CBA and IFN-γ ELISPOT) were performed 
to monitor the immunogenicity of p53-SLP® combined with IFN-α injection. After the 
two vaccinations, 4 (p25, p26, p29, p30) out of 9 patients showed vaccine-induced 
proliferative responses as determined by LST. All 4 patients responded against pep-
tide pool 5, whereas for patients p25 and p26 also responses against peptide pool 3 















































table 2. Adverse events of patients enrolled
Patient AE description Relation Action CTC Type Duration
p20 -Swelling at site 1











p21 -Swelling at site 1
-Swelling at site 2
-Pain at both site 1,2





















p22 -Swelling at site 1











p23 -Swelling at site 1











p24 -Swelling at site 1
-Fever after vaccination 1
















p25 -Swelling at site 1











p26 -Swelling at site 1
-Fever after vaccination 1
















p27 -Swelling at site 1
-Fever after vaccination 1
















p29 -Swelling at site 1#











P30 -Swelling site 1
-Swelling at site 2
















Note: all adverse events (AE) recorded for each patient included in this trial during the entire follow 
up period. AE were detected either at site 1 (the site of the first vaccination) or at site 2 (the site of 
the second vaccination). No AEs were reported with respect to the injection site of either the first 
or the second IFN-α administration. The heading AE provides a description of all the AE reported 
on in each patient. For each EA it is stated whether there was a plausible relation of the AE to the 
vaccination and whether the AE required any actions of the trial coordinator. All AEs were graded 
according to the Common Terminology Criteria for Adverse Events v4.0 as published by the EORTC 
(www.eortc.org). Grade I implicates mild AE defined as asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not indicated. Grade II implicates moderate AE defined as 
minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities 
of daily living. Grade III or IV AEs were not observed during this trial. The heading Type reports on 
how the AE was diagnosed; this was either at the injection site (Type I), as a systemic response (Type 
2), in the laboratory (Type 3) or otherwise such as pain which cannot be objectified (Type 4). Finally 
the duration of the AE was listed. The description “Ongoing” implicates that the AE was still present 
at the final follow up visit. Patient number 28 was not mentioned in this table because consent was 
withdrawn before vaccination 1 and therefore no AE were recorded. 
# The swelling did not occur until 1.5 weeks after the first vaccination. In all other cases the 
swelling post vaccination occurred directly or within 1 hour after vaccination. 
* Because of the pain in the arm after the first vaccination p22 withdrew consent to participate 
in the trial. The patient stated that this exact pain had also been present before the vaccination 









































129Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
our cutoff criteria, PBMCs of patient p21 displayed a proliferative response against 
p53 peptide pools 1 and 6 at baseline that disappeared after vaccination. Patient p27 
showed a positive proliferative response against peptide pool 6 after vaccination. 
However, this response was not induced by vaccination as it may have already been 
present at baseline, although just below the cut-off. Except for patients p20 and p24, 
a proliferative response against the recall antigens in the memory response mix was 
detected both at baseline and after vaccination (data not shown). 
Supernatants isolated at day 6 from the cultures of all PBMC samples tested in 
the LST were used for the analysis of antigen-specific production of cytokines (IFN-γ, 
TNF-α, IL-2, IL-4, IL-5, and IL-10) by CBA. After vaccination, 6 out of 9 patients (p20, 
p23, p24, 25, p26, p30) showed detectable induction of IFN-γ (median 55, average 
134; range, 26 – 618 pg/mL). IFN-γ production was induced by the vaccine as shown 
upon stimulation of PBMCs with peptide pool 1 (p26), pool 2 (p24), pool 3 (p20, 
p24, p25, p26), pool 4 (p24, p30) and/or pool 5 (p20, p23, p25, p26) (Figure 1B). One 
patient (p21) showed IFN-γ production against peptide pool 5 following vaccination, 
however, also displayed production of this cytokine already prior to the vaccinations. 
table 3. Comparison of patient characteristics p53 vaccination study with and without iFn-α
Characteristic p53-SlP® (n=10) P53-SlP® + iFn-α (n=9)
Sex (%male) 8 (80%) 6 (68%)















































CeA (screening, average) 3,7 2.2
Abbreviations: TNM: Tumor Node Metastasis Stage at time of diagnosis primary tumor. p53 
status IHC. 1: expression of p53 in <25% of the tumor cells; 2: expression of p53 in ≥25% 
but <75% of the tumor cells; 3: expression of p53 in ≥75% of the tumor cells. * in patients 
















































Moreover, the IFN-γ production at baseline was mainly found after stimulation with 
p53 peptide pools 1 or 6 in patients p21 and p25 (median 251, average 220; range, 
23 – 505 pg/mL) (Figure 1B). Vaccine-induced production of TNF-α, albeit at very low 
amounts, was detected in PBMCs of patients p25, p26, and p27 (median 48, average 
75; range, 22 – 175 pg/mL). IL-5 production was found in patients p20, p24, p25, p26 
(median 33, average 40; range, 22 – 74 pg/mL) and IL-10 in patient p20, p24, p25 and 
p26 (median 28, average 30; range, 21 – 39 pg/mL) after the vaccinations. No IL-2 was 
Figure 1. results of three complementary t-cell assays with either freshly isolated PbMCs: (A) 
lSt and (b) iFn-γ in CbA, or cryopreserved PbMCs: (C), iFn-γ eliSPot.
Results are depicted for each individual patient (n = 9) before vaccination (pre-vaccination; 
left) and 3 weeks after vaccination (post-vaccination; right); each peptide pool is represented 
by a symbol. (A) Proliferative responses upon stimulation with the indicated peptide pools of 
p53 are depicted as a stimulation index (SI); a SI ≥ 3 (indicated line) was defined as a positive 
response. (B) Concentration of IFN-γ (pg/mL) as measured by CBA in the supernatants isolated 
at day 6 from the proliferation assay; production of ≥ 20 pg/mL (indicated line) was defined 
as a positive response. (C) IFN-γ ELISPOT results; number of T cells per 105 PBMCs specifically 
producing a spot of the cytokine IFN-γ after stimulation with the indicated p53 peptide pools 
are shown; antigen-specific T-cell frequencies were considered to be positive when specific 








































131Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
detected, most likely because IL-2 was consumed by the cells during the 6 days of 
culture. In none of the cultures, IL-4 could be detected.
The IFN-γ ELISPOT assay was used to determine the number of IFN-γ producing 
p53-specific T cells. In all patients, p53-SLP® vaccination combined with IFN-α injec-
tion induced p53-specific T-cell responses (Figure 1C). Up to 162 specific spots per 
105 PBMC against at least one of the vaccine-representing p53 peptide pools were 
found. Out of 9 patients, 6 patients (p20, p21, p23, p24, p25, p26) displayed an IFN-
γ-associated T-cell response to at least 3 or 4 peptide pools that represented the 
vaccine (Figure 1C). In patients p20 and p21, IFN-γ-producing T cells were detected 
in the baseline samples mainly against peptide pools 1 and/or 6 that represented 
peptides outside the vaccine pool of peptides. These responses were not boosted 
after vaccination. Five patients displayed an IFN-γ-associated T-cell response to the 
positive control (memory response mix; data not shown). In contrast to patients 
with p53-negative tumors determined by immunohistochemstry (p27, p29), higher 
vaccine-induced cytokine levels were found in patients that exhibited p53-positive 
tumors, as determined by CBA and IFN-γ ELISPOT. In conclusion, the three immune 
monitoring assays showed that injection of IFN-α in close proximity of the p53-SLP® 
vaccine induced p53-specific IFN-γ-producing T cells in all cases. 
Intracellular cytokine staining (ICS) detects p53-specific activated T-cells capable of 
producing IFN-γ/IL-2 
To phenotype and enumerate p53-specific T cells, freshly isolated PBMCs from blood 
samples drawn before the first and after the second vaccination were directly ex vivo 
stimulated overnight with p53 peptide pools, followed by analysis of the expression 
of the T-cell markers: CD3, CD4 and CD8; in combination with the T-cell activation 
markers: CD137 and CD154; and cytokines: IFN-γ and IL-2 by multiparametric flow 
cytometry (Figure 2A). In 8 of the 9 vaccinated patients an increase in the percent-
age of p53-specific CD4+ T cells expressing CD137 and/or CD154 was found after 
vaccination (Figure 2B). In general, the production of the cytokines IFN-γ (Figure 
2C) and/or IL-2 (Figure 2D) in these activated cells was also boosted after vaccina-
tion. Notably, the CD4+ T cells of patient p24 displayed CD137 and CD154 expression 
before vaccination, suggesting that this patient already had a pre-existing response 
to p53, however, only after vaccination these activated T cells produced IFN-γ and 
IL-2 (Figures 2B, 2C, 2D). In 1 out of the 9 tested patients (p20) activated CD8+ T cells, 
which also produced IFN-γ, were detected in the freshly isolated PBMCs obtained 









































































Figure 2. Ex vivo measurement of the percentage of p53-specific activated t cells, and their 
production of iFn-γ and il-2, as determined by multiparametric flow cytometry.
Freshly isolated PBMCs of patients before the first and three weeks after second vaccination 
were intracellularly stained directly ex vivo after an overnight stimulation with medium or 
peptide pools p53.2 to p53.5. (A) depicts ICS results from patient p20 pre- and post-vaccination. 
Freshly isolated PBMCs were stained directly ex vivo after incubation in medium or stimulation 
with p53 peptide pools. Depicted are the IL-2 and/or IFN-γ-producing cells in the CD3+CD4+ 
(upper) or CD3+CD8+ (lower) T-cell population. The numbers in the quadrants indicate the 
percentage (%) of positive cells within this population. (B) displays percentages (%) of p53 
specific CD4+ T cells stained positively with the activation markers CD154 and/or CD137; results 
are depicted before (left) and after (right) vaccination. (C and D) displays the percentages (%) 
of IFN-γ+ (C) and IL2+ (D) activated CD4+ T cells subdivided for expression of the activation 








































133Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
T cells cultured from skin biopsies harbor p53-specific reactivity
From 6 out of 9 skin biopsies taken from the second vaccination site sufficient T 
cells could be cultured to perform multiparametric flow cytometry using the same 
markers as described above for PBMCs. The CD4+ T cells from 5 out of these 6 skin 
biopsy cultures (p25, p26, p27, p29, p30) displayed elevated expression levels (at least 
twice the non-stimulated sample) of the activation marker(s) upon stimulation with 
p53-SLP® vaccine-specific peptides (Figure 3A); a median frequency of 21% CD137+ 
and/or CD154+CD4+ T cells could be observed in the p53-peptide stimulated samples 
versus 2.2% in the non-stimulated T-cell culture control. The vast majority of these 
activated CD4+ T cells produced IFN-γ and/or IL-2 (Figures 3B and 3C). Moreover, in 
biopsies from 3 patients (p25, p26 and p30) both p53-specific IFN-γ producing CD4+ 
and CD8+ T cells were found (Figure 3D).
Figure 3. Measurement of the percentage of p53-specific activated t cells cultured from skin 
biopsies of the p53-SlP® injection site, which produce iFn-γ and/or il-2, as determined by 
multiparametric flow cytometry.
These cultured T cells were incubated in medium or stimulated with peptide pools p53.2 to 
p53.5. (A) displays percentages (%) of CD4+ T cells stained positively for the activation markers 
CD154 and/or CD137. (B and C) displays the percentages (%) of IFN-γ+ (B) and IL2+ (C) activated 
CD4+ T-cells subdivided for expression of the activation markers CD137 and/or CD154. (D) 
depicts the ratio of the percentage (%) of IFN-γ+CD8+ T cells of p53 peptides stimulated versus 
















































Addition of IFN-α to p53-SLP® results in increase of IFN-γ producing p53-specific 
CD4+ T cells
The characteristics of the two patient cohorts vaccinated in the current and our 
previous trial are generally similar (Table 3), thereby allowing us to compare the 
p53-specific immune responses after administration of the two different vaccine 
modalities in terms of their immunogenicity, with the limitation that the two vaccine 
modalities were not directly compared in the same trial.
To enable comparison of the results with those from the first trial, available cryo-
preserved PBMCs from patients in the first clinical trial (i.e. p01, p02, p03, p04, p07, 
p10, p11), vaccinated with p53-SLP® only, and cryopreserved PBMC samples from the 
patients in the current trial were thawed and subsequently head-to-head tested in a 
direct ex vivo ICS assay, optimized for detecting both antigen-specific CD4+ and CD8+ 
Figure 4. results from patients injected with p53-SlP® and iFn-α compared to the results from 
colorectal cancer patients injected with p53-SlP® only.
(A) The bar plot shows a graphical comparison of the percentages of activated CD4+ T-cells 
(CD137+CD154- in black, CD137-CD154+ in gray and CD137+CD154+ in white) between the two 
vaccination studies. (B and C) displays the percentages (%) of IFN-γ+ (B) and IL2+ (C) activated 
CD4+ T-cells subdivided for expression of the activation markers CD137 and/or CD154. (D) 
depicts the ratio of the percentage (%) of IFN-γ+CD8+ T cells of p53 peptides versus medium 
stimulated PBMC. The line indicated a 2-fold increase; ≥ 2-fold increase is defined as a positive 
response. (A-D): results of patients vaccinated with only p53-SLP® (left) and vaccinated with 
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T-cell responses in one single cryopreserved PBMC sample using long overlapping 
peptides as antigens 25 (Figures 4A-D). In PBMCs from patients receiving p53-SLP® 
in combination with IFN-α not only significantly more CD154+CD4+ were found 
(p=0.002), but also a significantly higher frequency of these activated CD4+ T-cells 
produced IFN-γ (p= 0.008), when compared to the activated CD4+ T cells isolated from 
patients that received the p53-SLP® vaccine only. Importantly, in 4 out of 9 patients 
(p20, p25, p27 and p29), who received p53-SLP® and IFN-α, also low numbers of IFN-
γ-producing CD8+ T-cells were found, while patients vaccinated with p53-SLP® only, 
showed no p53-specific CD8+ T-cell reactivity (Figure 4D). Of note, cryopreserved 
PBMCs, stored in the vapour phase of liquid nitrogen, reacted similarly over a period 
of at least 4 years indicating that the influence of cryopreservation time is unlikely 
(data not shown). 
ELISPOT plates from the previous trial were reanalyzed using the same ELISPOT 
reader conditions as the current trial to obtain a fair comparison. Addition of IFN-α 
to the p53-SLP® clearly results in a broader response per vaccinated patient (Figure 
5A). Patients that were injected with both p53-SLP® and IFN-α showed a significantly 
higher median frequency of IFN-γ producing T cells after vaccination (p=0.018) 
compared to patients that received the p53-SLP® only vaccine (Figure 5B). These 
data recapitulate the results obtained in the direct ex vivo ICS assay conducted on 
cryopreserved PBMCs.
Comparison of the IgG responses to p53 in serum of p53-SLP® vaccinated patients 
with and without IFN-α 
In order to analyze whether vaccination also resulted in the induction of a p53 
peptide-specific antibody response we developed a p53 peptide-specific ELISA and 
subsequently analyzed the sera of the patients obtained prior to the first and after 
the second vaccination. These analyses were performed simultaneously on the sera 
obtained from patients participating in the current trial and our previous vaccina-
tion study. In the current trial p53-specific IgG antibody responses were detected 
in 7 out of the 8 patients of whom both serum samples (pre- and post-vaccination) 
were available. In one patient (p29) no antibody response to p53 was detected. On 
average, the number of p53 peptides to which IgG antibodies were detected in these 
8 patients was 2.3 (range 0-5), with an obvious peak in the recognition of those 
peptides that were present in the vaccine (peptides 9-15; Figure 6). In sera of 3 out 
of the 9 tested patients from our previous colorectal cancer trial p53-specific IgG 
responses were detected. Here on average the number of peptides recognized was 
0.4 (range 0-2). Patients in the current trial recognized significantly more peptides 
than those from the first trial (p=0.02). The results of the ELISA therefore indicate a 















































p53-SLP®      p53-SLP® & IFN-α
         Peptide pools       Peptide pools
1 2 3 4 5 6 1 2 3 4 5 6
V V V V V V V V
P01 <1 <1 <1 29 45 3 <1 13 137 <1 40 <1 P20
P02 <1 <1 5 59 71 <1 <1 4 32 12 91 7 P21
P03 2 10 <1 <1 <1 <1 <1 5 31 25 70 12 P23 <10
P04 5 17 15 29 2 18 2 139 162 140 106 14 P24 10-50
P05 <1 <1 <1 <1 9 <1 <1 <1 89 20 33 <1 P25 50-100
P07 <1 <1 <1 <1 <1 <1 2 10 109 12 67 4 P26 >100
P08 <1 2 17 143 81 4 <1 <1 12 <1 <1 <1 P27
P09 <1 5 26 69 62 4 <1 <1 <1 19 41 <1 P29
P10 <1 <1 <1 <1 <1 <1 <1 <1 10 2 55 2 P30
P11 <1 <1 <1 59 72 14
Median NA 13.5 17 59 71 16 NA 13 60.5 19.5 61 13
Positive (%) 0 20 30 60 50 20 0 33 89 67 89 22
Figure 5. Comparison of iFn-γ eliSPot results in colorectal cancer patients vaccinated with p53-
SlP® only or in combination with iFn-α.
(A) The heat map reflects the IFN-γ ELISPOT results from both trials. The ELISPOT plates of 
the first trial (p53-SLP® only) were reanalyzed with the same settings of the reader as the 
current trial (p53-SLP® and IFN-α). The number of positive spots per 105 PBMC is given for 
every patient. Every value is colored in relation to the number of positive spots per 105 PBMC. 
White corresponds with a count of < 10 positive spots 105 PBMC, light grey ≥ 10  and < 50, dark 
grey ≥ 50 and < 100 and black ≥ 100 spots per 105 PBMC. On the bottom of the heat map the 
median and the percentages of the positive responses are given per peptide pool. Peptide pools 
represented by the vaccine are indicated by a ‘V‘. (B) the median (plus interquartile range) of 
all specific spots as determined by IFN-γ ELISPOT in the two trials before and three weeks after 
the second vaccination are compared. Not only the number of specific spots in both cohorts 
was significantly higher after vaccination compared to pre-vaccination, this increase in specific 
spots was significantly better in the patients that also received the IFN-α injections besides the 
p53-SLP® vaccine. (A-B): results of patients vaccinated with only p53-SLP® (left) and vaccinated 
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diSCuSSion
Results from previous studies suggest that colorectal cancer vaccines should aim 
at inducing strong type 1-associated immunity to obtain a clinical response 11;33-35. 
Although in patients, vaccination with the p53-SLP® resulted in the induction of 
p53-specific CD4+ T-cell immunity, the production of Th1-associated cytokines such as 
IFN-γ and IL-2 was probably too low to become truly effective 6. Combining vaccines 
with immune modulating adjuvants should allow polarization of the vaccine-induced 
immune response. Here we show that the clinical grade p53-SLP® vaccine combined 
with IFN-α induced p53-specific Type 1-polarized CD4+ and CD8+ T-cell responses in 
all and 6 of 9 colorectal cancer patients, respectively.
We have previously shown that the p53-SLP® vaccine was safe 6;7. The addition 
of IFN-α in the current trial also resulted in no serious AEs. However, in contrast 
to vaccination with p53-SLP® only 6, this time all vaccinated patients showed long 
lasting local swelling and inflammation of at least one of the peptide but not the 
IFN-α injection sites. As the groups of vaccinated patients were highly comparable 
Peptide



















Figure 6. the heat map represents the number of peptides that were recognized by the 
individual patients based on their specific igg antibody responses. 
The peptides are listed on the x-axis, the individual patients on the y-axis. Peptides are 
numbered and cover the whole p53 protein sequence. Patients p1-p10 represent the study 
cohort of the first trial, who received solely p53-SLP® injections, patients p20-p30 represent the 
study cohort of the second trial in which patients received both p53-SLP® and IFN-α injections. 
Negative responses are white (< 2); positive responses are displayed in light grey: ≥ 2 and < 
5, dark grey ≥ 2 and < 5-fold and black ≥ 10-fold increase of p53-specific IgG response after 
vaccination compared to prior to vaccination. There is an obvious peak, mainly present in the 
second cohort, representing the recognition of peptides that were actually covered by the 















































(Table 3), this suggests that addition of IFN-α potentiates inflammation at the vac-
cination sites where p53 antigen is present, thereby improving the antigen presenta-
tion conditions and subsequently the priming of T cells. 
The vaccine-induced p53-specific antibody and cellular response of patients 
vaccinated with the combination p53-SLP® and IFN-α were compared with those 
of patients vaccinated with p53-SLP® only. They were analyzed in a head-to-head 
comparison of cryopreserved PBMC samples by ICS and serum samples in the peptide 
ELISA assay. Although, these materials were obtained in two independent trials, 
they were similarly isolated from successfully treated colorectal cancer patients with 
highly comparable disease state and preserved under the same conditions. Within 
these limitations, our results indicate that addition of IFN-α to p53-SLP® induces 
an immune response against a broader range of peptide pools and also a higher 
frequency of vaccine-specific activated IFN-γ producing T cells. Addition of IFN- α to 
p53-SLP® also increased the amount of p53-specific IgG antibodies, indicating the 
underlying improved Th cell induction.
In the current trial, one of the peptides was excluded from the original p53-SLP® 
vaccine composition, due to low yield of purified material of this particular long 
peptide 6. The peptide not included was the last 13 amino acid overlapping peptide 
from the C-terminal section of the p53 sequence used in the previous vaccination 
trial 6. Our data comparing p53-specific T-cell responsiveness was not focused on the 
measurement of responses to individual peptides, therefore, it is difficult to estimate 
how the exclusion of this specific peptide altered the immunogenicity of the vaccine. 
However, in the current trial the responsiveness after vaccination was significantly 
increased compared to the previous trial, despite the lack of this one peptide. 
In the literature, it has been suggested that the p53-specific CD8+ T-cell repertoire 
is severely restricted due to self-tolerance 36;37. Consequently, p53-specific vaccina-
tion will result mainly in the induction of p53-specific high affinity CD4+ T-cells and 
low affinity CD8+ T cells. Our results indicated that addition of IFN-α might have 
increased the number of p53-specific CD8+ T cells as we were able to detect them 
in 6 out of 9 patients from the present trial and in none of the patients from the 
previous trial. The 6 patients with p53-specific CD8+ T cells included the following 4 
patients: one patient (p20) who showed a response when PBMC were freshly tested 
and the others (p25, p26 and p30) displayed p53-specific CD8+ T cells in the cells cul-
tured from the biopsy of the vaccine site. Most CD8+ T-cells responses were found in 
cryopreserved PBMCs (p20, p25, p27 and p29). The reason why we were better able 
to detect p53-specific CD8+ T cells in the cryopreserved samples lies in the fact that 
the ICS assay used for analyzing thawed PBMC is optimized to detect antigen-specific 








































139Vaccinating colorectal cancer patients with p53-SLP® & IFN-α
It also differs from the assay used to analyze the fresh PBMC samples by the addition 
of TLR3 agonist poly I:C to activate the peptide-loaded antigen presenting cells 25.
Together, we have found that combining p53-SLP® with IFN-α injection results in 
enhanced inflammation, p53-specific type 1-polarized CD4+ and CD8+ T-cell responses. 
We have not studied the effect on DC activity, therefore we can only speculate on 
the exact function of IFN-α. However, from literature it is clear that IFN-α improves 
antigen cross-presentation 38 and enhances survival of activated T cells 39. A recent 
study also found a reduction in regulatory T cells following high-dose IFN-α 40.
We can conclude that the addition of IFN-α clearly induces both a qualitatively 
and quantitatively better p53-specific T-cell response compared to p53-SLP® vaccina-
tion alone. These data provide support to the notion of combining cancer vaccines 
with immune modulating agents such as IFN-α to augment and polarize the vaccine-
induced immune response. However, the minimal requirements of a vaccine-induced 
immune response in order to obtain a clinical response are undefined. Therefore it is 
tempting to perform an efficacy study with p53-SLP® combined with IFN-α to deter-
mine whether the strength and quality of the response are good enough to prevent 
recurrence or metastasis in stage II and stage III colorectal cancer patients, who have 
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SuMMAry
In this dissertation, the triad immune system, colorectal cancer and immunotherapy 
was explored to understand how they interact, to develop immunotherapeutic 
approaches and to improve prognosis of colorectal cancer patients in the future.
Immune cell infiltration and HLA class I expression in colorectal tumors 
Many factors present on tumor cells and in the cancer microenvironment influence 
the function of the immune cells and enable tumor cells to escape from immunity. 
One of these might consist of down-regulation of human leukocyte antigen (HLA) 
class I on tumor cells, thereby prohibiting presentation of tumor antigens to cyto-
toxic T lymphocytes (CTL), and keeping CTL from tumor cell lysis. There are strong 
indications that complete absence of HLA class I expression in colorectal tumors 
is particularly found in colon tumors with a high level of microsatellite instability 
(MSI-H) 1;2. Unfortunately previous studies that evaluated the prognostic impact of 
HLA class I expression in colorectal cancer, used cohorts consisting of both colon and 
rectal cancer patients including both microsatellite stable (MSS) and MSI-H tumors 
3;4. These studies described a survival advantage for patients with HLA class I nega-
tive tumors, probably being the MSI-H tumors 3;4. To study the prognostic impact of 
HLA class I loss in MSS tumors, we decided to determine HLA class I expression in a 
population of rectal cancer patients, as rectal tumors mainly consist of MSS tumors 
5-7. In chapter 2 our results indicated that low expression of HLA class I in rectal 
tumors was associated with poor overall and disease free survival of rectal cancer 
patients 8. Therefore these results indicated that rectal cancer cells down-regulate 
expression of HLA class I molecules to escape CTL mediated immunity. Our results in 
rectal tumors might be extrapolated to patients with a MSS colon tumor. The clinical 
impact of HLA class I expression remains to be established for patients with a MSI-H 
colon tumor. 
It is generally accepted that of all immune cell markers, especially presence of the 
T-cell markers CD3 and CD8 is positively associated with prognosis of colorectal can-
cer patients 9. Down-regulation of HLA class I surface molecules is generally thought 
to be a tumor immune escape mechanism aimed at evading CTL cell recognition 
and elimination 3;4;8. Cytotoxic activity of Natural Killer (NK) cells is regulated by a 
balance of activating receptors and inhibitory receptors 10;11. The most prominent 
inhibitory receptor in humans being: HLA class I. Consequently down-regulation of 
HLA class I potentially activates Natural Killer (NK) cells. Previously it has been shown 
that presence of CD8+ lymphocytes in colorectal cancer cells correlated with absence 
of HLA class I 12. Whether intratumoral CD8+ cells represented CTL, NK or NK-T cells 















































expression would benefit most if these CD8+ T-cells represented NK cells. In chapter 
3 we showed that NK cells form only a minor fraction of the total tumor-infiltrating 
leukocyte population in all colorectal tumors, using CD56 to detect NK cells 13. A 
potential pitfall is formed by the expression of CD56. Two subpopulations of NK 
cells exist i.e.: CD56dim NK cells appear to be primarily cytotoxic effector cells while 
CD56bright NK cells have predominately regulatory functions 14. A possible explana-
tion for the low number of NK cells might be that immunohistochemical techniques 
are not capable to detect CD56dim cells. Therefore, a four-color-immunofluorescence 
staining technique was applied 15, demonstrating that tumors showing loss of MHC 
class I expression were more vigorously infiltrated by CD3+CD8+Granzyme B+ posi-
tive T-cells, confirming that tumors are poorly infiltrated with NK cells. A possible 
explanation for the lack of intratumoral NK cells might be that the main function 
of NK cells is on a systemic level, where they may be able to eliminate metastasized 
malignant cells 16;17. 
Migration of leukocytes into the cancer microenvironment
Effective anti-tumor immunity requires contact between cells of the immune 
system and tumor cells. Immune effector cells that developed in lymphoid organs 
and entered the circulation have to leave the vasculature and enter the cancer 
microenvironment. Homing of activated effector T-cells into the tumor consists of 
different steps. At the site of the tumor, endothelial cells are activated to express 
ligands for leukocyte adhesion. Once leucocytes attach to these ligands they have to 
pass the endothelium and enter the extravascular cancer microenvironment. From 
here, depending on their function, they have to migrate into the nests of tumor 
cells. The mechanisms governing homing of effector cells into tumors remain poorly 
understood, but this whole process is affected and coordinated by cytokines. One 
group of cytokines influencing the migration of leukocytes comprises of chemo-
kines. In chapter 4 we showed, using a rat tumor model that low expression of the 
chemokine CXCL5 in tumor cells resulted in rapid tumor growth and increase in the 
number of metastases, while in vitro no difference was found in proliferation rate 
between clones with either high or low expression of CXCL5 18. The relevance of 
these results for humans was confirmed, as low expression of CXCL5 in cancer cells 
was significantly associated with poor prognosis in a population of colorectal cancer 
patients. Finally a positive correlation between expression of CXCL5 and presence of 
intra-tumoral CD8+ T-cell infiltration in humans was found. These results indicated 
that expression of CXCL5 is associated with intraepithelial infiltration of specific leu-
kocyte subtypes, resulting in tumor regression, tumor specific immunity and better 
prognosis 18. This concept has also been described for other chemokines in various 
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key role in shaping the tumor-immune microenvironment and thereby clinical course 
of patients 28. To finally influence the type of immune cells trafficking towards tumor 
cells it is important to determine the correlation between colorectal cancer pheno-
type and type of immune cell infiltrate in the cancer microenvironment.
Colorectal cancer vaccines
One of the most unique features of the immune system consists of its capacity 
to specifically search and destroy targets. As such, many have discussed if tumor 
cells represent one of the regular targets of the immune system and in addition 
if the patient’s own immune system can be used to specifically destroy tumor cells 
once tumor cells escaped immune surveillance 29. Subsequently, many have tried to 
reinforce the immune system to cure cancer patients, using different approaches. 
Here we focused on induction of tumor specific T-cells against predefined antigens. 
Distinction should be made between MSI-H and MSS tumors for immunotherapeutic 
purposes, as MSI-H colon tumors express neo-antigens “foreign” to the immune 
system while immunotherapy against MSS colorectal tumors depends on tumor 
associated “self”-antigens.
MSI-H tumors: frameshift mutated products, a unique class of tumor-specific 
antigens
Despite many years of work, the number of antigens recognized by TILs of colorectal 
cancer identified is limited 30-33. Consequently, vaccines so far have been developed 
on the basis of proteins that are selectively expressed by tumor cells but for which 
immunity can be blunted or may lead to autoimmunity 34;35. The exception com-
prises MSI-H tumors that, due to numerous of frameshift mutations in microsatellites 
express neo-antigens. MSI-H is a molecular feature of tumors associated with the 
familial Lynch or hereditary non-polyposis colorectal cancer (HNPCC) syndrome, 
accounting for approximately 5% of all colorectal cancer cases and for approxi-
mately 15% of all sporadic colorectal cancers 36-45. Since frameshift mutated protein 
products (FSPs) are foreign to the immune system, they represent a unique group 
of tumor-specific antigens. No tolerance and consequently strong T-cell responses 
are expected against these FSPs. A few studies have been performed to predict 
the immunogenic behavior of a selection of frameshift mutated genes which are 
frequently detected in MSI-H cancers 33;46;47. Unfortunately, relatively little is known 
on the immunogenic behavior of most of the FSPs 33. Therefore we developed a 
methodology, described in chapter 5 for predicting their immunogenic behavior 
that is based on accumulation and MHC class I presentation 46. Our data indicated 
that, out of the 15 FSPs examined in our study, 4 (TGFβR2-1, MARCKS-1, MARCKS-2 















































TCF7L2-2 and Baxα+1) are of moderate interest for further tumor immunological 
research 46. The data of others suggested that FSP-specific T-cells may be present in 
the circulation of patients with MSI-H colorectal cancer, healthy HNPCC syndrome 
mutation carriers, but not in patients with microsatellite stable (MSS) colorectal 
cancer or in healthy donors 47;48. In general, most FSPs consist of a relatively small 
number of amino acids downstream of the frameshift mutation, suggesting that 
the FSPs may contain a sequence that can only be presented by a limited number of 
HLA class I or HLA class II molecules. In order to treat patients, knowledge on which 
HLA class I and II molecules can present epitopes comprised by the FSPs should be 
obtained. Although MSI-H tumors comprise only about 15% of all colorectal tumors, 
patients with a MSI-H tumor are very interesting vaccination candidates because: 
1) strong effector responses are expected after vaccination using non-self-antigens; 
2) colorectal cancer is one of the major cancers in the western world; and 3) many 
families with Lynch or HNPCC syndrome at risk for a MSI-H tumor have been iden-
tified. The latter group may be amenable for prophylactic vaccination to prevent 
the outgrowth of MSI-H tumors. Hence, a rapid identification of the immunogenic 
non-self-segment of the frameshift products is required.
MSS tumors: p53 vaccination in colorectal cancer patients
In chapter 6 the safety and immunogenicity of a p53 synthetic long peptides (p53-
SLP®) vaccine were investigated in patients treated for metastatic colorectal cancer 
49. The vaccine proved to be safe and highly immunogenic. However, mainly p53-
specific CD4+ T cells were induced after vaccination. Since the p53-specific CD8+ T-cell, 
but not the CD4+ T-cell repertoire is known to be severely restricted by self-tolerance 
and might only consist of lower affinity p53-specific CD8+ T cells, these results con-
firmed previous studies 34;50. The presence of tumor-specific CD4+ T cells is important 
in cancer immunotherapy because IFN-γ secreting CD4+ Th1-cells play an important 
role in orchestrating and sustaining the local immune attack by CD8+ CTL and innate 
effector cells 51-54. Unfortunately, the overall production of pro-inflammatory cyto-
kines such as IFNγ by the p53-SLP® vaccine-induced T-cell population in our trial was 
low. Therefore a new study was designed (chapter 7) to modulate the induced p53-
specific CD4+ T-cells by combining the p53-SLP® vaccine with Interferon-alpha (IFNα). 
This study clearly illustrated that addition of an adjuvant such as IFN-α injection 
to the vaccine safely modified both the vaccine-induced p53-specific humoral and 
T-cell responses. Addition of IFN-α to the p53-SLP® vaccine significantly improved 
p53-immune response against a broader range of peptide pools and also induced a 
larger number of vaccine-specific IFN-γ+ T-cells. These results confirmed that IFN-α is 
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Future PerSPeCtiveS
Altogether this dissertation reports on the relation between the immune system, 
colorectal cancer and immunotherapy. This knowledge can be used to further 
optimize immunotherapeutic strategies to treat cancer patients. For colorectal 
cancer only a few trials focused on clinical efficacy, this comprised phase III trials 
using irradiated tumor samples 55;56. These trials suggested some clinical benefit in 
selected subpopulations but overall results were rather disappointing 55;56. Most 
of the vaccination trials for colorectal cancer patients have been designed to test 
safety and immunogenicity but have yet not resulted in the design and execution of 
phase III trials 57. Although in most trials no serious vaccine related adverse events 
were noted, lack of clinical results suggests that the vaccine-induced T-cell responses 
against these antigens are at this point not robust enough or of sufficient quality to 
confidently progress to efficacy trials. The most recent vaccine developments suggest 
that some of the current cancer vaccine strategies do harbor the capacity to induce 
strong immune responses in cancer patients even to self-antigens 49;58-64. While these 
vaccines may still have to be optimized, the data suggest that the vaccine-induced 
activation of tumor-specific T-cell reactivity is no longer an issue of concern. However, 
other relevant questions remain:
•	 What are the tumor antigens recognized by tumor-infiltrating T-cells, and which 
antigens would be most appropriate in colorectal cancer?
•	 Which immune cells are to be induced during vaccination and does vaccination 
only enhance effector T-cells or also suppressive T-cells?
•	 Which adjuvants should be combined with vaccines to optimize the induced vac-
cine response?
•	 Do vaccine-induced tumor-specific leukocytes migrate to the tumor and mediate 
an antitumor effect?
•	 Which cancer patients are most likely to benefit from immunotherapy?
What are the tumor antigens recognized by tumor-infiltrating T-cells, and which 
antigens would be most appropriate in colorectal cancer?
New vaccine strategies have resulted in vaccines that are able to efficiently induce 
vaccine specific immune responses. However, vaccine strategies in colorectal cancer 
still suffer from a lack of antigens that may be used for vaccination. Whereas for 
other types of tumors the reactivity of tumor-infiltrating T-cells validate the choice of 
antigen used in the vaccines for that type of cancer 65, this is still limited in colorectal 
cancer and calls for more in-depth studies on the specificity of T-cells infiltrating the 















































the role of role of CD4+ T-cell help to the induction, sustainment and migration of 
CD8+ T-cells, it is advisable to screen not only for tumor-specific CD8+ T-cell responses 
but also for tumor-specific CD4+ T cells. 
Which immune cells are to be induced during vaccination and does vaccination only 
enhance effector T-cells or also suppressive T-cells?
The history of constant interactions between tumor and immune system shapes both 
tumor and the immune system of an individual patient in a way that is difficult to 
mimic in animal tumor models. It is of utmost importance that vaccines only boost 
the reactivity of immune cells that mediate an antitumor effect and not that of 
immune cells that support tumor growth. As most tumor associated antigens are 
intracellular proteins and results from observational studies show that especially 
presence of intra-epithelial activated CD8+ T-cells has a positive impact on prognosis 9, 
immunotherapeutic strategies start by inducing tumor-specific CD8+ T-cell responses. 
The activation of cytotoxic T-cells depends on a network of collaborating leukocytes. 
Consequently vaccines should create a CD8+ T-cell friendly and supportive cancer 
microenvironment. Indeed data from different studies indicate that especially a Th1 
associated type of cancer microenvironment is beneficial to the prognosis of cancer 
patients 66-68. 
From immunohistochemical studies it is clear that colorectal cancers are amongst 
others infiltrated by both CD4+ and CD8+ Foxp3+ T-cells 69;70. The number of Foxp3+ 
Regulatory T-cells (Tregs) correlates with disease stage and survival in colorectal 
cancer in several studies 70-72. Notably, the analyses of the antigens recognized by 
colorectal cancer infiltrating Tregs revealed that they recognized colorectal cancer-
associated antigens, in particular Mucin, Her-2/neu, and CEA 31. Hence, therapeutic 
vaccination with these antigens may not only boost CD4+ and CD8+ effector T-cells 
but also the Treg population. Vaccine-induced expansion of such antigen-specific 
Tregs has been observed previously in a mouse tumor model 73 and also in humans 
58. In the p53-SLP® vaccination trial, strong p53-specific CD4+ T-cell responses were 
found but this did not coincide with the expansion of p53-specific CD4+Foxp3+ T-cells 
49. This fits with the observation that the T-cell response to p53 in colorectal cancer 
patients is not under control of Tregs 31. 
Which adjuvants should be combined with vaccines to optimize the induced vaccine 
response?
It is not likely that colorectal cancer vaccines are able to induce the desired clinical 
responses on their own, but need to be combined with other modalities that target 
regulatory mechanisms in order to improve the local microenvironment. The current 








































Summary and future perspectives 151
therapeutic vaccines, blockers of immunosuppressive mechanisms and conventional 
therapies are applied jointly to overcome immunological tolerance and promote 
tumor regression. In general, a stronger focus should be put on how to induce the 
strongest and best qualified leukocyte population by vaccination. Vaccines should 
be combined with adjuvants to induce a vaccine specific type 1 polarized response 
and suppress a type 2 response. At the moment many candidate adjuvants are avail-
able. Also chemotherapeutics and monoclonal antibodies comprise strong immune 
modulating agents that can be used to polarize a response after vaccination. Various 
mechanisms may explain the reported synergistic effects of chemotherapy and T-cell 
restricted immunotherapy. Direct effects of chemotherapy on tumor or host environ-
ment, such as induction of tumor cell death, elimination of regulatory T cells, and/
or enhancement of tumor cell sensitivity to lysis by CTL may account for enhance-
ment of immunotherapy by chemotherapy. On the other hand, immunotherapy may 
directly modulate the tumor’s sensitivity to chemotherapy 74. Indeed, results have 
suggested that a vaccine encoding the tumor antigen 5T4 can be layered on top of 
chemotherapy regimens in patients with metastatic colorectal cancer without any 
evidence of enhanced toxicity or reduced immunological or therapeutic efficacy 75. 
Monoclonal antibodies are designed to interfere with specific signaling pathways. 
Recently, the CTLA-4 blocking antibody Ipilimumab has been successfully used in 
the treatment of melanoma patients 76. In human beings several approaches have 
been used to delete Tregs 77. Notably, decreases in CD4+CD25+Foxp3+ cells have been 
detected when patients with hepatocellular cancer were treated with low cyclophos-
phamide 78, as well as in metastatic melanoma patients treated with the anti-CD25 
antibody Daclizumab 79, or after using denileukin diftitox 80.Based on their mecha-
nisms of action it is highly likely that these antibodies will synergize with vaccines 
as they will block the negative feed-back on vaccine-induced tumor-specific T cells. 
Do vaccine-induced tumor-specific leukocytes migrate to the tumor and mediate an 
antitumor effect?
We showed that expression of CXCL5 by tumor cells was positively related with both 
strong intra-epithelial infiltration of the tumor cell nests by CD8+ T cells and a better 
clinical prognosis of colorectal cancer patients. Indeed chemokine expression as well 
as that of endothelial adhesion molecules and extracellular matrix has been associ-
ated with the migration of leukocytes into colorectal carcinoma 18;81-83. This suggests 
that tumor cells themselves play a key role in shaping the tumor-immune micro-
environment. The tumor phenotype, i.e. the status of tumor gene expression that 
attracts, activates or inhibits immune defense, determines the magnitude and type 
of immune infiltration and thereby clinical course of patients and represents a target 















































how the trafficking of these different cell populations is coordinated can be exploited 
for the development of successful immunotherapeutic strategies. One can start by 
comparing gene profiles of colorectal tumors with a high number of tumor infiltrat-
ing leukocytes versus those with a low number of tumor infiltrating leukocytes.
Optimization of vaccination studies may result in clinical success
To gain a thorough understanding of the immunological events occurring in patients 
in vaccination trials it is crucial to comprehensively perform immune monitoring dur-
ing vaccination trials. Results from immune monitoring make it possible to under-
stand possible clinical effects, to guide the optimization of vaccination strategies and 
may even encourage investigators to move a product forward into phase III trials 84. 
Unfortunately, most immunotherapeutic vaccine trials mostly report on one particu-
lar aspect of the desired immune response (e.g. HLA-multimer+ cells, IFN-γ-producing 
cells). They do not include more detailed analyses of the total vaccine-modulated 
immune response 57. Therefore implementation of assays that allows correlation of a 
broad array of immune cells with disease parameters is a prerequisite.
Although many studies determined the induced immune response after immuni-
zation, no gold standard has been set to define clinical response after vaccination 
85. Many different bioassays have been developed for immune monitoring: enzyme-
linked immunosorbent spot (ELISA), carboxyfluorescein succinimidyl ester-based 
proliferative assays, HLA peptide multimer staining and flow cytometry-based tests. 
Unfortunately substantial variability in results among laboratories prohibits data 
reproducibility and prevents meaningful comparison among studies. Therefore ini-
tiatives have been put up to standardize immune monitoring and harmonize cellular 
immune assays. Harmonization will establish the use T-cell-based assays as a repro-
ducible gold standard for immunotherapy and reliable parameter to determine the 
correlation between induced T-cell responses and clinical events 86-88. 
Which cancer patients are most likely to benefit from immunotherapy?
An important question that remains is which cancer patients are best candidates to 
study clinical endpoints once safety and immunogenicity of a therapeutic vaccine 
strategy have been established. So far most trials have included end-stage patients 
only. Although regression of tumor mass can be very convincing and objectively 
measured, vaccination of end-stage patients may present with several drawbacks 
that negatively influence the immunotherapeutic effect. Major drawbacks are the 
suppressed immune status, the general short survival period that may obscure clini-
cal effects of therapy at later time points 89, a large immunosuppressive tumor mass, 
variety of treatments before vaccination, and co-morbidity. Therefore clinical end-
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patients, who have no measurable tumor mass and a relatively normal functioning 
immune system are expected to respond optimally to immunization. 
FinAl
There is a clear role for tumor-specific T-cell immunity in the final clinical outcome 
of colorectal cancer patients. Immune escape variants of tumor cells indicate the 
selective force of the immune system. A continued effort will be put to exploit this 
force in the development of vaccines and vaccine strategies against colorectal cancer. 
Despite that some of the current vaccines are able to induce strong antigen-specific 
immune responses in the absence of serious adverse events, there is hardly any 
evidence generated to show the clinical impact of these vaccines in patients with 
colorectal cancer. It is not likely that colorectal cancer vaccines are able to induce 
the desired clinical responses on their own, but need to be combined with immune 
modulating modalities to redirect the force of the immune system into an effective 
anti-tumor response in vivo. Studies suggest that these modalities should primarily 
induce a type 1 polarized immune response and suppress a type 2 response. As che-
motherapeutics are already used in the treatment of cancer patients, they should be 
the first tested for their immune modulating capacity. For current vaccination studies 
it is of utmost important to monitor and link the type of induced immune response 
after vaccination to clinical cancer effect, to know which immune are to be induced 
after vaccination. To obtain proof-of-concept, the immunotherapy of colorectal 
cancer may want to first concentrate on the treatment of tumors with microsatellite 
instability as they are known to be heavily infiltrated by T cells and express tumor-
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Een van de meest unieke kenmerken van het afweersysteem bestaat uit het ver-
mogen om specifieke doelen te herkennen en deze eventueel te vernietigen. Er is 
uitgebreide discussie of tumorcellen een doel vormen voor het afweersysteem en 
vervolgens of het afweersysteem gebruikt kan worden om tumorcellen te vernieti-
gen. In dit proefschrift werd de interactie tussen het afweersysteem en dikkedarm- / 
rectumkanker onderzocht met als uiteindelijk doel T-cel gemedieerde immuunthera-
pie van colorectale tumoren verder te ontwikkelen.
In hoofdstuk 2 werd de klinische impact van (verminderde) expressie van Humaan 
Leukocyten Antigeen (HLA) klasse I onderzocht voor patiënten behandeld aan rec-
tumkanker. HLA klasse I moleculen presenteren antigenen aan cytotoxische T lymfo-
cyten (CTL). Hierdoor kunnen CTL, cellen herkennen die een bedreiging vormen voor 
het lichaam om ze daarna eventueel vernietigen. Verminderde expressie van HLA 
klasse I op tumorcellen maakt het mogelijk dat tumorcellen kunnen ontsnappen 
aan de CTL. Eerdere studies toonden dat verminderde expressie, in het bijzonder 
volledige afschakeling van HLA klasse I moleculen in dikkedarm- en rectumkanker 
geassocieerd is met een betere overleving van de patiënt. Echter, het lijkt erop 
dat volledige afschakeling van HLA klasse I expressie in colorectale tumoren voor-
namelijk voorkomt in tumoren met een hoge graad van microsatellietinstabiliteit 
(MSI-H). Patiënten met een MSI-H tumor zouden een betere overleving hebben t.o.v. 
patiënten met een microsatellietstabiele (MSS) tumor. In eerdere studies naar het 
prognostische effect van HLA klasse I afschakeling, werden patiëntcohorten gebruikt 
welke bestonden uit patiënten geopereerd aan dikkedarm- of rectumkanker zonder 
onderscheid te maken tussen MSS en MSI-H tumoren. Omdat in deze studies niet 
gecorrigeerd werd voor de prognostische impact van microsatelliet-instabiliteit, 
kunnen de statistische berekeningen dus tot een onzuivere schatting van het 
overlevingsvoordeel van patiënten met HLA klasse I afgeschakelde tumoren heb-
ben geleidt. Zoals in hoofdstuk 2 wordt aangetoond, bestaan rectumtumoren bijna 
geheel uit MSS tumoren. Onze resultaten tonen dat afschakeling van HLA klasse I 
expressie in rectumtumoren is geassocieerd met onafhankelijk slechtere overleving 
van rectumkankerpatiënten. Volledige afschakeling van HLA klasse I werd nauwelijks 
teruggevonden in rectumtumoren. Deze resultaten suggereren dat afschakeling van 
HLA klasse I een manier is voor tumorcellen om aan CTL-gemedieerde immuniteit te 
ontsnappen.
In hoofdstuk 3 werd de infiltratie van natural-killer (NK) cellen in dikkedarm-
tumoren bestudeerd. De HLA klasse I negatieve tumorcellen kunnen een doelwit 















































HLA klasse I te elimineren. Onze studie toonde aan dat er relatief weinig NK cellen 
dikkedarmtumoren infiltreerden. Dit gold ook voor tumoren zonder HLA klasse I 
expressie. NK cellen lijken dus geen rol te spelen in een tumor, maar hypothetisch 
kunnen zij wel een rol spelen in het bestrijden van systemische uitzaaiingen van HLA 
klasse I negatieve tumorcellen.
Effectieve antitumor T cel immuniteit vereist niet alleen presentatie van anti-
genen aan CTL, een andere voorwaarde is dat T cellen naar de tumor migreren en 
contact maken met de tumorcellen. Migratie van leukocyten naar en in de tumor 
is een gecompliceerd en slecht begrepen proces waarin chemokines een sleutelrol 
vervullen. In hoofdstuk 4 werd gevonden dat lage expressie van een specifiek 
chemokine: CXCL5, in een rat-tumormodel, resulteerde in snelle tumorgroei en 
toename van het aantal van metastasen, terwijl in vitro geen verschil in o.a. del-
ingssnelheid werd gevonden tussen klonen met hoge of lage expressie van CXCL5. 
Hoge expressie van CXCL5 bleek in twee verschillende cohorten van patiënten met 
colorectale kanker geassocieerd te zijn met een betere prognose. Daarnaast werd 
een positieve correlatie gevonden tussen expressie van CXCL5 en het aantal in de 
tumor gelokaliseerde CD8+ T cellen. Deze gegevens pleiten ervoor dat tumorcellen 
zelf een belangrijke rol kunnen spelen in de migratie van immuuncellen en op deze 
wijze de antitumorimmuunreactie beïnvloeden.
In het laatste deel van het proefschrift wordt de versterking van de tumorspecifieke 
T cel reactie m.b.v. vaccinatie tegen vooraf gedefinieerde antigenen beschreven. 
Voor colorectale tumoren moet onderscheid worden gemaakt tussen MSI-H- en 
MSS tumoren voor immuuntherapeutische doeleinden. MSI-H tumoren hebben 
als unieke eigenschap dat zij vele nieuwe antigenen tot expressie brengen die als 
lichaamsvreemd door het immuunsysteem kunnen worden gezien. De afweerreactie 
tegen MSS tumoren berust veel meer op het herkennen van lichaamseigen antigenen 
waarvoor het afweersysteem mogelijk tolerant is. Tot nu toe is T cel-gemedieerde 
immuuntherapie geen standaardbehandeling voor colorectale kankerpatiënten. 
Slechts in enkele subanalyses van studies zijn er aanwijzingen dat immuunthera-
peutische strategieën een klinische impact kunnen hebben voor colorectale kanker-
patiënten. Notabene de meeste van deze studies zijn uitgevoerd als fase I en/of fase 
II. Deze studies tonen wel aan dat vaccins goed in staat zijn een tegen het vaccin 
gerichte afweerreactie te kunnen induceren.
In hoofdstuk 5 werd een methode beschreven om het afweeractiverende vermo-
gen van frameshiftgemuteerde eiwitten, zoals die voorkomen in MSI-H tumoren, te 
voorspellen. MSI-H tumoren brengen, door mutaties in frameshifts, unieke tumor-
specifieke antigenen tot expressie die als lichaamsvreemd door het immuunsysteem 









































afweerreactie op te wekken voor de meeste van de frameshift gemuteerde eiwitten. 
Wij ontwikkelden daarom een selectiemethode voor de identificatie van frameshift 
gemuteerde eiwitten die van belang kunnen zijn voor immuuntherapeutische 
doeleinden. Deze methode is gebaseerd op accumulatie van eiwitten en Major His-
tocompatibility Complex (MHC) klasse I presentatie. Onze gegevens tonen dat 8 van 
de 15 frameshiftgemuteerde eiwitten onderzocht in onze studie, verder bestudeerd 
moeten worden. In het bijzonder 4 antigenen die zeer sterk tot expressie komen 
en goed gepresenteerd worden in MHC klasse I, lijken zeer relevant te zijn voor 
immuuntherapie van kanker. Hoewel MSI-H tumoren slechts ongeveer 15% van alle 
colorectale tumoren omvatten, zijn patiënten met een MSI-H tumor zeer interes-
sante vaccinatiekandidaten omdat: 1) een sterke effectieve afweerreactie wordt 
verwacht na vaccinatie met lichaamsvreemde antigenen; 2) colorectale kanker 
één van de meest voorkomende kankersoorten in de westerse wereld is; en 3) vele 
families met genetische belasting voor het Lynchsyndroom, die bijna allemaal MSI-H 
tumoren krijgen, zijn geïdentificeerd. De laatstgenoemde groep zou profylactisch 
gevaccineerd kunnen worden om uitgroei van MSI-H tumoren te voorkomen.
In hoofdstuk 6 werd van een p53 synthetische lange peptide (p53-SLP®) vaccin 
de veiligheid en de capaciteit om een afweerreactie op te roepen onderzocht bij 
patiënten behandeld aan gemetastaseerd colorectaal kanker. Het vaccin bleek veilig 
en zeer immunogeen te zijn. Voornamelijk p53-specifieke CD4+ T cellen werden 
geactiveerd m.b.v. het vaccin. Het ontbreken van p53-specifieke CD8+ T cellen, lijkt 
resultaten van eerdere studies te bevestigen die suggereren dat het p53-specifieke 
CD8+ T cel repertoire ernstig verstoord is door tolerantie van het afweersysteem voor 
lichaamseigen eiwitten. IFN-γ producerende CD4+ Th1 cellen spelen een belangrijke 
rol in het coördineren en ondersteunen van de lokale afweerreactie door CD8+ CTL 
en andere immuuncellen. Helaas blijkt de totale productie van cytokinen zoals IFN-γ 
door de p53-SLP® vaccin geactiveerde T cel populatie in onze studie erg klein te 
zijn. In hoofdstuk 7 werd daarom bestudeerd of het combineren van p53-SLP® vac-
cin met Interferon-alfa (IFN-α) injecties tot een verbetering van de p53-specifieke 
IFN-γ productie kon leiden. Deze studie illustreert duidelijk dat toevoeging van een 
adjuvans zoals IFN-α injectie aan een vaccin veilig is. Tevens bleek dat toevoeging 
van IFN-α aan het p53-SLP® vaccin de IFN-γ geassocieerde p53-specifieke T cel reactie 
verbeterde. 
tot beSluit
Er is een duidelijke (toekomstige) rol voor tumorspecifieke T cel therapie in de 















































relatie tussen het immuunsysteem en colorectale kanker op basis van zowel observa-
tionele - als interventiestudies. Het is niet waarschijnlijk dat alleen het gebruik van 
vaccins voor de behandeling van colorectale kanker tot het gewenste klinische effect 
zullen leiden. Meer waarschijnlijk is dat zij gecombineerd zullen moeten worden met 
immuunmodulerende modaliteiten om een effectieve antitumorreactie in vivo te 
genereren. Belangrijk hierbij zal zijn om de resultaten van observationele studies te 
gebruiken voor het ontwerpen van nieuwe interventiestudies met uiteindelijk doel 
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